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 1 
Abstract 
 
Pancreas/duodenum homeobox protein 1 (PDX1) is a transcription factor (TF) essential for 
pancreas development and adult β-cell function. Loss-of-function mutations of PDX1 
affecting both alleles result in pancreatic agenesis, while heterozygous mutations are linked 
to maturity-onset diabetes of the young 4 (MODY4) or type 2 diabetes (T2D). However, it 
remains unclear how PDX1 coordinates human pancreas development at the molecular 
level. Moreover, it is not well understood how some very common missense mutations such 
as the P33T and C18R mutations in the transactivation domain of PDX1 predispose to 
diabetes mellitus. In order to address these questions, we here generated induced 
pluripotent stem cell (iPSC) lines from patients’ fibroblasts carrying heterozygous PDX1P33T/+, 
PDX1C18R/+ mutations. To circumvent the effects related to the genetic background of the 
patient-derived line and study the impact of different PDX1 doses, we also engineered 
isogenic cell lines carrying homozygous PDX1P33T/P33T, PDX1C18R/C18R mutations and a 
heterozygous PDX1 loss-of-function mutation (PDX1+/-) using CRISPR/Cas9 gene editing. 
We showed that those iPSC lines were pluripotent and could be differentiated into pancreatic 
progenitors (PPs) and β-like cells using an established in vitro protocol. In order to find PDX1 
target genes, we performed chromatin immunoprecipitation sequencing. Remarkably, we 
identified several novel PDX1 target genes in human including regulatory factor 3 (RFX3) 
and delta like canonical Notch ligand 1 (DLL1). Moreover, we found that both heterozygous 
and homozygous P33T and C18R mutations result in impaired β-cell differentiation and 
function. Mechanistically, in the PDX1+/- and PDX1P33T/P33T mutant lines PDX1 failed to 
activate its target genes including TFs motor neuron and pancreas homeobox 1 (MNX1) and 
PDX1 as well as insulin resistance gene carboxylesterase 1 (CES1) already at the PP stage 
and reduced the differentiation efficiency of PPs. Finally, both PDX1P33T/+ and PDX1P33T/P33T 
mutations resulted in downregulation of the expression of PDX1-bound genes at the PP 
stage, including the insulin synthesis and secretion genes maternally expressed 3 (MEG3) 
and neuronatin (NNAT).  
In summary, our data provide a clear map of stage-specific target genes of PDX1 in PPs. 
Furthermore, we show evidence that the regions carrying the T2D-associated SNPs are 
active in PPs and three of these SNPs are bound by PDX1. Finally, our data reveal 
mechanistic details of how common coding mutations in PDX1 affect human pancreatic 
endocrine lineage formation and β-cell function.  
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1 Introduction 
 
1.1  Stem cells 
 
Stem cells (SCs) have the ability to self-renew and differentiate into other cell lineages. 
Based on the level of potency, SCs are further classified as totipotent, pluripotent, 
multipotent and unipotent cells (Figure 1.1) (De Los Angeles et al., 2015). Totipotent stem 
cells can give rise to all kinds of cells of an organism, which includes both placental and 
extraembryonic cells of the trophoblast. Pluripotent stem cells can differentiate into any cell 
type of the embryo, but not into extraembryonic lineages. Mouse embryonic stem cells 
(mESCs) and human embryonic stem cells (hESCs) are derived from the inner cell mass of 
the blastocyst and are classified as pluripotent stem cells. mESC and hESC lines were 
isolated and established in 1981 and 1998, respectively (Martin, 1981; Thomson, 1998). ESC 
lines have been successfully used to generate insulin-producing β cells, different types of 
neurons, cardiac myocytes, liver hepatocytes among other cell types. 
 
Figure 1.1 Potency levels of stem cells  
 
1.2  Signaling pathways and pluripotent TFs 
 
Understanding how embryonic stem cells maintain their pluripotency at the molecular level 
and which signaling pathways maintain the pluripotent identity is crucial knowledge to keep 
their pluripotency in culture maintained. For mouse ES cells, the two key factors, leukemia 
inhibitory factor (LIF) and bone morphogenetic protein 4 (BMP4), play an important role in 
maintaining pluripotency (Ying et al., 2003). LIF activates the canonical JAK/STAT3 pathway 
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and BMP4 inhibits extracellular receptor kinase (ERK) and p38 mitogen-activated protein 
kinase (MAPK) pathways and thereby maintains pluripotency (Matsuda et al., 1999; Ying et 
al., 2003). However, hESCs need different signaling pathways to maintain their pluripotency. 
hESCs do not require LIF, but instead, they rely on fibroblast growth factor 2 (FGF2) and 
activin A (James, 2005; Vallier, 2005). Key pluripotency factors including Oct4, Sox2, and 
Nanog play a pivotal role in maintaining pluripotency in both mESCs and hESCs. Those core 
TFs orchestrate a pluripotency transcriptional network and cooperate with each other to 
activate their target genes to sustain pluripotency and repress differentiation genes (Boyer et 
al., 2005). Besides these core TFs, several other TFs, lncRNAs, and miRNAs fine-tune and 
contribute to regulating pluripotency (Leonardo et al., 2012; Rosa and Ballarino, 2016; Zhang 
et al., 2008). 
 
1.3  History of cellular reprogramming 
 
In the 1950s, Briggs and King established the somatic cell nuclear transfer technique (SCNT) 
for reprogramming of a somatic cell to acquire pluripotency (Briggs and King, 1952). SCNT is 
also called cloning, which means that the nucleus of a somatic cell is transplanted into an 
enucleated oocyte for the creation of a new individual, indicating that the oocyte cytoplasm 
contains reprogramming factors to reverse a differentiated nucleus back to a totipotent status.  
The first organism used in SCNT was tadpoles of Rana pipiens, followed by a frog Xenopus 
laevis and finally, SCNT gave rise to Dolly the sheep in 1996 (Briggs and King, 1952; 
GURDON, 1962; Wilmut et al., 1997). The cloning of Dolly and other mammals from adult 
cells demonstrated that silenced genes in terminally differentiated cells can be fully re-
activated and the chromatin code connected with cell identity can be erased and modified to 
make terminal differentiated cells become totipotent again by nuclear reprogramming. Due to 
the low efficiency of successful cloning and the ethical concerns regarding harvesting human 
unfertilized eggs, this technology is not suitable for use in humans. Another method for 
reprogramming a somatic cell to pluripotency is by fusing it with an ESC, as first reported for 
hESCs in 2005 (Cowan et al., 2005). However, these pluripotent cells generated by fusion 
also have an abnormal complement of chromosomes.  
 
1.4  Human induced pluripotent stem cells (hiPSCs) 
 
Somatic cell nuclear transfer and cell fusion with pluripotent stem cells approaches suggest 
that cell fate can be changed by exposing cell nuclei to reprogramming factors. Working on 
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this concept, Takahashi and Yamanaka in 2006 found these reprogramming factors that can 
be used for reprogramming. Those initial TFs used for reprogramming are OCT4, SOX2, 
KLF4, c-MYC. At first, they used these factors to reprogram mouse somatic cells to be 
pluripotent stem cells, known as induced pluripotent stem cells (Takahashi and Yamanaka, 
2006). One year later, the same group reported that they can reprogram human fibroblasts 
into pluripotent stem cells using the same combination of transcriptions factors (Figure 1.2) 
(Takahashi et al., 2007). The fully reprogrammed iPSCs are similar to ESCs including 
morphology, pluripotency gene expression pattern, DNA demethylation of the promoter 
regions of OCT4 and NANOG, global patterns of histone methylation and the function such 
as the ability to differentiate into all germ layers (Takahashi and Yamanaka, 2016). However, 
the mechanisms of iPSCs reprogramming are still not fully understood (Takahashi and 
Yamanaka, 2016). Due to several issues, it is not feasible to derive patient-specific ESCs for 
disease modeling. Induced pluripotent stem cells have solved these issues. Because these 
iPSCs can be easily obtained from different somatic cells. Especially, these patient-specific 
iPSCs provide a valuable platform to gain the mechanistic insight into various diseases. Cells 
differentiated from patient-specific iPSCs can be used for disease modeling, for instance 
drug screening approaches. Importantly, patient-specific-mutated iPSCs can be corrected in 
vitro using gene-editing strategies. The corrected patient-specific iPSCs could then be 
directly differentiated into the affected somatic cell type and subsequently transplanted back 
into the patient for cell-therapy (Figure 1.3). Due to the importance of this discovery, Shinya 
Yamanaka received the Nobel Prize in Physiology and Medicine in 2012 for pioneering the 
iPSCs technology.  
 
Figure 1.2 Generation of iPSCs using Yamanaka factors 
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Figure 1.3 Application of hiPSCs for disease modeling, drug screening and cell-
therapy (The figure is adapted, with permission from Robinton and Daley, 2012) 
 
Several approaches have been used to express pluripotency factors in somatic cells to 
reprogram them into stem cells. However, the efficiency of reprogramming and the safety of 
iPSCs are different depending on the method used. The original method for hiPSCs 
reprogramming used active retroviral vectors that stably integrated into the host cell genome 
to introduce OCT4, SOX2, KLF4 and c-MYC expression cassettes (Takahashi et al., 2007). 
The retroviral transgenes are then silenced during the reprogramming process. However, the 
reprogramming process is often not fully completed, resulting in partially reprogrammed 
hiPSCs, in which the endogenous pluripotency genes are not fully activated. More recently, 
researchers used lentiviral vectors for reprogramming to improve the reprogramming 
efficiencies (Yu et al., 2007). However, lentiviral vectors also integrate into the genome and 
the insertion of vectors can lead to mutations in the iPSCs; therefore, this approach is also 
not suitable for human therapy. In order to overcome these obstacles for cell-based therapy, 
researchers developed integration-free reprogramming methods of hiPSCs involving non-
viral reprogramming methods such as mRNA transfection, miRNA transfection, episomal 
plasmids and protein delivery (Anokye-Danso et al., 2011; Kim et al., 2009; Warren et al., 
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2010; Yu et al., 2011). Overall, episomal reprogramming is a relatively safe strategy to 
generate footprint-free iPSCs. Efficiencies, however, are low compared to viral vectors.  
These advances in reprogramming will help us to use hiPSCs for cell therapy purposes. For 
instance, it has been shown that hiPSCs-derived neural progenitor cells can be used to treat 
spinal cord injury disease in non-human primate models(Kobayashi et al., 2012).  
    
1.5  Gene-editing in stem cells  
 
The isolation of human embryonic stem cells and the discovery of hiPSCs reprogramming 
have been a big breakthrough in stem cell biology, in vitro disease modeling and drug 
discovery (Avior et al., 2016). For disease modeling, studies normally compared 
differentiated cells generated from patient-derived hiPSCs with control hiPSCs derived from 
healthy donors. Due to the genetic diversity in humans, it is possible that the observed 
phenotypes result from differences in the genetic background of cells from the control and 
the patient. A very powerful approach to overcome this problem is to use zinc-finger 
nucleases (ZFN), transcription activator-like effector nucleases (TALEN) and clustered 
regularly interspaced short palindromic repeat and CRISPR-associated protein 9 
(CRISPR/Cas9) technologies that enable precise modification of the genomic sequences of 
endogenous human pluripotent stem cell (hPSC) to generate the isogenic controls. 
A significant breakthrough in gene targeting came with the discovery of CRISPR/Cas9 
system (Ran et al., 2013). The Cas endonuclease protein was originally found in bacteria as 
a part of an acquired immune system against foreign DNA. The CRISPR/Cas9 system has 
become a method of choice for gene editing in human pluripotent stem cells due to its 
efficiency and simplicity. This gene editing system is based on two components to achieve a 
DSB: the Cas9 nuclease protein and a single guide RNA (sgRNA). The first twenty 
nucleotides of a sgRNA guide Cas9 to a specified complementary DNA target sequence via 
RNA-DNA hybridization. The DNA target sequence is located upstream of an invariant 
protospacer adjacent motif (PAM) sequence. After correct hybridization the Cas9 nuclease 
creates a DSB located 3-base pair (bp) upstream of the PAM site. DSBs are being induced 
at the point of interest in the target genome, and custom alterations by homology-directed 
repair-mediated cellular repair response are initiated. This novel targeting technology has 
been successfully used to create knock-outs and knock-ins in hiPSCs (Hendriks et al., 2016) 
(Figure 1.4). Nevertheless, progress in gene editing tools now enables more rapid 
engineering of the genome in hPSCs using platforms such as ZFN, TALEN, and 
CRISPR/Cas9.  
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Figure 1.4 Site-specific genome editing with CRISPR/Cas9. (The figure is adapted, with 
permission from Charpentier and Doudna, 2013). 
 
1.6  Diabetes 
 
Diabetes mellitus is defined as a group of complex, heterogeneous, chronic and metabolic 
disorders characterized by hyperglycemia. This disease is caused by the loss and/or 
dysfunction of the pancreatic insulin-producing β-cells. According to the diagnostic criteria, 
etiology and genetics, diabetes mellitus can be classified as type 1 diabetes (T1D), type 2 
diabetes (T2D), gestational diabetes (GD), and monogenic diabetes caused by genetic 
defects of β-cell function such as maturity onset diabetes of the young (MODY) and neonatal 
diabetes mellitus (NDM). Today over 451 million people worldwide suffer from different types 
of diabetes and this number is predicted to reach 693 million by 2045 (International Diabetes 
Foundation, 2017). 
T1D, one of the most common chronic diseases manifesting in the childhood, is caused by 
insulin deficiency as a result of autoimmune destruction of the insulin-producing pancreatic β-
cells (DiMeglio et al., 2018). However, the most common form of diabetes is T2D, a 
multifactorial disease caused by a complex interplay including genetic, epigenetic and 
environmental factors. T2D mostly develops in adulthood. The reduced insulin sensitivity 
makes β cells to increase their insulin secretion. Finally, the β cells are dysfunctional and the 
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remaining β cells cannot produce enough insulin for glucose maintenance (Kahn et al., 
2014). GD is characterized by glucose intolerance arising during the second or third trimester 
of pregnancy (Chollet and Pettitt, 2006).  
Monogenic diabetes is caused by mutations in single genes linked to β-cell development 
function (Hattersley and Patel, 2017). This type of diabetes includes MODY and NDM. 
MODY is inherited in an autosomal dominant inheritance pattern and develops early in life 
(normally before the age of 25 year), and it was first discovered by Tattersall in 1974 
(Tattersall, 1974). MODY is caused by defects in developing a sufficient number of β cells or 
failure in β-cell function. There are at least 14 types of MODY diagnosed in 1-2% of diabetes 
patients (Table 1.1). These types are caused by mutations in several essential genes, such 
as GCK, ABCC8, NEUROD1, HNF1A, HNF1B and PDX1 (Heuvel-Borsboom et al., 2016). 
MODY2 and MODY3 are the most common types of MODY, caused by the mutations of 
GCK and HNF1A, respectively (Fajans et al., 2002). MODY4 is caused by heterozygosity in 
the PDX1 gene and so far only a single family of patients has been identified (Staffers et al., 
1997).  In terms of treatment for MODY patients, sulfonylureas and insulin have been used to 
treat HNF1A-, HNF4A- and HNF1B-MODY patients (Murphy et al., 2008; Pearson et al., 
2003).  
Table 1.1 MODY subtypes and their clinical features 
MODY TYPE GENE LOCUS CLINICAL FEATURE 
1 HNF4A Defects in insulin secretion 
2 GCK Fasting hyperglycemia 
3 HNF1A Defects in insulin secretion, Renal glycosuria 
4 PDX1 Defects in insulin secretion, obesity 
5 HNF1B Pancreatic hypoplasia 
6 NEUROD1 Moderate to severe β-cell dysfunction 
7 KLF11 Pancreatic atrophy 
8 CEL Exocrine pancreatic insufficiency 
9 PAX4 Ketosis prone to diabetes 
10 INS Wide clinical spectrum 
11 BLK Obesity 
12 ABCC8 Progressive insulin secretory defect 
13 KCNJ11 Progressive insulin secretory defect 
14 APPL1 Obesity 
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1.7  The transcription factor PDX1 and MODY4 
 
Pdx1, formerly known as insulin promoter factor 1 (Ipf1), encodes a TF protein containing a 
transactivation domain and a DNA-binding homeodomain. In mice, Pdx1 is located on 
chromosome 5qG3; in humans it is located on the syntenic region of chromosome 13q12.1 
(Fiedorek and Kay, 1995; Inoue et al., 1996; Stoffel et al., 1995). This gene has two exons 
and the promoter region contains several highly conserved regulatory elements. Many 
endoderm and pancreas specific TFs including Hnf1β, Foxa1/2, Mafa as well as Pdx1 itself 
bind to these regions to initiate and maintain Pdx1 expression (Gao et al., 2008; Gerrish K. et 
al., 2004). During embryonic development, Pdx1 protein starts to be detectable in the dorsal 
and ventral pancreatic endoderm and duodenum at E8.5 (Ahlgren et al., 1996; Guz et al., 
1995). During the later stages of development and adulthood, Pdx1 is synthesized in β-and 
δ-cells of the pancreatic islets and in some cells of the duodenum and stomach (Ahlgren et 
al., 1998; Guz et al., 1995; Offield et al., 1996). 
Pdx1 is a master regulator of pancreas development and genetic lineage-tracing studies 
showed that Pdx1 is important for differentiation of all exocrine and endocrine cells (Gu et al., 
2002). Homozygous Pdx1-deficient mice fail to generate a pancreas, while heterozygous 
animals do develop a pancreas, but later on become diabetic (Brissova et al., 2002; Holland 
et al., 2005; Johnson et al., 2003; Jonsson et al., 1994). In humans, homozygous loss-of-
function mutations of PDX1 also lead to pancreas agenesis, whereas certain heterozygous 
mutations lead to MODY4 (Staffers et al., 1997; Stoffers et al., 1997, 1998). However, not all 
heterozygous mutations cause monogenic diabetes, most of them being associated with T2D 
(Gragnoli et al., 2005; Hani et al., 1999; Macfarlane et al., 1999). So far, there are more than 
150 missense coding mutations described for PDX1 (gnomad.broadinstitute.org); however, 
how these PDX1 mutations predispose to diabetes mellitus is not well understood. 
 
1.8 Pancreas structure, development and function 
 
The pancreas is of high importance for the regulation of energy consumption and metabolism 
and has two distinct components: the exocrine compartment and the endocrine compartment. 
The exocrine compartment contains acinar cells producing the nutrient-digestive enzyme 
juice including lipases, proteinases and amylases and ductal cells transporting enzymes into 
the small intestine and the duodenum to break down fats, proteins and carbohydrates for 
absorption. The endocrine compartment plays an important role in maintaining glucose 
homeostasis by producing a cocktail of hormones that are released into the blood circulation. 
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The endocrine compartment includes five endocrine cell types, which reside in small clusters 
called islets of Langerhans (Figure 1.5). These five endocrine cell types are: glucagon-
producing α-cells, insulin-producing β-cells, somatostatin-producing δ-cells, pancreatic 
polypeptide-producing PP-cells and ghrelin-producing ε-cells (Bakhti et al., 2019; Jennings et 
al., 2015; Pan and Brissova, 2014; Shih et al., 2013; Zhou and Melton, 2018). Defects of 
these hormone-producing cells can contribute to diabetes mellitus.  
 
Figure 1.5 The anatomy of the pancreas. The location of the pancreas is very close to the 
stomach and the duodenum. The acinar cells produce the digestive enzymes that are 
transported to the duodenum and intestine by ductal cells. The islets of Langerhans contain 
five endocrine cell types (glucagon-producing α-cells, insulin-producing β-cells, somatostatin-
producing δ-cells, pancreatic polypeptide-producing PP-cells and ghrelin-producing ε-cells) 
that secrete the hormones to regulate the blood glucose levels. (The figure is adapted, with 
permission from Shih et al., 2013)  
 
1.8.1 Pancreas development, induction and specification in mice 
 
Pancreas development is well understood in mice where pancreas formation starts with the 
specification of dorsal and ventral pancreatic buds from foregut endoderm around embryonic 
day (E) 9. Later, these two pancreatic buds elongate alongside the duodenum and stomach 
and eventually fuse into a single organ at E12.5, which give rise to pancreatic endocrine and 
exocrine cells. At the same time, the size of the pancreatic buds increases due to cell 
proliferation. In parallel, the pancreatic buds change their morphology and begin to form 
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branched tubules/tubes in a process called branching morphogenesis. This early phase of 
pancreatic development is known as the primary transition. This stage is characterized by the 
massive proliferation of pancreatic progenitors to generate a stratified epithelium and the 
formation of multiple microlumens and their subsequent fusion. The first glucagon-producing 
α-cells start to appear in the dorsal bud at this stage of development (Herrera, 2000; 
Kesavan et al., 2009; Pictet et al., 1972; Villasenor et al., 2010).  
Several TFs control pancreas induction and formation from multipotent progenitors in the 
foregut endoderm. Among the earliest TFs that mark the pancreatic region are Pdx1, Ptf1a 
and Sox9 (Ahlgren et al., 1996; Guz et al., 1995; Krapp et al., 1998; Seymour et al., 2007). 
Furthermore, a number of signaling pathways are involved in the early pancreas 
development. For instance, Notch signaling regulates the expression of Hes1 and Sox9, 
which plays an important role in the early pancreas specification (Kageyama et al., 2007; 
Shih et al., 2012). Hes1 deletion during pancreas development forces progenitors to 
differentiate into endocrine cells, which in turn results in pancreatic hypoplasia (Horn et al., 
2012; Jensen et al., 2000). Moreover, the deletion of Sox9 during early pancreas 
development decreases early pancreatic growth (Seymour et al., 2007). 
Pancreas development requires communication between the pancreatic epithelium and the 
surrounding mesenchyme. Seminal studies in the 1960s demonstrated the importance of the 
mesenchyme environment for early pancreatic formation (Golosow and Grobstein, 1962; 
RUTTER et al., 1964; Wessells and Cohen, 1967). However, we are only beginning to 
understand which mesenchymal signals control the specification of the early pancreas. The 
mesenchyme produces several signaling factors, such as FGF10, EGF and Wnt, which have 
been shown to be important for pancreas development (Ahnfelt-Rønne et al., 2010; Attali et 
al., 2007; Bhushan et al., 2001; Jonckheere et al., 2008; Kim and Hebrok, 2001; Tulachan et 
al., 2006). FGF10 activates the FGF signaling pathway via its receptor FGFR2 that induces 
proliferation and growth of pancreatic progenitor by enhancing and maintaining Pdx1 and 
Ptf1a expression (Bhushan et al., 2001). During the early growth phase of the pancreatic 
buds, Sox9, FGF10 and FGFR2 build a feed-forward loop. In this loop, FGF10 maintains 
Sox9 expression and Sox9, in turn, controls FGFR2 expression to allow FGF10 signaling. 
Disruption of this loop at any point results in loss of identity of pancreatic epithelia cells, 
which then activates a liver gene program (Seymour et al., 2012). 
During the secondary transition, which starts around E12.5, the microlumina expand and 
start to fuse to form a continuous network. The endocrine, acinar and ductal cells are 
generated during this stage. By the end of this secondary transition, endocrine cells together 
with endothelial, mesenchymal and neuronal cells are clustering together to form the islets of 
Langerhans (Cleaver and Dor, 2012; Thorens, 2014). One of the most important steps 
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occurring during this stage is the segregation of multipotent progenitor cells (MPCs) into tip 
and trunk domains. The tip domain will further differentiate into acinar cell lineages and 
express Ptf1a, c-Myc, Nr5a2 and Cpa, whereas the trunk domains form bi-potent endocrine 
or duct progenitor cells expressing Nkx6.1, Sox9, Hnf1b, Nkx2.2 and Pdx1 (Zhou et al., 
2007). The segregation into tip or trunk domains is mainly regulated by the TFs Nkx6.1 and 
Ptf1a. Nkx6.1 expression induces trunk formation by repressing the tip fate, whereas the 
expression of Ptf1a induces tip domain formation by blocking the trunk program (Schaffer et 
al., 2010). Besides’ this, the Notch pathway also regulates the tip-trunk patterning by 
regulating Nkx6.1 and Ptf1a expression. Furthermore, the mesenchymal and endothelial 
cells also play an important role in determining the tip and trunk fate. However, how the 
Notch pathway and the interconnection between epithelium and endothelial cells regulate the 
tip-trunk patterning is still poorly understood.  
 
1.8.2 The formation of pancreatic exocrine and endocrine cell types in mice 
 
95% of the pancreas consists of acinar and ductal cells. Acinar cell differentiation starts from 
the distal tip epithelium at E13.5 by upregulating expression of Ptf1a, while downregulating 
the expression of TFs that maintain the MPC identity. This process is regulated by the TFs 
Ptf1a, Rbp-jl and Nr5a2/LRH-1 (Holmstrom et al., 2011; Masui et al., 2007, 2010). More 
genes were found to contribute to the acinar cell differentiation, expansion and maintenance, 
which includes c-Myc and β-catenin (Murtaugh, 2005; Sánchez-Arévalo Lobo et al., 2018; 
Wells et al., 2007). During the secondary transition, some cells in the bi-potent trunk 
progenitor pool start to express the TF Neurogenin3 (Ngn3), which marks the initiation of the 
endocrine cell differentiation (Gradwohl et al., 2000). The remaining cells of the trunk domain 
that do not activate Ngn3 expression will eventually form the ductal network (Beucher et al., 
2012; Wang et al., 2010). Several TFs including Sox9, Hes1, Hnf1b and Glis3 play important 
roles in ductal cell fate determination (Cereghini et al., 2015; Delous et al., 2012; Kang et al., 
2010; Shih et al., 2012). Knockout of either of these TFs in mice causes malfunction of ductal 
cells and leads to duct-related defects. Furthermore, the Notch signaling pathway is 
important for the ductal cell determination. High level of Notch signaling blocks the activation 
of Ngn3 and promotes ductal cell differentiation, whereas low level of Notch signaling 
increases the expression of Sox9 and further activates the expression of Ngn3 (Shih et al., 
2012). The mechanisms regulating differential Notch signaling activity within the progenitor 
pool  have been investigated recently (Löf-Öhlin et al., 2017; Mamidi et al., 2018).  
As discussed above, the endocrine progenitors are derived from the bi-potent trunk domain. 
These progenitors transiently express Ngn3 (Gradwohl et al., 2000; Gu et al., 2002). Ngn3 
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acts upstream of several TFs, including Pax4, Arx, Rfx6, NeuroD1, Pax6, Isl1, Nkx2.2 (Petri 
et al., 2006). The Ngn3+ cells give rise to five different cell types: glucagon-producing α-cells, 
insulin-producing β-cells, somatostatin-producing δ-cells, pancreatic polypeptide-producing 
PP-cells and ghrelin-producing ε-cells. Endocrine cell differentiation is regulated by several 
signaling pathways including Notch signaling, Wnt signaling and sphingosine-1-phosphate 
signaling (Kim and Hebrok, 2001). 
 
1.8.3 Endocrine lineage allocation, differentiation and maturation in mice 
 
It is unclear when exactly the decision to differentiate to a specific hormone-producing cell is 
made. We just begin to understand how specific TFs control the endocrine subtype 
allocation, development and maturation. Specification of glucagon-producing α-cells requires 
a set of TFs including Arx, Pax6, Rfx6, Foxa2 and Mafb, whereas Pax4, Pdx1, and Nkx6.1 
are essential for the formation of insulin-producing β-cells (Collombat et al., 2003; Gannon et 
al., 2008; Henseleit, 2005; Kesavan et al., 2009). Little is known about TFs controlling the δ-
cells, PP-cells and ε-cells development. 
After specification, the endocrine cells acquire physiological ability in a maturation process. 
In α- and β-cells, this process is guided by two essential TFs, Mafa and Mafb  (Artner et al., 
2006, 2010; Hang and Stein, 2011). Specifically, Mafb is expressed in both cell types, 
however, during the maturation process, its expression becomes restricted  to α-cells to 
maintain α-cell identity (Artner et al., 2007; Conrad et al., 2015). In contrast, maturing β-cells 
cease to express MafB and start expressing MafA instead, which is essential for β-cell and 
its identity (Nishimura et al., 2006). This switch from MafB+ to MafA+ in β-cells also increases 
Pdx1 expression (Artner et al., 2006; Nishimura et al., 2006). Other TFs including Pdx1, 
Nkx6.1, NeuroD1, Nkx2.2, Pax6 and Rfx6 are also involved in this maturation process 
(Oliver-Krasinski and Stoffers, 2008; Pan and Wright, 2011). Furthermore, mature β-cells 
express markers such as  Glucokinase (Gck), Slc2a2 (Glut2), Urocortin3 (Ucn3) and Flattop 
(Fltp) (Bader et al., 2016; Blum et al., 2012; Taniguchi et al., 2000; Thorens, 2015). 
 
1.8.4 Human pancreas development and regeneration 
 
In contrast to mouse pancreas development, the formation of the human embryonic 
pancreas remains unclear due to the limited access to human material. In general, the key 
events and molecular markers of pancreatic differentiation are conserved in mouse and 
human, although differences in timing and developmental factors have been reported. 
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Recently, three reviews compared major specification events and their time of appearance in 
mouse and human pancreas development (Jennings et al., 2015; Nair and Hebrok, 2015; 
Pan and Brissova, 2014). Unlike mouse pancreas development, the human pancreas only 
has a single wave of endocrine cell formation during development. Furthermore, the human 
pancreatic progenitors do not express the TF NKX2.2; however, this protein is later 
expressed in endocrine progenitors. Another substantial difference between human and 
mouse is the composition and morphology of the islet. In human, α- and β-cells are evenly 
distributed throughout the islet and present at a ratio of 1:1 (α: β), while in mice, α- and β-
cells are located at the islet periphery and core, respectively and their ratio is approximately 
1:4 (α: β). These differences in composition and morphology between mouse and human 
islets implicate distinct functions. For example, it has been shown that human islets do not 
show synchronized Ca2+ oscillations in response to glucose compared to the mouse islets. 
Moreover, due to the high number of α-β contacts in human islets it was proposed that alpha 
cells might regulate  β-cell function, which is in line with α-β  communication positively 
regulating glucose-stimulated insulin secretion (GSIS) (Cabrera et al., 2006; Huypens et al., 
2000; Wojtusciszyn et al., 2008). The knowledge gained from human development will help 
us to generate fully functional β-cells from stem cells in the coming years, which could be 
used for cell therapy and will aid the understanding of the human pancreas development. 
 
1.9 β-cell differentiation from pluripotent stem cells 
 
Understanding human pancreas development is fundamental to treat endocrine pancreas-
associated diseases. One promising treatment is replacing or re-generating β-cell mass. Due 
to limited human islets from cadaveric donors, directed differentiation of hESCs or hiPSCs 
into mature insulin-producing cells is a promising approach and might provide an unlimited 
source of material for cell therapy in the future. The first report of insulin-producing cells 
generated from hESCs was published in 2001 using spontaneous differentiation (Assady et 
al., 2001). More recently, D’Amour et al established a protocol to differentiate hESCs into 
cells of the pancreatic lineages using small molecules (D’Amour et al., 2006). Similar 
protocols were then published by other groups (Rezania et al., 2012; Xu et al., 2011). Those 
protocols relied on Activin A and WNT for definitive endoderm induction, and retinoic acid 
(RA) and inhibitors of sonic hedgehog (Shh) and bone morphogenetic protein (BMP) for 
inducing the pancreatic differentiation. However, a low percentage of the generated cells 
were insulin positive. Furthermore, these cells also expressed other hormones, such as 
glucagon (GCG) and somatostatin (SST), but not β-specific TFs, such as PDX1, NKX6.1. 
Importantly, when these in vitro generated pancreas progenitors were transplanted into mice, 
 15 
they were fully differentiated into mature endocrine and exocrine cells. Specifically, these 
endocrine cells were functional and responsive to glucose and were able to regulate glucose 
homeostasis in diabetic animal models.  
In order to generate mono-hormonal and functional β-cells in vitro, researchers have 
developed new protocols to improve differentiation. In 2014, the Melton and Kieffer groups 
both reported the generation of glucose-responsive β-cells from hPSCs through several 
stages that mimic pancreas development in vivo (Figure 1.6 and Figure 1.7) (Pagliuca et al., 
2014; Rezania et al., 2014). Later on, the Hebrok group also developed a short and more 
simple protocol to generate β-cells from hPSCs in vitro (Figure 1.8) (Russ et al., 2015). Most 
of the hPSC-derived β-cells from these three labs are mono-hormonal, express the relevant 
TFs, including the PDX1, NKX6.1 and MAFA, and are responsive to glucose in a static assay. 
Furthermore, diabetes reversal in a mouse model following hPSC-derived β-cells 
transplantation was faster compared to the previous publications using hPSC-derived 
pancreas progenitors for transplantation. However, these stem cell-derived β-cells (SC-β) 
were less functional compared to the human islets. Specifically, the SC-β cells failed to 
rapidly secrete insulin in dynamic perfusion assays. In order to improve the β-cell function, 
the Hebrok group used a method of isolating and re-aggregating immature SC-β cells to form 
islet-sized enriched β-clusters to improve the maturity (Nair et al., 2019). Also recently, the 
Millman group modulated transforming growth factor β signaling, using an enriched serum-
free media to generate SC-β cells with first- and second-phase dynamic insulin secretion 
similar to that of human islets (Velazco-Cruz et al., 2019). Although the SC-β cells generated 
by those two groups have greatly improved β-cell function, allowing us to study the β-cell 
physiology and functional toxicology, the expression of maturation markers such as MAFA 
and UCN3 is still much lower compared to that of human islets. This suggests that we still 
have a long way to go before making fully functional mature β cells from stem cells.  
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Figure 1.6 Overview of the seven-stage differentiation protocol from the Kieffer lab. 
(The figure is modified from Rezania et al., 2014). 
 
 
Figure 1.7 Overview of the differentiation protocol from the Melton lab. (The figure is 
modified from Pagliuca et al., 2014). 
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Figure 1.8 Overview of the differentiation protocol from Hebrok lab. (The figure is 
modified from Russ et al., 2015). 
 
1.10 Diabetes disease modeling using human iPSCs 
 
Patient-derived iPSCs can be used to study disease mechanisms and to develop novel 
therapies. Therefore, iPSCs have been generated from patients carrying mutations in a 
single gene that causes MODY types 1, 2, 3, 5 and 8, or Wolfram syndrome (Kondo et al., 
2018). The Gadue and Huangfu groups investigated the function of GATA6 during human 
pancreas development using human PSCs and gene editing technologies (Shi et al., 2017; 
Tiyaboonchai et al., 2017). Haploinsufficient GATA6 mutations are associated with human 
pancreatic agenesis. However, mice lacking Gata6 expression do not develop obvious 
pancreatic defects (Carrasco et al., 2012). Both studies consistently showed that GATA6 
haploinsufficiency has only a mild effect on pancreas development but instead affects β-cell 
differentiation and function.  
The Egli group generated a patient iPSC line with Wolfram syndrome (Shang et al., 2014), 
which is caused by WFS1 mutations leading to diabetes mellitus. However, the phenotype 
observed from animal models for Wolfram syndrome is different from that observed in 
humans, necessitating the use of human model systems. The investigators showed 
increased endoplasmic reticulum (ER) stress level and a decrease in β-cell numbers in 
differentiations from Wolfram syndrome iPSCs. These cells also failed to respond to glucose. 
Subsequently, the Egli group reported the generation of a permanent neonatal diabetes 
mellitus (PNDM) patient iPSC line carrying a point mutation in the start codon of the insulin 
gene (Ma et al., 2018). Furthermore, gene-editing technology was used to correct the 
mutation in the patient iPSCs (Ma et al., 2018). It was found that pancreatic endocrine cells 
derived from patient iPSCs expressed β-cell makers and insulin mRNA, but did not have 
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insulin protein. In contrast, the corrected iPSCs could be differentiated to pancreatic 
endocrine cells that produced the same levels of insulin compared to those of controls (Ma et 
al., 2018). At the same time, the Otonkoski group also reported the establishment of a 
different patient-derived iPSC model of neonatal diabetes (Balboa et al., 2018). In this study, 
the author’s generated iPSCs from patients carrying INSULIN gene mutations and 
engineered isogenic CRISPR/Cas9 mutation-corrected lines, which were differentiated into 
β-like cells. Insulin-mutant β-like cells showed reduced insulin secretion and increased ER-
stress upon transplantation into mice. Moreover, cell size, mTORC1 signaling and respiratory 
chain subunits expression were reduced in insulin-mutant β-like cells. Furthermore, the 
Otonkoski group investigated the function of STAT3 during human pancreas development 
using hiPSCs (Saarimäki-Vire et al., 2017). Activating germline mutations in STAT3 was 
recently identified as a cause of neonatal diabetes mellitus associated with β-cell 
autoimmunity. This study revealed that the K392R STAT3 mutation could cause premature 
endocrine differentiation through direct induction of NEUROG3 expression. In summary, 
stem cell differentiations combined with gene-editing technologies enable the study of human 
β-cell formation and pathomechanisms, and may provide a valuable source of β-cells for 
therapy in the future (Zeng et al., 2016). 
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1.11 Aims of the thesis 
 
Maturity Onset Diabetes of the Young (MODY) is a monogenic form of diabetes with an 
autosomal dominant inheritance pattern, however the pathomechanisms of MODY4 have not 
been understood well. Therefore, in this thesis, I used hiPSCs to model monogenic diabetes 
in order to understand the following questions: 
Aim 1: Analysis of PDX1 target genes in human pancreatic progenitors 
In human, homozygous loss-of-function mutations of PDX1 leads to pancreas agenesis, 
whereas heterozygous mutations can contribute to MODY4 or T2D. How PDX1 controls 
human pancreas development is not understood well. It is clear that the role of PDX1 is 
different in pancreas progenitors (PPs) and in adult β cells; however, the PDX1 target genes 
and binding patterns in PPs and in adult β-cells have not been well investigated. Furthermore, 
it has been reported that single nucleotide polymorphisms (SNPs) may contribute to T2D and 
are located in islet enhancers (Pasquali et al., 2014). However, whether these regions with 
SNPs are bound by PDX1 or these regions are active in PPs has not been investigated so 
far. The first aim of the project was to identify the PDX1 target genes at the PP stage and to 
analyze the PDX1 binding pattern in PPs and in adult β-cells. Furthermore, the additional aim 
of this project was to screen PDX1-bound SNPs and to check whether these regions carry 
SNPs or PDX1-bound SNPs are active. This will help us to understand how PDX1 
coordinates early pancreas development at the molecular level, with the purpose of 
improving in vitro-directed differentiation of functional β-cells from stem cells in the future. 
Aim 2: Analysis of the consequences of point mutations in the PDX1 transactivation 
domain during human β-cell development and function 
Heterozygous amino acid exchanges in the coding region of PDX1 predispose to type 2 
diabetes mellitus but the underlying mechanisms are poorly understood. The second aim of 
the project was to screen human subjects with a high risk of developing diabetes and identify 
patients carrying mutations in the PDX1 gene. Furthermore, the additional aim of this project 
was to investigate how these common mutations (PDX1 C18R and P33T) affect human 
pancreas development and function using stem cell, CRISPR/Cas9 and in vitro differentiation 
technologies. This will help to better understand disease progression on the molecular level 
and might improve the diagnosis and therapy of diabetic patients. 
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2 Discussion 
 
2.1 Genome-wide analysis of PDX1 target genes in human pancreatic 
progenitors 
 
One promising approach for the treatment of diabetes is to restore β-cell mass using cells 
generated from directed differentiation of hESCs and hiPSCs (Benthuysen et al., 2016). 
Stem cells have the potential to provide unlimited material; however, the efficient generation 
of fully functional and mature β-cells still remains a major challenge (Pagliuca et al., 2014; 
Rezania et al., 2014; Russ et al., 2015). Due to the incomplete understanding of the 
molecular pathways orchestrating pancreas development, current protocols used for the 
generation of β-cells fail to fully mimic the in vivo development. Therefore, it is crucial to 
understand the molecular mechanisms and gene regulatory networks controlling the 
specification of early human pancreatic lineages, in order to generate β-cells with similar 
physiological functions as in mature human islets. PDX1 plays a crucial role during pancreas 
development, yet the temporal expression patterns of its target genes during human 
development are not well characterized. In the first study, we performed a genome-wide 
analysis of PDX1 target genes in human pancreatic progenitors (PPs). This identified novel 
target genes that are important in human pancreas development and might help to improve 
the directed differentiation of functional β-cells in vitro. 
 
2.1.1 The PDX1 binding sites at pancreatic progenitors 
 
Although the target genes of Pdx1 are well studied in mice (Ohlsson et al., 1993; Oliver-
Krasinski et al., 2009; Svensson et al., 2007), it is not clear what are the PDX1 target genes 
at the pancreatic progenitor (PP) stage in humans. Furthermore, as PDX1 plays different 
roles in PPs and β-cells, it remains unclear how PDX1 target genes change during the 
process of pancreas and endocrine cell development. To address these questions, we 
generated a novel integration-free iPSC line from a healthy individual and established a 
highly efficient differentiation protocol towards early pancreatic progenitors. With this 
protocol, we differentiated our new iPSC line into early pancreatic progenitors, and 
performed PDX1 and H3K27ac chromatin immunoprecipitation (ChIP-seq) and mRNA 
profiling. Global characterization of PDX1 binding sites in iPSC-derived PPs identified in total 
8088 PDX1-binding sites that map to 5644 genes. Those genes included developmental 
regulatory factors, GATA4 and HNF1B, and TFs such as PDX1, NKX2-2 and RFX6, which 
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are important for mature β-cell function. Many of the PDX1-bound genes are differentially 
expressed between iPSCs and PPs. Moreover, several identified PDX1 target genes have 
not been previously reported in humans. Among these, RFX3 and DLL1 play important roles 
in mouse pancreas development (Ait-Lounis et al., 2010; Apelqvist et al., 1999; Kim et al., 
2010).  RFX3 is a member of the regulatory factor X family of transcription factors and 
contains a highly conserved winged helix DNA-binding domain (Reith et al., 1994). 
Homozygous Rfx3 knockout mice have reduced numbers of β-cells with decreased mRNA 
levels of insulin, Slc2a2 (Glut2) and Gck, resulting in glucose intolerance and impaired 
glucose-stimulated insulin secretion in these animals. These findings demonstrate that Rfx3 
is important for the differentiation and function of mature β-cells in mice (Ait-Lounis et al., 
2010). DLL1 is one of the Notch ligands. Notch signaling is important for the differentiation 
and maintenance of pancreatic cells. Dll1 Knockout mice have increased expression of 
Ngn3, which causes premature depletion of the endocrine progenitor pool and accelerates 
differentiation of pancreatic progenitors to the endocrine cells, ultimately leading to abnormal 
pancreatic development (Apelqvist et al., 1999; Kim et al., 2010). However, the roles of RFX3 
and DLL1 in human pancreas development have not been investigated so far.  
To our knowledge, here we report the PDX1 CHIP-seq on hiPSC-derived early PPs. 
Surprisingly, however, we found significant differences in PDX1 binding pattern compared to 
previous PDX1 datasets from hESC-derived PPs (Teo et al., 2015; Wang et al., 2015). Many 
theories could explain these different results. First, the efficiency of differentiation towards 
the PDX1+ cells at PP stage is different between our system and the previous reports. For 
instance, Teo et al. (2015) generated around 65% PDX1+ cells at PP stage compared to 
around 85% PDX1+ cells with our differentiation protocol. Second, the basic medium and 
factors used for pancreatic progenitor differentiation protocol differ, Teo et al. (2015) used 
Activin A, BMP4 for endoderm and FGF2, Retinoic acid, Nicotinamide and DAPT for PP 
stage; in contrast, our protocol uses Activin A and Wnt3A for endoderm, and FGF7, SANT-1, 
Retinoic acid and Noggin for PP.  These different protocols may produce different patterning 
of gut tube towards ventral/dorsal pancreas and pancreas/duodenum/stomach progenitors  
Moreover, one of the best protocols from the Melton group still produced gut endocrine cells 
in the islet cells differentiation (Veres et al., 2019), suggesting that the correct patterning of 
early pancreas development is not yet fully understood. Lastly, it is likely that the cells used 
for ChIP-seq experiments in different laboratories differ regarding their exact stage; this could 
explain many of the differences between our data and those from Wang et al., 2015, as their 
cells already expressed NKX6.1. It is well known that TF targets are dynamically activated 
over time (early response genes vs late response genes), thus the difference might reflect 
temporal changes of TF target gene activation. Collectively, the reported PDX1 binding sites 
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differ between labs with different protocols and different cell lines; therefore, it is important to 
compare all the PDX1 binding datasets and use the overlap of the PDX1 binding sites. 
 
2.1.2 The functions of PDX1 in development and adult  
 
During pancreas development, PDX1 starts to be expressed in the early pancreatic buds and 
duodenum, but its expression becomes restricted to β-and δ-cells of the pancreatic islets and 
the selected cells of the duodenum and stomach. This suggests that the functions of PDX1 in 
the early pancreatic progenitors and in the mature islets can be different. Therefore, we 
compared the PDX1 binding sites in iPSC-derived PPs to those in the adult human islets. 
Our results showed that only 15% of PDX1-bound genes are shared between PPs and adult 
human islets. In adult islets, specific PDX1-bound genes are related to the β-cell function 
such as insulin secretion, energy metabolism and β-cell maturation. These islet-specific 
PDX1-bound genes include the K+ channel KCNJ11 and the glucose transporter SLC2A2, 
which are essential for adult β-cell function, and TFs such as NKX6-1 and MAFA, which play 
an important role in β-cell maturation. On the other hand, in PPs, the specific PDX1-bound 
genes are related to early pancreas development. These PP-specific PDX1-bound genes 
include TFs GATA4, HHEX and HNF1A. The common PDX1-bound genes include TFs 
NKX2-2 and PAX4, which are associated with endocrine development. This data suggest 
that PDX1 binding is dynamic during pancreas development to meet different stage-specific 
functional requirements. Identifying the PDX1 target genes in PPs and in human islets will 
help us to understand stage specific function of PDX1 and also help us to identify genes and 
pathways that are dysregulated in dedifferentiated diabetic β-cells. 
 
2.1.3 The diabetes risk of early pancreas development 
 
Single-nucleotide polymorphisms (SNPs) are a very common type of genetic variation. Most 
SNPs are located in the non-coding regions, hence they often have no effect on human 
development or health (Shastry, 2002). However, some SNPs can increase the risk of a 
particular disease. Most T2D-associated SNPs occur in the non-coding regions and can 
increase the susceptibility to T2D. Furthermore, it has been shown that the active regulatory 
regions in the adult islets harbor a plethora of T2D-associated SNPs (Pasquali et al., 2014). 
Some T2D-associated SNPs can affect DNA-binding of a given TF or change the activity of 
an enhancer (Pasquali et al., 2014). Interestingly, we also found the active regulatory regions 
at the pancreatic progenitor stage to be enriched in T2D-associated SNPs. This suggests 
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that the genetic variation of these regions may interfere with the regulation of gene 
expression at the PP stage and further affect the developmental programs. Consequently, 
T2D-associated SNPs might cause decreased β-cell mass at birth and therefore the 
susceptibility to T2D is increased. This is in agreement with the previous findings that the β-
cell mass in children is different and individuals with lower β-cell mass have higher risk of 
diabetes (Meier and Bonadonna, 2013; Meier et al., 2008). We identified three SNPs within 
stage-specific binding site of PDX1 at PP stage. Among them is the SNP rs11263763, 
located in the first intron of HNF1B and a recent study showed that rs11263763 can 
downregulate the mRNA level of HNF1B (Painter et al., 2015). In addition, there are several 
SNPs in the first and second intron of HNF1B, which are associated with T2D. In mice, Hnf1β 
plays an important role in the regulation of proliferation and survival in multipotent pancreatic 
progenitors and the loss of this gene leads to pancreatic hypoplasia. Furthermore, Hnf1β 
regulates the Ngn3 expression, which in turn drives the specification of endocrine progenitors 
(Cereghini et al., 2015). In humans, heterozygous mutations in the HNF1B gene cause 
MODY5 (Horikawa et al., 1997); however, the function of HNF1B in human pancreas 
development is not well understood. A recent study showed that HNF1BS148L/+ causes 
pancreatic hypoplasia and has a compensatory up-regulation of key TFs such as FOXA2, 
SOX17 and PDX1 during early development (Teo et al., 2016). Another two SNPs, 
rs12762233 and rs7087006 within PP-specific PDX1 binding sites are very closely located to 
the gene TCF7L2. This gene, also known as Tcf4, is a transcription factor involved in the 
canonical Wnt pathway (Lickert et al., 2000). GWAS studies showed that this gene is the 
most significant T2D risk gene and SNPs within theTCF7L2 locus have the highest risk for 
developing T2D in Europeans (McCarthy and Zeggini, 2009). In mouse, Tcf7l2 plays a 
crucial role in β-cell development and function, and the regulation of β-cell mass (da Silva 
Xavier et al., 2012). In human, TCF7L2 regulates β-cell survival and promotes β-cell 
generation, and individuals carrying the polymorphisms have impaired insulin secretion 
(Schäfer et al., 2007; Shu et al., 2008). TFs HNF1B and TCF7L2 play an important role in the 
pancreas development. These three SNPs in PDX1-bound regions might affect early 
pancreas developmental processes that increase the susceptibility to develop T2D later in 
adulthood. In the future, it will be interesting to study whether these three SNPs affect human 
pancreas development using stem cell and gene editing technologies. 
 
2.2 Point mutations in the PDX1 transactivation domain impair human 
β-cell development and function 
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Due to differences among species, it is important to understand the mechanism behind 
human endocrine cell formation, function and failure.  However, due to the scarcity of human 
primary material, it is difficult to study the dynamics of pancreas development in humans 
(Bakhti et al., 2019). By using established protocols for in vitro differentiation of β-cells from 
pluripotent stem cells (Pagliuca et al., 2014; Rezania et al., 2014; Russ et al., 2015), we can 
mimic human pancreas development in a culture dish and establish diabetes models that can 
be used to identify pathomechanisms and for drug screenings. Furthermore, these 
technologies can be used to study the effects of mutations of MODY genes during the 
pancreas development, which will help to find new target genes for drug screening. For 
example, it has been shown that sulfonylurea can be used for treating diabetes caused by 
the mutation of the potassium channel (Hattersley and Ashcroft, 2005). 
 
2.2.1 The impact of P33T and C18R on PDX1 expression 
 
We generated human iPSCs from patients carrying common heterozygous mutations (P33T, 
C18R) in the PDX1 gene and used in vitro differentiation system to study the impact of these 
mutations on human pancreas development and function. To exclude the effect from the 
genetic background and to study dose-dependent effects, we also generated homozygous 
iPSC lines of these two mutations from the control iPSC line. We found that both mutations 
affected human β-cell development and function. Interestingly, PDX1P33T/+, PDX1C18R/C18R and 
PDX1C18R/+ mutations did not affect early pancreas development. However, PDX1P33T/P33T 
impacted the early stage of pancreas development by reducing the protein level of PDX1, 
which in turn decreased NKX6.1 expression at the PP2 stage. It has been shown that Pdx1 
can regulate its own expression in a positive auto-regulatory manner (Gerrish et al., 2001; 
Gerrish K. et al., 2004; Marshak et al., 2000).  In the P33T mutation, replacement of proline 
with threonine may cause severe changes in the structure of the PDX1 transactivation 
domain and further affect the recruitment of transcriptional co-activators required for the 
induction of target gene expression, including PDX1 itself. We also found that expression of 
lncRNA PLUTO was upregulated in the PDX1P33T/P33T mutant PP cells. It has been reported 
that PLUTO can regulate PDX1 expression (Akerman et al., 2017). In Endoc-βH1 cells and 
human islets, knockdown of PLUTO leads to decreased PDX1 mRNA expression. In our 
system, upregulated expression of the lncRNA PLUTO in the PDX1P33T/P33T mutant PP cells 
might act to compensate for the reduced PDX1 expression. Due to reduction in PDX1 levels 
at PP1 stage, the differentiation efficiency of PDX1P33T/P33T iPSCs towards the PP2 stage was 
significantly decreased. This is in line with the fact that the high protein levels of PDX1 are 
important for the induction of endocrine progenitors during endocrine-lineage specification 
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(Mamidi et al., 2018). Thus, the reduced levels of PDX1 in human PDX1P33T/P33T mutant 
progenitors perturb the endocrine-lineage specification. This is also in line with the 
phenotype we found in the PDX1P33T/P33T and PDX1+/- iPSC lines, which suggests that the 
P33T mutation causes a significant loss-of PDX1 function. Interestingly, PDX1 levels at PP1 
and PP2 stages are not affected in PDX1C18R/C18R mutants. These differences might be due to 
the different effects on these two mutations on the PDX1 protein structure. 
 
2.2.2 The down-regulated genes in mutant PPs 
 
Through RNA-seq profiling, we found 21 genes that were consistently down-regulated in all 
isogenic mutant PPs compared to the control. These include insulin resistance-associated 
genes MEG3 and CES1 and diabetes risk genes LARGE1 and ANPEP. MEG3 is a 
maternally expressed and imprinted gene, which codes for a long noncoding RNA. In the 
mouse, Meg3 is located in the distal region of chromosome 12, and in humans, it is located 
in the syntenic region of chromosome 14. It has been shown that expression of Meg3 is 
important for the function of pancreatic β-cells including insulin synthesis and secretion (You 
et al., 2016). In humans, islets from T2D patients have lower levels of MEG3 gene 
expression compared to islets from healthy subjects, which suggests MEG3 might be 
important for human β-cell development and/or function (Kameswaran et al., 2014). 
Furthermore, MEG3 is bound by PDX1. The next deregulated gene is Carboxylesterase 1 
(CES1). It is highly expressed in fat tissue, gall bladder, lung and stomach. Furthermore, 
Ces1 is associated with obesity, hepatic steatosis and hyperlipidemia. Ces1 knockout mice 
show abnormal insulin tolerance in muscles and adipose tissue (but not in the liver) and 
impaired energy homeostasis (Quiroga et al., 2012). In humans, dysregulation of CES1 is 
linked to abnormal insulin resistance and an increased risk of obesity (Marrades et al., 2010). 
Furthermore, it has been reported that some mutations in LARGE1 could increase the risk of 
diabetes by enhancing insulin resistance, and some SNPs in the ANPEP gene are linked to 
increased risk of diabetes (Grarup et al., 2018; Locke et al., 2015). Although MEG3, CES1 
and LARGE1 are associated with diabetes and they regulate insulin resistance, it has not 
been investigated whether these genes play a role in human β-cell development and 
function. It will be interesting to study these genes using stem cell models in the future. Due 
to the homozygous P33T mutation affecting PDX1 protein levels, many genes are commonly 
downregulated in the PDX1P33T/P33T and PDX1+/- PPs, including the TF MNX1 and the 
imprinted gene NEURONATIN (NNAT). During embryonic and postnatal stages in mouse, 
MNX1 initiates and maintains β-cell homeostasis (Pan et al., 2015). Homozygous mutation in 
MNX1 in humans can cause permanent neonatal diabetes mellitus (PNDM) (Flanagan et al., 
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2014); however, how MNX1 coordinates human β-cell development needs to be investigated. 
NNAT is an imprinted gene and is strongly expressed in the brain, endocrine tissues, 
placenta and metabolic tissues including muscles, pancreas, duodenum and small intestine. 
Moreover, expression of NNAT can be regulated by hormones and glucose (Millership et al., 
2018). SNPs in the NNAT gene can contribute to risk of obesity (Vrang et al., 2010). In 
mouse, knockout of Nnat in β-cells shows reduced insulin content and affects glucose-
stimulated insulin secretion (Millership et al., 2018), which suggests a role in β-cell function. 
However, the function of NNAT in human pancreas development has not been investigated 
yet. Considering the fact that Nnat is important for mouse pancreas development and NNAT 
is bound by PDX1, it would be interesting to study its function in human pancreas 
development and β-cell function. 
 
2.2.3 The common deregulated genes in PDX1P33T/+ and PDX1P33T/P33T mutant 
PPs 
 
Since the PDX1P33T/+ patient was diagnosed with gestational diabetes before, we further 
investigated differentially expressed genes in the heterozygous P33T mutant cell line. 
Moreover, we were interested to find common deregulated genes in PDX1P33T/+ and 
PDX1P33T/P33T PPs.  In total, 88 genes were deregulated in PDX1P33T/+ PPs compared to the 
control PPs, of which 21 genes were bound by PDX1. Most of the deregulated genes are 
associated with pancreas development and insulin secretion. The comparison between 
PDX1P33T/+ PPs and PDX1P33T/P33T PPs showed 5 genes that have the same expression 
pattern. These five genes are ZNF676, C19orf33, MEG3, NNAT and POSTN. It has been 
shown that the ZNF676 can regulate human telomere homeostasis (Mangino et al., 2012). 
MEG3 and NNAT are linked to insulin secretion. Periostin, which is encoded by the POSTN 
gene, plays an important role in bone, tooth and heart development and also stimulates EMT 
(epithelial-mesenchymal transformation) (Yan and Shao, 2006). Postn knockout mice show 
impaired β-cell regeneration and the injection of Periostin into the adult pancreas can 
enhance the regeneration of β-cells and further improve the glucose tolerance (Smid et al., 
2015). Therefore, it is evident that MEG3, NNAT and POSTN are playing an important role in 
pancreas and β-cell biology. Especially, MEG3 and NNAT might regulate the mature function 
of human β-cells and Periostin might be important for the differentiation transition from 
pancreas progenitors to endocrine progenitors by undergoing transient EMT; however, their 
exact function in human pancreas development still needs to be investigated in future 
studies. 
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2.2.4 The impact of P33T, C18R on human β-cell development and function  
 
Both PDX1P33T/P33T and PDX1C18R/C18R mutations impair human β-cell development and 
function by downregulating gene expression of important TFs, such as NEUROD1 and ISL1.  
Furthermore, the expression levels of UCN3 are downregulated in PDX1P33T/P33T and 
PDX1C18R/C18R β-cells. These data suggest that the proper PDX1 TF function is important for 
β-cell development and maturation, which is in line with the previous studies of Pdx1 in 
rodents (Bastidas-Ponce et al., 2017). Our group has shown that loss of proper TF Pdx1 
activity impairs the β-cell maturation in male double knock-in reporter mice and causes 
diabetes and downregulation expression levels of Ucn3 (Bastidas-Ponce et al., 2017). 
Furthermore, female mice develop gestational diabetes during pregnancy but are generally 
protected from the development of T2D (Bastidas-Ponce et al., 2017). As mentioned 
previously, the PDX1P33T/+ patient had gestational diabetes and homozygous P33T mutation 
reduces the UCN3 expression in iPSCs-derived β-cells. This suggests that β-cells from this 
patient might be very heterogeneous in terms of their functionality, which can become 
obvious under stress conditions. This is very similar to the above-described mouse model, 
which suggests an evolutionarily conserved function of PDX1 in β-cell development and 
function.  
The β-cells from PDX1 mutant iPSC lines were less functional compared to the control as 
shown by static GSIS. It has been shown that reduction of Pdx1 in mice affects GSIS by 
reducing the Glut2 expression (Brissova et al., 2002). INS, ABCC8, KCNJ11, SLC30A8 were 
downregulated in β-like cells carrying PDX1P33T/P33T and PDX1C18R/C18R mutations. This finding 
highlights the importance of this TF in insulin synthesis and secretion in human β-cells. This 
is also in line with the result that even heterozygous P33T or C18R mutant PDX1 protein can 
decrease the binding activity to the human insulin promoter and reduce the insulin 
expression level in INS-1 and NES2Y cell lines (Gragnoli et al., 2005; Macfarlane et al., 
1999). 
In summary, we found common heterozygous and homozygous missense mutations in the 
transactivation domain of PDX1 resulting in the reduction of target gene expression in 
pancreatic progenitors and insulin-producing β-cells, which further impairs β-cell 
development and function. Furthermore, we found that the more common P33T (compared 
to C18R) amino-acid exchange leads to a loss of target gene activation already at the 
pancreatic progenitor stage in a heterozygous and homozygous background. This systematic 
functional analysis of coding mutations in genes associated with diabetes predicts an 
increased risk and predisposition for T2D. 
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3 Materials and methods 
 
3.1 Human iPSC lines generation 
 
Primary fibroblasts from patients and controls were provided by the Medical Faculty of the 
Eberhard Karls University, Tübingen.  Fibroblasts were reprogrammed into pluripotent stem 
cells by using a non-integrating Episomal iPSC Reprogramming Kit (Invitrogen, 
Cat.no.A14703). This kit was mixed with three vectors having the oriP/EBNA-1 (Epstein-Barr 
unclear antigen-1) backbone that delivers six reprogramming TFs: OCT4, SOX2, NANOG, 
LIN28, KLF4, and L-MYC. Fibroblasts were transfected using the Amaxa 4D-Nucleofector 
transfection system. After transfection, Cells were plated onto geltrex-coated culture dishes 
and incubated in supplemented fibroblast medium. This medium was prepared with knockout 
DMEM/F-12 (Life technologies), 10% FBS of ESC-qualified (Life technologies), 1% MEM 
non-essential amino acids (Life technologies), 10 uM HA-100 (Santa Cruz) and 4 ng/ml 
bFGF (Life technologies). 24 hours after transfection, the medium was switched to N2B27 
medium including 0.5 µM PD0325901 (Stemgent), 3 µM CHIR99021 (Stemgent), 0.5 µM A-
83-01 (Stemgent), 10 µM HA-100 (Santa Cruz), 10 ng/ml hLIF (Life technologies) and 100 
ng/ml bFGF. The basic N2B27 medium was prepared with DMEM/F12 with HEPES (Life 
technologies), 1x N2 supplement (Life technologies), 1x B27 supplement (Life technologies), 
1% MEM non-essential amino acids, 1x Glutamax (Life technologies) and 1x β-
Mercaptoethanol (Life technologies). On day 15 after transfection, the medium was switched 
to the Essential 8 medium. Around 3 weeks after transfection, undifferentiated iPS colonies 
were picked and expanded.  
 
3.2 iPSC characterization 
 
DNA from hiPSCs was extracted using in-house standard procedure. In order to exclude the 
transgene integration, markers for the episomal backbone were amplified by semi-
quantitative PCR. Primers are as follows: oriP forward: TTCCACGAGGCTAGTGAACC. oriP 
reverse: TCGGGGGTGTTAGAGACAAC; EBNA-1 forward: ATCGTCAAAGCTGCACACAG. 
EBNA-1 reverse: CCCAGGAGTCCCAGTAGTCA. For karyotype analysis, the hiPSCs 
growing in logarithmic phase were used for experiments. Once the hiPSCs were ready and 
treated with colcemid for 2 hours. After that, hiPSCs were trypsinized, treated with hypotonic 
solution (0.075 M KCl) for 20 min and fixed with methanol: acetic acid (3:1). Metaphases of 
hiPSCs were spread on microscope slides. Using the standard G banding technique, 
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chromosomes were classified according to the International System for Human Cytogenic 
Nomenclature. For teratomas, 2x106 iPSCs were injected into the right hind leg of 
immunocompromised NOD/SCID mice. After 2 months, the teratomas were excised, fixed, 
embedded in paraffin, sectioned and stained with hematoxylin/eosin. 
 
3.3 Cell culture  
 
hiPSCs were cultured on Matrigel (BD Biosciences, CA, Cat #354277) in mTeSR™1 medium 
(STEMCELL technologies, Cat #85850). At ~70–80% confluency, cells were washed once 
with 1× DPBS without Mg2+ and Ca2+ (Invitrogen, Cat #14190) and incubated with TrypLE 
Select Enzyme (1×) (Life Technologies, Cat #12563011) for 3–5 min at 37 °C. Single cells 
were rinsed with mTeSR™1 medium, and spun at 1,000 rpm for 3 min. The resulting cell 
pellet was re-suspended in mTeSR™1 medium supplemented with 10 μM Y-27632 (Sigma-
Aldrich; MO, Cat #Y0503), and the single cell suspension was seeded at ~0.75 × 105 
cells/cm2 on Matrigel-coated surfaces. Cultures were fed every day with mTeSR™1 medium 
and differentiation was initiated 72 h following seeding with ~90% starting confluency. All the 
cell lines were mycoplasma free. 
 
3.4 1st pancreatic lineage differentiation protocol 
 
3.4.1 S1: definitive endoderm  
 
Cells were first washed once with 1× DPBS without Mg2+ and Ca2+ and then switched to 
MCDB 131 medium (Life Technologies, Cat #10372-019) further supplemented with 1.5 g/l 
sodium bicarbonate (Sigma, MO, Cat #S6297), 1× Glutamax (Life Technologies, Cat 
#35050-079), 10 mM final glucose (Sigma, Cat #G8769) concentration, 0.5% bovine serum 
albumin fraction V, fatty acid free (Sigma, Cat # 10775835001), 100 ng/ml Activin-A (R&D 
Systems Inc, Cat #338-AC-050/CF), and 3 μM or 5 μM of CHIR-99021 (GSK3β inhibitor, 
SelleckChem, Cat #S2924) for day 1. At day 2, MCDB 131 medium with 0.5% BSA, 1.5 g/l 
sodium bicarbonate, 1× Glutamax, 10 mM glucose, 100 ng/ml Activin-A and 0.3 μM CHIR-
99021 was added to the cells. At day 3, MCDB 131 with 0.5% BSA, 1.5 g/l sodium 
bicarbonate, 1× Glutamax, 10 mM glucose and 100 ng/ml Activin-A was added to the cells. 
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3.4.2 S2: primitive gut tube 
 
Cells were washed once with 1× DPBS without Mg2+ and Ca2+ and further cultured in MCDB 
131 medium further supplemented with 1.5 g/l sodium bicarbonate, 1× Glutamax, 10 mM 
final glucose concentration, 0.5% BSA, 0.25 mM ascorbic acid (Sigma, Cat #A4544), 50 
ng/ml FGF7 (R & D Systems, Cat #251-KG-010/CF) or/and 1.25 μM IWP-2 (Tocris 
Bioscience, Cat #3533) for 2 d. 
 
3.4.3 S3: posterior foregut 
 
Cells were then exposed to  MCDB 131 medium supplemented with 2.5 g/l sodium 
bicarbonate, 1× Glutamax, 10 mM glucose concentration, 2% BSA, 0.25 mM ascorbic acid, 
50 ng/ml FGF7, 0.25 μM SANT-1 (Sigma, Cat #S4572), 1 μM retinoic acid (RA; Sigma, Cat 
#R2625), 100 nM LDN193189 (LDN; BMP receptor inhibitor, Stemgent, CA, Cat #04-0019), 
1:200 ITS-X (Life Technologies, Cat #51500056), and 200 nM TPB for 2 d (PKC activator, 
custom synthesis, ChemPartner).  
 
3.4.4 S4: pancreatic endoderm 
 
MCDB 131 medium supplemented with 2.5 g/l sodium bicarbonate, 1× Glutamax, 10 mM 
final glucose concentration, 2% BSA, 0.25 mM ascorbic acid, 2 ng/ml of FGF7, 0.25 μM 
SANT-1, 0.1 μM retinoic acid, 200 nM LDN193189, 1:200 ITS-X, and 100 nM TPB  was 
added to the cells for 3 d. 
After 3 d of culture, 10 μM Y-27632 was added to the S4 cells for 4 h before further 
experiments. Cells were then washed once with 1× DPBS without Mg2+ and Ca2+. TrypLE 
Select Enzyme (1×) (Life Technologies, Cat #12563011) was added to the cells for 3–5 min 
at 37 °C. The released cells were rinsed once with basal MCDB 131 medium and centrifuged 
at 1,000 rpm for 3 min. Cell pellets were exposed to S5-7 media with S5 chemical 
supplements and put onto the membrane of transwell insert filters (6-well plate: Corning 
3414) for air-liquid interface culture. We put 10 µl/spot and ~10 spots per well.  Each spot 
was around 0.5 million cells. For each well, ~1.5 ml S5-7 media with supplements were 
added to the bottom of each insert.  
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3.4.5 S5: pancreatic endocrine precursors 
 
S4 Cells were further exposed to MCDB 131 medium supplemented with 1.5 g/l sodium 
bicarbonate, 1× Glutamax, 20 mM glucose, 2% BSA, 0.25 μM SANT-1, 0.05 μM retinoic acid, 
100 nM LDN193189, 1:200 ITS-X, 1 μM T3 (3,3′,5-Triiodo-L-thyronine sodium salt, Sigma, 
T6397), 10 μM ALK5 inhibitor II (Enzo Life Sciences, NY, Cat #ALX-270-445), 10 μM zinc 
sulfate (Sigma, Z0251) and 10 μg/ml of heparin (Sigma, H3149) for 3 d.  
 
3.4.6 S6: immature β-like cells 
 
MCDB 131 medium further supplemented with 1.5 g/l sodium bicarbonate, 1× Glutamax, 20 
mM glucose, 2% BSA, 100 nM LDN193189, 1:200 ITS-X, 1 μM T3, 10 μM ALK5 inhibitor II, 
10 μM zinc sulfate, 100 nM gamma secretase inhibitor XX (EMD MilliPore, MA, Cat #565789) 
and 10 μg/ml of heparin was added to the S5 cells for 7 d. 
 
3.4.7 S7: mature β-like cells 
 
MCDB 131 medium supplemented with 1.5 g/l sodium bicarbonate, 1× Glutamax, 20 mM 
final glucose concentration, 2% BSA, 1:200 ITS-X, 1 μM T3, 10 μM ALK5 inhibitor II, 10 μM 
zinc sulfate, 1 mM N-acetyl cysteine (N-Cys, Sigma, Cat #A9165), 10 μM Trolox (Vitamin E 
analogue, EMD, Cat #648471), 2 μM R428 (AXL inhibitor, SelleckChem, Cat #S2841) and 10 
μg/ml of heparin was added to the S6 cells for 14 d. For all stages of differentiation, the 
medium was changed every day.  
 
3.5 2nd generation pancreatic progenitor differentiation protocol 
 
3.5.1  S1: definitive endoderm 
 
Day 1, iPSCs  were first washed once with 1× DPBS without Mg2+ and Ca2+ (Invitrogen) and 
then exposed to RPMI 1640 medium (Invitrogen, Cat #21875-034) further supplemented with 
1.2 g/L sodium bicarbonate (Sigma), 0.2% ESC-qualified FBS (Life Technologies, Cat 
#16141-079), 100 ng/mL Activin-A (R&D Systems), and 20 ng/mL of Wnt3A (R&D Systems, 
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Cat #5036-WN-010) for day 1 only. Cells were switched to RPMI with 0.5% FBS, 1.2g/L 
sodium bicarbonate and 100 ng/mL Activin-A at day 2 & 3. 
 
3.5.2 S2: primitive gut tube 
 
Cells were washed once with 1× DPBS (without Mg2+ and Ca2+) once and DMEM-F12 (Life 
Technologies, Cat #21041025) medium further supplemented with 2 g/L sodium bicarbonate, 
2% FBS and 50 ng/mL of FGF7 (R&D Systems)  was added to the cells for 3 days. 
 
3.5.3 S3: posterior foregut 
 
DMEM-HG medium (Life Technologies, Cat #41966029) supplemented with 0.25 µM SANT-
1 (Sigma-Aldrich), 2 µM retinoic acid (RA; Sigma-Aldrich), 100 ng/mL of Noggin (R&D 
Systems, Cat #6057-NG-025), and 1% B27 (Invitrogen, Cat #17504044) was added to the 
cells for another 4 days. 
 
3.6 Generation of clonal hiPSC mutant lines using gRNA or 
gRNA/ssDNA transfection in hiPSCs 
 
The established protocol was used to generate all the mutant cell lines. We got the plasmid 
for transfection (pU6-(BbsI) sgRNA_CAG-venus-bpA, Addgene ID86985) as a gift from Dr. 
Ralf Kühn. This plasmid had BbsI site for single or multiple gRNAs, the Venus genes and the 
Cas9 gene. hiPSCs were cultured for two days and then dissociated using TrypLE select. 
The single hiPSCs were replated onto Matrigel-coated plates and after half an hour, hiPSCs 
were transfected in suspension with gRNAs or gRNA/ssDNA using Lipofectamine RNAiMAX 
(Thermo Fisher Scientific, Cat #13778-150) according to manufacturer’s instructions.  0.75 × 
106  hiPSCs were seeded for one well of 6-well plates. 2.5 ug plasmid of gRNA was used for 
one transfection for the PDX1+/- knockout cell lines. For the PDX1 point mutations, 2.5 ug 
plasmid with the gRNA together with 30 pmol ssDNA were added for one transfection. First, 
gRNAs or gRNA/ssDNA and Lipofectamine RNAiMAX were diluted separately in Opti-MEM 
(Thermo Fisher Scientific, Cat # 31985070). After that, the two buffers were mixed together 
for 5 min at room temperature and added to the hiPSCs drop by drop.  
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3.7 Establishment of clonal hiPSC mutant lines 
 
48 hours after the transfection, hiPSCs were dissociated into single cells using TrypLE 
select. We sorted the cells positively expressing Venus by FACS. After that, the sorted 
Venus-positive cells were re-plated at a low density (500-1,000 cells per 10 cm dish). The left 
cells were used to extract genomic DNA. We performed the T7 endonuclease I assay to 
assess the CRISPR mutagenesis efficiency. Individual colonies were picked, mechanically 
disaggregated and replated in mTeSR™1 medium into individual wells of 96-well plates. The 
PCR was performed using Herculase II Fusion DNA Polymerase (Agilent Technologies, Cat 
#600679) followed by Sanger sequencing to screen  mutant clones. Primers for PDX1 are as 
follows: forward: TACCTGGGCCTAGCCTCTTAGTG, reverse: 
TGAGAACCGGAAAGGAGAAAGGG. Clonal cell lines having desired mutations were further 
expanded.  
 
3.8 Immunofluorescence imaging 
 
Cells were fixed with 4% paraformaldehyde, permeabilized and blocked. After that, cells 
were incubated with primary antibodies overnight at 4 °C and later on with the secondary 
antibodies for 1 hour at room temperature. Images were acquired on a TCS SP5 laser-
scanning microscope (Leica). The following antibodies and dilutions were used for our 
experiments: goat anti-OCT-3/4 (1:500, Cat #sc-8628, Santa Cruz), goat anti-SOX2 (1:500, 
Cat #sc-17320, Santa Cruz), mouse anti-TRA-1-81 (1:50, Cat #MAB4381, Millipore), mouse 
anti-SSEA4 (1:500, Cat #4755, Cell Signaling), rabbit anti-FOXA2 (1:250, Cat #8186, Cell 
Signaling), goat anti-SOX17 (1:500, Cat #GT15094, Acris/Novus), goat anti-PDX1 (1:500, 
Cat #AF2419, R&D Systems), rabbit anti-NKX6.1 (1:300, Cat #NBP1-82553, Acris/Novus), 
guinea pig anti-C-Peptide (1:100, Cat #ab30477, Abcam), mouse anti-Glucagon (1:500, Cat 
#G2654, Sigma), rat anti-Somatostatin (1:300, Cat #MA5-16987, Invitrogen). 
 
3.9 Flow cytometry 
 
Cells were dissociated to have single-cell solution using 1× TrypLE Select Enzyme. Cells 
were washed, fixed and permeabilized. After that, the cells were incubated with rabbit anti-
FOXA2 (1:200, #8186, Cell Signaling), goat anti-SOX17 antibody (1:200, Cat #GT15094, 
Acris/Novus), goat anti-PDX1 antibody (1:100, Cat #AF2419, R&D Systems), rabbit anti-
NKX6.1 antibody (1:200, Cat #NBP1-82553, Acris/Novus), guinea pig anti-C-Peptide 
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antibody (1:100, Cat #ab30477, Abcam), mouse anti-Glucagon (1:500, Cat #G2654, Sigma), 
for 30 min at room temperature and then stained with appropriate AlexaFluor-555 and -647 
secondary antibody for 30 min at room temperature. We performed Flow cytometry using 
FACS-Aria III (BD Bioscience). FACS data were analyzed using the software of FlowJo. The 
PDX1 positive population was first gated and then median fluorescence intensity (MFI) for 
PDX1 was calculated using BD FACS software.  
 
3.10  RNA isolation and qPCR 
 
Total RNA from cells was extracted using the miRNeasy mini kit (Qiagen). The high-capacity 
RNA-to-cDNA kit (Applied Biosystems) was used to perform the cDNA synthesis. ViiA7 
(Applied Biosystems) and TaqMan Fast Advanced Master Mix (Applied Biosystems) were 
used for qPCR. The housekeeping genes 18S ribosomal RNA (RNA18S) and glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) were used as references genes. Taqman probes 
(Applied Biosystems): INS, Hs02741908_m1; GCG, Hs01031536_m1; SST, 
Hs00356144_m1; PDX1, Hs00236830_m1; GAPDH, Hs02758991_g1; 18S, 
Hs99999901_s1;  NKX6.1, Hs01055914_m1;  MAFA, Hs01651425_s1; NEUROD1, 
Hs01922995_s1; UCN3, Hs00846499_s1; PAX6, Hs01088114_m1; ABCC8, 
Hs01093752_m1;  KCNJ11, Hs00265026_s1; SLC30A8,  Hs00545183_m1. 
SYBR qPCR was performed under standard conditions using ViiA7 (Applied Biosystems) 
and SYBR™ Green PCR Master Mix (Applied Biosystems). Samples were normalized to the 
housekeeping gene ACTB. Primers were as follows:  
HHEX forward: ACGGTGAACGACTACACGC.  
HHEX reverse: CTTCTCCAGCTCGATGGTCT;  
MEIS1 forward: GGGCATGGATGGAGTAGGC.  
MEIS1 reverse: GGGTACTGATGCGAGTGCAG; 
ONECUT1 forward: GAACATGGGAAGGATAGAGGCA. 
ONECUT1 reverse: GTAGAGTTCGACGCTGGACAT; 
RFX6 forward: AAGCAGCGGATCAATACCTGT. 
RFX6 reverse: ACCGTGGTAAGCAAACTCCTT; 
ACTB forward: CCCAGAGCAAGAGAGG. 
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ACTB reverse: GTCCAGACGCAGGATG. 
 
3.11  Affymetrix microarray 
 
The miRNeasy Mini kit (Qiagen, Cat# 217004) was used to extract the total RNA for 
microarray analysis. The quality of RNA integrity was checked using Agilent 2100 
Bioanalyzer (Agilent RNA 6000 Pico Kit) and  cDNA was amplified with the Ovation PicoSL 
WTA System V2 (Nugen, 3312) together with the Encore Biotin Module (Nugen, USA). All 
subsequent computational analysis was analyzed in R using Bioconductor packages. Using 
the oligo package (version 1.38.0), expression data was RMA normalized and probe sets 
were defined using the package hugene20sttranscriptcluster.db (version 8.5.0). Differential 
expression analyses were analyzed on prefiltered data, containing the 30562 probe sets 
having highest expression values. P-values were adjusted for multiple testing by Benjamini-
Hochberg correction using the limma package (version 3.30.7). If the adjusted p-value (FDR) 
was below a threshold of 0.1 and the fold-change was greater than or equal to 2, a gene was 
considered differentially expressed. Functional enrichments were performed using HOMER. 
The term affiliations of functional annotations were based on literature research and 
HOMER. 
 
3.12  RNA-seq and analysis 
 
At the PP1 stage, RNA samples from PDX1+/-, PDX1P33T/P33T, PDX1C18R/C18R and XM001 iPSC 
lines were collected using the above-mentioned RNA isolation method. All of samples for 
RNA-seq were produced by 1st differentiation protocol. Using miRNeasy Mini kit (Qiagen, 
#217004), total RNA from PDX1+/-, PDX1P33T/P33T, PDX1C18R/C18R and XM001 lines was 
extracted and RNA integrity was evaluated using Agilent 2100 Bioanalyzer (Agilent RNA 
6000 Pico Kit). Libraries were processed using the TruSeq Stranded mRNA Library Prep 
(Illumina). The RNA-seq analysis was described in (Wang et al., 2019). 
 
3.13  Static glucose-stimulation insulin secretion 
 
Static glucose-stimulated insulin secretion (GSIS) of the generated β-like cells was done 
according to  previous protocols (Shi et al., 2017; Zhu et al., 2016). Briefly, 5-8 aggregates 
were hand-picked and washed three times with KRBH buffer (129 mM NaCl, 4.8 mM KCl, 2.5 
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mM CaCl2, 1.2 mM MgSO4, 1 mM Na2HPO4, 1.2 mM KH2PO4, 5 mM NaHCO3, 10 mM 
HEPES and 0.1% BSA in deionized water and sterile filtered) and then cultured in KRBH 
buffer at 37 °C for 1 h. After that, aggregates then were incubated in KRBH buffer having 2.8 
mM glucose for 60 min at R.T. We collected the supernatants and the aggregates were 
switched to KRBH buffer with 16.7 mM glucose for 60 min. Supernatants were collected once 
more. After the experiment, cell aggregates were dissociated into single cells and the cell 
numbers were calculated to normalize the GSIS. Mercodia Human Insulin ELISA kit 
(Mercodia, Cat# 10-1113-01) and Human C-peptide ELISA kit (Mercodia, Cat# 10-1141-01) 
were used to measure the insulin and C-peptide content in supernatant samples according to 
manufacturer’s protocols. 
 
3.14  Western Blotting 
 
PP1 Cells were harvested and lysed using cell lysis buffer with protease inhibitors. A 10% 
SDS-PAGE gel was used to separate to the samples. The samples were transferred to 
PVDF Pre-Cut Blotting Membranes and blocked with 5% milk in Tris-based saline with 
Tween 20 (0.1% TBST) buffer for 1 h at R.T. The PVDF membrane was incubated with 1ST 
primary antibodies overnight at 4°C and later on incubated with HRP conjugated secondary 
antibodies at R.T. for 1 h. ECL western blotting detection reagent (Bio-rad, Cat #1705061) 
was used to detect the protein bands. The following antibodies were used for experiments: 
goat anti-PDX1 (R&D, Cat #AF2419, 1:1,000), mouse anti-ACTB (b-Actin) (Cell Signaling 
Technology, Cat #3700S, 1:10,000). 
 
3.15  Statistics 
 
One-way ANOVA followed by Bonferroni's multiple comparisons test in GraphPad Prism 
(version 8.0.0 for Windows, GraphPad Software, San Diego, California USA) was used, and 
statistical significance was determined. A value of P<0.05 was regarded as statistically 
significant.   
 
3.16  Accession Numbers 
 
Microarray, RNA-seq and ChIP-seq data has been submitted to the GEO database at NCBI 
under the accession number GSE125770 and GSE106950. 
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EN                                                endocrine precursors 
FACS                                            fluorescent activated cell sorting 
gRNA                                            guide RNA 
GSIS                                             glucose-stimulated insulin secretion 
hESC                                            human embryonic stem cell 
iPSC                                             induced pluripotent stem cell 
mESC                                           mouse embryonic stem cell 
MODY                                           maturity-onset diabetes of the young 
PDX1                                             pancreas/duodenum homeobox protein 1 
PGT                                               primitive gut tube 
PP1                                                pancreatic progenitor stage 1/ posterior foregut 
PP2                                                pancreatic progenitor stage 2/ pancreatic endoderm 
qPCR                                             quantitative polymerase chain reaction 
RNA-seq                                        RNA sequencing 
SC-β                                               stem cell derived-β cell 
SCNT                                             somatic cell nuclear transfer 
SNP                                                single-nucleotide polymorphism 
ssDNA                                            single-stranded DNA 
TALEN                                            transcription activator-like effector nuclease 
ZFNs                                               zinc-finger nucleases 
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Objective: Homozygous loss-of-function mutations in the gene coding for the homeobox transcription factor (TF) PDX1 leads to pancreatic
agenesis, whereas heterozygous mutations can cause Maturity-Onset Diabetes of the Young 4 (MODY4). Although the function of Pdx1 is
well studied in pre-clinical models during insulin-producing b-cell development and homeostasis, it remains elusive how this TF controls
human pancreas development by regulating a downstream transcriptional program. Also, comparative studies of PDX1 binding patterns in
pancreatic progenitors and adult b-cells have not been conducted so far. Furthermore, many studies reported the association between
single nucleotide polymorphisms (SNPs) and T2DM, and it has been shown that islet enhancers are enriched in T2DM-associated SNPs.
Whether regions, harboring T2DM-associated SNPs are PDX1 bound and active at the pancreatic progenitor stage has not been reported
so far.
Methods: In this study, we have generated a novel induced pluripotent stem cell (iPSC) line that efficiently differentiates into human pancreatic
progenitors (PPs). Furthermore, PDX1 and H3K27ac chromatin immunoprecipitation sequencing (ChIP-seq) was used to identify PDX1 tran-
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adulthood, we compared PDX1 binding profiles from PPs and adult islets. Moreover, combining ChIP-seq and GWAS meta-analysis data we
identified T2DM-associated SNPs in PDX1 binding sites and active chromatin regions.
Results: ChIP-seq for PDX1 revealed a total of 8088 PDX1-bound regions that map to 5664 genes in iPSC-derived PPs. The PDX1 target
regions include important pancreatic TFs, such as PDX1 itself, RFX6, HNF1B, and MEIS1, which were activated during the differentiation
process as revealed by the active chromatin mark H3K27ac and mRNA expression profiling, suggesting that auto-regulatory feedback
regulation maintains PDX1 expression and initiates a pancreatic TF program. Remarkably, we identified several PDX1 target genes that
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and the ligand of the Notch receptor DLL1, which is important for endocrine induction and tip-trunk patterning. The comparison of PDX1
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derived PPs. Two of these SNPs fall into PDX1 occupied sites that are located in the intronic regions of TCF7L2 and HNF1B. Both of these
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Original ArticleConclusions: Our data provide stage-specific target genes of PDX1 during in vitro differentiation of stem cells into pancreatic progenitors that
could be useful to identify pathways and molecular targets that predispose for diabetes. In addition, we show that T2DM-associated SNPs are
enriched in active chromatin regions at the pancreatic progenitor stage, suggesting that the susceptibility to T2DM might originate from imperfect
execution of a b-cell developmental program.
 2018 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Diabetes mellitus is a group of heterogeneous disorders characterized
by hyperglycemia and the progressive loss or dysfunction of the
insulin-producing b-cells in the pancreas. Today, over 415 million
people worldwide have been diagnosed with diabetes and the number
is expected to rise to 642 million by 2040 [1]. There are four main
types of diabetes mellitus: Type 1 Diabetes Mellitus (T1DM), Type 2
Diabetes Mellitus (T2DM), Gestational Diabetes and Maturity Onset
Diabetes of the Young (MODY).
The most common form of diabetes is T2DM, a multifactorial disease
that is caused by a complex interplay between genetic, epigenetic, and
environmental factors. This form predominantly occurs in adulthood
due to the failure of b-cells to produce sufficient amounts of insulin for
maintenance of normoglycemia. For decades, analyses of natural
genetic variation have been used to understand the pathogenesis of
T2DM and to improve diagnosis and treatment for the people who
suffer from this disease [1,2].
MODY is inherited in an autosomal dominant fashion and presents
early in life due to defects in developing enough b-cells or failure in
function. There are at least 13 types of MODY that are diagnosed in 1e
2% of diabetes patients, which are caused by mutations in several
essential genes, such as GCK, HNF1A, HNF1B, and PDX1 [3].
Among these genes, PDX1 encodes one key TF, regulating b-cell
development and function [4,5]. In humans, the PDX1 gene is located
on chromosome 13q12.1 and encodes for a protein of 283 amino
acids. Typically for a TF it contains a transactivation domain and a
homeodomain that binds to DNA. In mouse, the expression of Pdx1 is
first evident at embryonic day (E) 8.5e9.0 and becomes restricted to
b- and d-cells in adult islets [6e9]. Homozygous Pdx1 knockout mice
form pancreatic buds but fail to develop a pancreas [10]. On the
contrary, heterozygous Pdx1 knockout mice develop a pancreas but
become diabetic in adulthood and b-cells increasingly undergo
apoptosis [11e13]. In humans, PDX1 is expressed in the developing
pancreas and heterozygous mutations in the PDX1 gene cause a strong
form of monogenic diabetes, called MODY4 [14,15]. Contrary to the
numerous studies highlighting the importance of Pdx1 during mouse
pancreas development, little is known about the role of this TF in
human b-cell development, homeostasis and function. Specifically, it
is important to unravel the PDX1 target gene program to understand its
cell-type specific function during development and its contribution to
MODY and T2DM in adulthood. Genome-wide association studies have
identified multiple loci associated with the susceptibility to T2DM,
including TCF7L2, SLC30A8, HHEX, CDKAL1, CDKN2A/B, and IGF2BP2
[16,17]. It has been shown that islet enhancers are enriched in T2DM-
associated SNPs [18]; however, it is unknown if these SNPs affect
PDX1 bound cis-regulatory regions and play a role during pancreas
development.
Here, we generated a novel iPSC line from a healthy female donor and
confirmed its efficient in vitro pancreatic differentiation. We performed
transcriptome analysis combined with ChIP-seq profiling of active
H3K27ac histone modifications and PDX1 binding sites in PPs and
compared these to adult islets to investigate stage-specific functions of58 MOLECULAR METABOLISM 9 (2018) 57e68  2018 The Authors. Published by Elsevier GmbH. ThiPDX1 in progenitors and adult b-cells. Furthermore, through screening
for T2DM-associated SNPs in active chromatin regions of PPs, we
suggest that some SNPs might increase the diabetes risk by affecting
pancreas and b-cell development.
2. MATERIALS AND METHODS
2.1. Ethics statement
The choice of appropriate human donors and the procedures for skin
biopsy, isolation, and characterization of dermal fibroblasts were
performed in accordance with study protocols approved by the Ethics
Committee of the Medical Faculty of the Eberhard Karls University,
Tübingen. The study design followed the principles of the Declaration
of Helsinki. All study participants gave informed consent prior to entry
into the study. All mice were housed in the facilities at the Helmholtz
Zentrum München e German Research Center for Environmental
Health (HMGU) and treated in accordance with the German animal
welfare legislation and acknowledged guidelines of the Society of
Laboratory Animals (GV-SOLAS) and of the Federation of Laboratory
Animal Science Associations (FELASA). The teratoma generation pro-
cedure was approved by the Institutional Animal Care and Use Com-
mittee (IACUC) of HMGU and notified to the local regulatory supervisory
authority.
2.2. Skin biopsy, isolation, and characterization of dermal
fibroblasts
A full-thickness skin specimen was taken by punch biopsy from the
upper arm in the deltoid muscle region. After removal of adipose tissue
remnants and visible blood vessels, the sample was digested overnight
at 4 C with 10 U/mL dispase II (Roche Diagnostics, Mannheim,
Germany) in 50 mM HEPES pH 7.4, 150 mM NaCl. Thereafter, the
digest was incubated for 30 min at 37 C under continuous shaking
(1200 rpm). Using forceps, the dermis was separated from the
epidermal layer, and fibroblasts were isolated from the dermis by
digestion with 0.2% collagenase CLS I (Biochrom, Berlin, Germany) in
DMEM, 10% BSA for 45 min at 37 C under continuous shaking
(1200 rpm). For purification of the fibroblasts, the digest was filtered
through a 70 mm mesh and centrifuged. The pelleted cells were
resuspended, grown for three days in DMEM, 10% FCS, and subse-
quently further expanded in Medium 106 supplemented with low
serum growth supplement (Invitrogen, Thermo Fisher Scientific, Wal-
tham, MA, USA). Samples of dermal fibroblasts were tested for the
presence of viruses, pathogenic to humans, i.e., HBV, HCV, and HIV,
with Genesig PCR-based detection kits from Primerdesign Ltd.
(Chandler’s Ford, UK) and for the presence of mycoplasma with a PCR
test kit from PanReac AppliChem (Darmstadt, Germany) and, in par-
allel, by DNA staining with DAPI. All cultures were found to be negative
for the tested contaminants.
2.3. XM001 iPSCs generation
Primary fibroblasts from a healthy female donor were reprogrammed
into pluripotent stem cells using a non-integrating Episomal iPSC
Reprogramming Kit (Invitrogen, Cat. no. A14703). This kit contains as is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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mixture of three vectors, which have the oriP/EBNA-1 (EpsteineBarr
nuclear antigen-1) backbone that delivers six reprogramming factors:
OCT4, SOX2, NANOG, LIN28, KLF4, and L-MYC [20]. Human fibro-
blasts, at 75e90% confluency, were transfected using the Amaxa 4D-
Nucleofector transfection system and a nucleofector kit for human
dermal fibroblasts (Lonza, Cat. no. VPD-1001), plated onto geltrex-
coated culture dishes and incubated in supplemented fibroblast me-
dium. The fibroblast medium contained knockout DMEM/F-12 (Life
Technologies), 10% ESC-qualified FBS (Life Technologies), 1% MEM
non-essential amino acids (Life Technologies), 10 mM HA-100 (Santa
Cruz) and 4 ng/mL bFGF (Life Technologies). At 24 h after transfection,
the medium was exchanged with N2B27 medium supplemented with
0.5 mM PD0325901 (Stemgent), 3 mM CHIR99021 (Stemgent), 0.5 mM
A-83-01 (Stemgent), 10 mM HA-100 (Santa Cruz), 10 ng/mL hLIF (Life
Technologies) and 100 ng/mL bFGF (Life Technologies). The basic
N2B27 medium contained DMEM/F12 with HEPES (Life Technologies),
1  N2 supplement (Life Technologies), 1  B27 supplement (Life
Technologies), 1% MEM non-essential amino acids, 1  Glutamax
(Life Technologies) and 1  b-Mercaptoethanol (Life Technologies).
On day 15 after transfection, the medium was changed to Essential 8
medium and monitored for the emergence of iPSC colonies. Around 3
weeks after transfection, undifferentiated iPSC colonies were picked
and transferred onto fresh geltrex-coated culture dishes for expansion.
2.4. XM001 iPSCs characterization
DNAwas extracted from iPSCs using standard procedure. Markers for the
episomal backbone were amplified by semi-quantitative PCR to exclude
transgene integration. Primers were as follows: oriP forward: TTCCAC-
GAGGCTAGTGAACC. oriP reverse: TCGGGGGTGTTAGAGACAAC; EBNA-1
forward: ATCGTCAAAGCTGCACACAG. EBNA-1 reverse: CCCAGGAGTCC-
CAGTAGTCA. For karyotype analysis, we used the cells growing in log-
arithmic phase. These were fed with freshmedium the day before adding
colcemid for 2 h. Cells were then trypsinized, treated with hypotonic
solution (0.075 M KCl) for 20 min, and fixed with methanol:acetic acid
(3:1). Metaphases were spread on microscope slides, and chromosomes
were classified according to the International System for Human Cyto-
genic Nomenclature using the standard G banding technique. At least 20
metaphases were counted per cell line, and the final karyotype was
stated if it was present inmore than 85% of them. For teratomas, 2 106
iPSCs were injected into the right hind leg of immunocompromised NOD/
SCID mice. Tumors were excised after 8 weeks, fixed, embedded in
paraffin, sectioned and stained with hematoxylin/eosin [51].
2.5. XM001 iPSCs culture
XM001 iPSCs were cultured on 1:100 diluted Matrigel (BD Biosciences)
in mTeSR1 medium (Stem Cell Technologies). At w70e80% con-
fluency, cultures were rinsed with 1  DPBS without Mg2þ and Ca2þ
(Invitrogen) followed by incubation with 1 TrypLE Select Enzyme (Life
Technology) for 3e5 min at 37 C. Single cells were rinsed with
mTeSR1 medium, and spun at 1,000 rpm for 3 min. The resulting cell
pellet was resuspended in mTeSR1 medium supplemented with
10 mM Y-27632 (SigmaeAldrich) and the single cell suspension was
seeded atw1.5 105 cells/cm2 on Matrigel-coated surfaces. Cultures
were fed every day with mTeSR1 medium and differentiation was
initiated 48 h following seeding, resulting inw90% starting confluency.
2.6. Pancreatic progenitor differentiation
2.6.1. S1: Definitive endoderm (3 d)
XM001 iPSCs plated on 1:100 diluted Matrigel were first rinsed with
1  DPBS without Mg2þ and Ca2þ (Invitrogen) and then cultured inMOLECULAR METABOLISM 9 (2018) 57e68  2018 The Authors. Published by Elsevier GmbH. This is an ope
www.molecularmetabolism.comRPMI 1640 medium (Invitrogen) further supplemented with 1.2 g/L
sodium bicarbonate (Sigma), 0.2% ESC-qualified FBS (Life Technolo-
gies), 100 ng/mL Activin-A (R&D Systems), and 20 ng/mL of Wnt3A
(R&D Systems) for day 1 only. For the next 2 days, cells were cultured
in RPMI with 0.5% FBS, 1.2 g/L sodium bicarbonate and 100 ng/mL
Activin-A.
2.6.2. S2: Primitive gut tube (3 d)
Cells were rinsed with 1  DPBS (without Mg2þ and Ca2þ) once and
then exposed to DMEM-F12 (Life Technologies) medium further sup-
plemented with 2 g/L sodium bicarbonate, 2% FBS and 50 ng/mL of
FGF7 (R&D Systems) for 3 days.
2.6.3. S3: Pancreatic progenitors (PP)/posterior foregut (4 d)
Cultures were maintained for 4 days in DMEM-HG medium (Life
Technologies) supplemented with 0.25 mM SANT-1 (SigmaeAldrich),
2 mM retinoic acid (RA; SigmaeAldrich), 100 ng/mL of Noggin (R&D
Systems), and 1% B27 (Invitrogen).
2.7. Immunofluorescence imaging
Cells were fixed with 4% paraformaldehyde for 30 min and then
permeabilized in PBS containing 0.2% Triton X-100. Cells were
blocked with PBS containing 3% BSA, and incubated with primary
antibodies overnight at 4 C. Then secondary antibodies were incu-
bated for 1 h at room temperature after washing with PBS. Images
were acquired on a TCS SP5 laser-scanning microscope (Leica). The
following antibodies and dilutions were used: goat anti-OCT-3/4
(1:500, #sc-8628, Santa Cruz), goat anti-SOX2 (1:500, #sc-17320,
Santa Cruz), mouse anti-TRA-1-60 (1:1000, #4746, Cell Signaling),
mouse anti-TRA-1-81 (1:50, MAB4381, Millipore), mouse anti-SSEA4
(1:500, #4755, Cell Signaling), rabbit anti-FOXA2 (1:250, #8186, Cell
Signaling), goat anti-SOX17 antibody (1:500, #GT15094, Acris/Novus),
goat anti-PDX1 antibody (1:500, #AF2419, R&D Systems).
2.8. Flow cytometry
Cells were dissociated using 1  TrypLE Select Enzyme and washed
with cold FACS buffer (5% FBS in 1 DPBS). Cells were fixed with 4%
paraformaldehyde and permeabilized with donkey block solution (0.1%
tween-20, 10% FBS, 0.1% BSA and 3% donkey serum) containing
0.5% saponin. The cells were incubated with goat anti-SOX17 antibody
(1:500, #GT15094, Acris/Novus) and goat anti-PDX1 antibody (1:500,
#AF2419, R&D Systems) for 30 min at room temperature and then
stained with Alexa Fluor 555-conjugated donkey antibody directed
against goat (1:500, #A21432, Invitrogen) for 30 min at room tem-
perature. Flow cytometry was performed using FACS-Aria III (BD
Bioscience). FACS data were analyzed using FlowJo.
2.9. RNA isolation and qPCR
Total RNA was extracted from cells with the miRNeasy mini kit (Qiagen).
cDNA synthesis was performed with a high-capacity RNA-to-cDNA kit
(Applied Biosystems). TaqMan qPCR was performed under standard
conditions using ViiA7 (Applied Biosystems) and TaqMan Fast Advanced
Master Mix (Applied Biosystems). Samples were normalized to house-
keeping genes 18S ribosomal RNA (RN18S) and glyceraldehyde 3-
phosphate dehydrogenase (GAPDH). Taqman probes (Applied Bio-
systems): PDX1, Hs00236830_m1; SOX9, Hs01001343_g1; PTF1A,
Hs00603586_g1; HNF1B, Hs01001602_m1; OCT4, Hs00999632_g1;
NANOG, Hs04260366_g1; GAPDH, Hs02758991_g1; 18S,
Hs99999901_s1; NKX6.1, Hs01055914_m1; NKX2.2, Hs00159-
616_m1.n access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 59
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(Applied Biosystems) and SYBR Green PCR Master Mix (Applied
Biosystems). Samples were normalized to the housekeeping gene
ACTB. Primers were as follows:
HHEX forward: ACGGTGAACGACTACACGC.
HHEX reverse: CTTCTCCAGCTCGATGGTCT;
MEIS1 forward: GGGCATGGATGGAGTAGGC.
MEIS1 reverse: GGGTACTGATGCGAGTGCAG;
ONECUT1 forward: GAACATGGGAAGGATAGAGGCA.
ONECUT1 reverse: GTAGAGTTCGACGCTGGACAT;
RFX6 forward: AAGCAGCGGATCAATACCTGT.
RFX6 reverse: ACCGTGGTAAGCAAACTCCTT;
ACTB forward: CCCAGAGCAAGAGAGG.
ACTB reverse: GTCCAGACGCAGGATG.2.10. ChIP-seq
XM001 PP cells (2 106 cells) were cross-linked in 1% formaldehyde
in culture medium for 10 min at room temperature. The cross-linking
reaction was stopped by the addition of glycine to a final concentration
of 125 mM. For chromatin fragmentation, cells were resuspended in
lysis buffer (50 mM Tris-HCl (pH 8.0), 10 mM EDTA, 0.5% SDS) and
sonicated in a Covaris S220 sonicator with a duty cycle of 2%, a peak
incident power of 105 W and 200 cycles per burst for 20 min. The
fragmented chromatin was diluted 1:5 in IP-Buffer (10 mM Tris-HCl
(pH 7.5), 1 mM EDTA, 0.5 mM EGTA, 1% Triton X-100, 0.1% SDS,
0.1% Na-Desoxycholate, 140 mM NaCl, H2O, Protease Inhibitors) and
directly used for immunoprecipitation. For PDX1 ChIP, 60% of the
chromatin (equivalent of 1.2 106 cells) was processed in two parallel
ChIPs using magnetic beads, preloaded with 3 ml goat anti PDX1
antibody (kindly provided by C. Wright), for each ChIP. For H3K27ac
ChIP, 40% of the chromatin (equivalent 0.4  106 cells) was pro-
cessed in three parallel IPs using magnetic beads, preloaded with 3 mg
anti H3K27ac antibody (Diagenode, C15410174). For all ChIPs, anti-
body incubation was performed at 4 C for 5 h. Beads were then
washed 5 times using (1.) IP-Buffer, (2.) Washing-Buffer 1 (500 mM
NaCl, 50 mM Tris-HCl (pH 8.0), 0.1% SDS, 1% NP-40), (3.) Washing-
Buffer 2 (250 mM LiCl, 50 mM Tris-HCl (pH 8.0), 0.5% Na-
Deoxycholate, 1% NP-40) and (4. & 5.) Washing-Buffer 3 (10 mM
Tris-HCl (pH 8.0), 10 mM EDTA). Subsequently, protein-DNA com-
plexes were eluted from the beads in Elution-Buffer (50 mM Tris-HCl
(pH 8.0), 10 mM EDTA, 1% SDS) at 65 C for 20 min. Cross-links
were reversed at 65 C overnight, and DNA was purified for library
construction with the MicroPlex kit (Diagenode, C05010010). Libraries
were sequenced on an Illumina HiSeq 1500 (50 bp, single end).
2.11. ChIP-seq data analysis
Raw reads from PDX1 and H3K27ac ChIP-seq were processed with
Trimmomatic (0.35) to remove low quality bases and potential adapter
contamination. Next, reads were aligned to hg19 genome using
bowtie2 (2.2.6) with very-sensitive option and duplicate reads were
removed using samtools (1.3). Binding sites for PDX1 were then called
using GEM [52] and filtered, after visual inspection, using a Q-value
cut-off of 104 and overlapping regions were merged. Regions of
H3K27ac enrichment were called using BCP-HM [53] with default
parameters. PDX1 binding sites and H3K27ac enriched regions were
further filtered by removing blacklist regions [54]. Regions and binding
sites within 20 kb of a TSS or within a gene body were annotated with
the respective gene using bedtools (2.26.0). Motif analysis, annota-
tions with genomic features, and pathway enrichment analysis were60 MOLECULAR METABOLISM 9 (2018) 57e68  2018 The Authors. Published by Elsevier GmbH. Thiperformed using HOMER [55]. For publicly available data sets, raw
reads were downloaded from online repositories and processed as
described above (GSE54471 [22], GSE58686 [24], E-MTAB-1143 [28],
E-MTAB-1919 [18]). For clustering of H3K27ac profiles, first the reads
that fall in the intersection of enriched regions from all samples to be
compared were counted and normalization factors were calculated
using DESeq2. Next, the union of all identified regions from all samples
to be compared was merged and reads falling into these regions were
counted. Reads were then processed with DESeq2 using normalization
factors calculated before and normalized read counts were used to
calculate Pearson correlation coefficients that were subsequently
subjected to hierarchical clustering. To calculate enrichment of
H3K27ac at PDX1-bound sites, three sets of random sites were
generated by shuffling all 8088 PDX1 binding sites using bedtools
(2.26.0) shuffle. Then, H3K27ac reads were counted and the ratio of
the mean read count at PDX1 sites over the mean read count at
shuffled sites was calculated. For visualization, BIGWIG files, normal-
ized to 1  sequencing depth (Reads Per Genomic Content) using
deepTools bamCoverage, were used. H3K27ac and PDX1 tracks for
adult islets were generated from merged BAM files containing reads
from all available experiments. To generate high confidence PDX1
binding sites, the overlap of PDX1 sites from progenitor profiles
(XM001, [22,24]) or islet profiles [18,28] was calculated, and sites
found in two out of three progenitor data sets or three out of four islet
data sets were considered as high confidence binding sites.2.12. Enrichment of T2DM SNPs
To obtain positions and disease association P-values of T2DM-
associated SNPs, DIAGRAM 1000G GWAS meta-analysis Stage 1
Summary statistics [17] was downloaded and filtered to remove all
SNPs with an association P-value below 5  108. For islet H3K27ac,
the union of enriched regions from all 3 available experiments [18,22]
was generated and subsequently, regions closer than 1000 bp were
merged. Enrichment P-values were calculated using bedtools (2.26.0)
fisher and the SNPs overlapping regions of interest were identified
using bedtools (2.26.0) intersect. SNPs within 20 kb of a TSS or within
a gene body were annotated with the respective gene using bedtools
(2.26.0).2.13. Affymetrix microarray
For gene profiling, total RNA was extracted using miRNeasy Mini kit
(Qiagen, #217004), RNA integrity was checked using Agilent 2100
Bioanalyzer (Agilent RNA 6000 Pico Kit), and cDNA was amplified with
the Ovation PicoSL WTA System V2 (Nugen, 3312) in combination with
the Encore Biotin Module (Nugen, USA). Amplified cDNA was hy-
bridized on GeneChip Human Gene 2.0 ST arrays (Affymetrix,
902113). Expression console (v.1.3.0.187, Affymetrix) was used for
quality control. All subsequent computational analysis was performed
in R using Bioconductor packages. Expression data were RMA
normalized using the oligo package (version 1.38.0) and probe sets
were annotated using the package hugene20sttranscriptcluster.db
(version 8.5.0). Differential expression analyses were performed using
the limma package (version 3.30.7) and P-values were adjusted for
multiple testing by Benjamini-Hochberg correction. A gene was
considered as differentially expressed if the adjusted p-value (FDR)
was below a threshold of 0.05 and the fold-change was greater than
or equal to 2. Functional enrichments were conducted using HOMER
[55]. Gene set enrichment analysis was performed using GSEA 3.0
[56,57] with genes ranked by log2 ratio between XM001 PPs and
XM001 iPSCs.s is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1: Efficient differentiation of XM001 iPSCs into pancreatic progenitors. (A) Schematic of iPSC-derived pancreatic progenitor differentiation protocol. (B) Immuno-
staining for FOXA2 and SOX17 on day 3. Scale bar indicates 50 mm. (C) Representative FACS plot of SOX17þ cells at DE stage. A differentiated sample stained with only the
secondary antibody and XM001 iPSCs were used as negative controls. (D) FACS quantification of the percentage of SOX17þ cells at DE stage (n ¼ 3). (E) Immunostaining for PDX1
on day 10. Scale bar indicates 50 mm. (F) Representative FACS plot of PDX1þ cells at the PP stage. A differentiated sample stained with only the secondary antibody and XM001
iPSCs were used as negative controls. (G) FACS quantification of the percentage of PDX1þ cells at PP stage (n ¼ 3).
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Original Article2.14. Accession number
Microarray and ChIP-seq data have been submitted to the GEO data-
base at NCBI under the accession number GSE106950.
3. RESULTS
3.1. Efficient differentiation of XM001 iPSCs into pancreatic
progenitors
To generate the XM001 induced pluripotent stem cell (iPSC) line, pri-
mary adult skin fibroblasts from a healthy female donor were
reprogrammed into iPSCs by transfection with three episomal plasmids
encoding human OCT4, SOX2, NANOG, LIN28, KLF4, and L-MYC.
(Suppl. Figure 1A) [19,20]. We established the reprogramming protocol
including three stages: transfection, reprogramming and expansion
(Suppl. Figure 1B). Colonies with stem cell-like characteristics
appeared around day 15 post-infection and were handpicked by day 21
and subjected to quality controls. XM001 iPSCs were episomal vector
integration-free and of normal karyotype (Suppl. Figure 1CeD). Next,
we confirmed the expression of several pluripotency markers (TRA-1-
60 and TRA-1-81, SSEA-3, and SSEA-4) and pluripotency TFs (OCT4
and SOX2) by immunostainings in XM001 iPSCs (Suppl. Figure 2). To
rigorously demonstrate multi-lineage potency of the generated iPSC
line, we injected 2  106 iPSCs subcutaneously into None-obese
diabetic/severe combined immunodeficiency (NOD/SCID) mice to
generate teratomas. The histological analysis of the induced teratomas
revealed that tissues from all three germ layers were differentiated,
confirming pluripotency of our XM001 iPSCs in vivo (Suppl. Figure 3).
These data show successful reprogramming of fibroblasts into
pluripotent iPSCs that stably display human embryonic stem cell
(hESC)-like characteristics and multi-lineage potency.
Next, we differentiated XM001 iPSCs into pancreatic progenitors (PP)
using a previously established protocol recapitulating pancreas
development through three main stages: definitive endoderm (DE),
primitive gut tube (GT), and PPs of the posterior foregut (Figure 1A)Figure 2: mRNA profiles of XM001 PPs show expression of pancreas specific gene
microarray data obtained from XM001 iPSCs and PPs. Genes with significantly different exp
depicts increased expression in PPs, whereas brown depicts increased expression in iPSCs
from differentially expressed genes, shown in (A). (C) Gene set enrichment analysis of p
endocrine (E) and stem cell (F) related genes in XM001 iPSCs and PPs (n ¼ 3).
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and PP (PDX1) stages were verified by immunostaining and flow
cytometry at day 3 and 10, respectively. At the DE stage, cells co-
expressed FOXA2 and SOX17 (Figure 1B) and flow-cytometry anal-
ysis showed that approximately 95% of the cells were positive for the
DE marker SOX17 (Figure 1CeD). At the PP stage, the number of
PDX1-positive cells was around 85% as measured by flow cytometry
and shown by immunostaining (Figure 1EeG).3.2. mRNA profiles of XM001 PPs show expression of pancreas
specific genes
To characterize global gene expression changes during PP differenti-
ation, we performed Affymetrix microarray analysis on XM001 cells at
the pluripotency and PP stages. In total, we identified 2658 differen-
tially expressed genes between iPSCs and PPs (FC  2, FDR  5%),
including important pancreatic genes such as HNF1B, SOX9, ONE-
CUT1, HHEX, FOXA2 and RFX6 that are upregulated in PPs, as well as
pluripotency-associated genes including NANOG and SOX2 that are
specifically expressed in iPSCs and downregulated in PPs (Figure 2A).
Moreover, gene set enrichment analysis as well as unbiased gene
ontology (GO) term and pathway analysis showed significant enrich-
ment of terms associated with pancreas development in PP cells, while
terms associated with embryonic stem cells, cell cycle and prolifera-
tion were downregulated during the differentiation process
(Figure 2BeC). To verify the microarray results, we validated
expression changes of important genes involved in pancreas devel-
opment (HHEX, HNF1B, MEIS1, ONECUT1, PDX1, PTF1A, RFX6, and
SOX9), endocrine formation (NKX2-2, NKX6-1) and stem cell mainte-
nance (NANOG, OCT4) by quantitative PCR (qPCR) (Figure 2DeF).
Taken together, the XM001 iPSCs were efficiently differentiated into
PPs after 10 days of in vitro differentiation characterized by the
expression of lineage-specific genes and the downregulation of plu-
ripotency genes.s. (A) MA plot showing the mean log2 expression against the log2-fold change of the
ression (log2 fold change  1 and adjusted p-value  0.05) are drawn in color. Green
. (B) Bar graph of p-values from selected GO terms and KEGG and Reactome pathways
ancreas related GO terms. (DeF) qPCR validation of the expression of pancreas (D),
s is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Correct specification of tissue-specific enhancers is crucial for the
differentiation of individual cell types [22]. In this context, the histone
modification H3K27ac is strongly associated with active enhancers and
promoters [23]. Therefore, we analyzed this histone modification in
XM001 cells after 10 days of differentiation using chromatin immu-
noprecipitation followed by next generation sequencing (ChIP-seq) and
found that key pancreatic genes are marked by an active chromatin
configuration. Wang et al. [22] thoroughly characterized the active
H3K27ac chromatin mark at several stages of pancreatic endoderm
differentiation (embryonic stem cells (ESCs), definitive endoderm (DE),
gut tube (GT), posterior foregut (FG; corresponds to PP stage of this
study) and late pancreatic progenitors/pancreatic endoderm (PE)) and
showed that the chromatin state at lineage-specific enhancers is vital
for developmental competence [22]. We used H3K27ac profiles from
hESC in vitro differentiations into pancreatic progenitors [22] to
compare with our H3K27ac profile from differentiated XM001 iPSCs.
Unsupervised hierarchical clustering showed that after 10 days of
differentiation, the active chromatin landscape in XM001 iPSCs was
reminiscent of that in FG and PE stage derived from hESCs, indicating
that our iPSC-derived PPs represent an early stage of pancreas
development, shortly after PDX1 induction (Suppl. Figure 4).
3.3. Characterization of PDX1 binding in XM001 PP cells
Due to the crucial role of PDX1 in the specification and differentiation of
the pancreatic lineages, characterization of its transcriptional targets is
important to understand human pancreas development. To do so, we
employed ChIP-seq analysis of PDX1 to profile genome-wide PDX1
binding sites in XM001 iPSCs after 10 days of differentiation, a time
point at which PDX1 is robustly expressed in approximately 85% of
differentiated cells (Figure 1G). We identified a total of 8088 PDX1-
bound regions that are associated with 5664 genes which have
PDX1 binding sites within 20 kb of their TSS or within their gene body.
These include PDX1 itself and other pancreatic genes, such as RFX6,40
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www.molecularmetabolism.comMEIS1, and the MODY gene HNF1B (Figure 3A). Moreover, the active
histone modification H3K27ac was enriched at the PDX1-bound sites
(Figure 3B and Suppl. Figure 5), which were predominantly found in
intergenic (44.2%) and intronic (40.4%) regions. However, with 11.3%
of the binding sites occurring in promoter regions, PDX1 was enriched
at the transcription start sites (TSS) of its target genes (Figure 3CeD).
De novo motif analysis was used to discover enriched motifs within
peak regions. The most significantly enriched motif was found in
around 62% of all peak sequences and matched the PDX1 consensus
motif, confirming the efficiency and specificity of the PDX1 ChIP-seq
approach (Figure 3E). We also compared our data to previous pub-
lished datasets of PDX1 ChIP-seq from hESC in vitro-derived PPs
[22,24] and found that the profiles of PDX1 binding show obvious
differences that might reflect hESC and iPSC differences, genetic
background variations and differences in the in vitro differentiation
stage or protocol (Suppl. Figure 6).
3.4. Functional characterization of PDX1-bound genes
Next, we examined the expression levels and function of PDX1-
bound genes in XM001 PP cells. From the 5664 PDX1-bound
genes, 4523 were covered by the microarray. In XM001 PP cells,
755 PDX1-bound genes were differentially expressed between the
iPSC and PP stage, which accounts for 28.4% of the total differ-
entially expressed genes (Figure 4AeB). Notably, we found up-
regulation of RFX3 and DLL1 among PDX1-bound genes during the
differentiation process. The mouse orthologues of these genes are
known to be involved in endocrine differentiation [25e27], sug-
gesting a potential role of these genes also during human pancreas
development. GO term analysis revealed an association of PDX1-
bound genes enriched in XM001 PP cells with pancreas, endocrine
and b-cell development as well as Notch and Hippo signaling,
suggesting that PDX1 induces a pancreatic program and primes for
endocrine differentiation (Figure 4C).−1500 0 1500
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Figure 4: Functional characterization of PDX1-bound genes. (A) Venn diagram depicting the overlap of PDX1-bound genes and the differentially expressed genes identified by
microarray analysis. (B) MA plot showing the log2 fold change over the mean log2 expression of PDX1-bound genes. Differentially expressed genes are displayed in color. Green
indicates enrichment in PPs, whereas brown indicates enrichment in iPSCs. (C) Bar chart of log10 p-values from enriched GO terms and KEGG and Reactome pathways of PDX1-
bound genes upregulated in PPs. (D) Venn diagram showing the overlap of high confidence PDX1 binding sites from adult human islets and PPs and some annotated genes. (E) Bar
chart of log10 p-values from enriched gene ontology and KEGG/Reactome pathways from genes bound in adult islets and/or PPs.
Original ArticleBased on the tempo-spatial pattern of Pdx1 expression in mouse that
shows ubiquitous expression in all pancreatic progenitors and
restricted expression in mature b- and d-cells, we hypothesized that
the molecular programs controlled by Pdx1 might be stage specific. To
understand if PDX1 carries out different functions during development
and in adult b-cells, we compared PDX1 binding sites from PPs and
adult human islets. To that end, we derived a set of high confidence
PDX1 binding sites for PPs and adult islets, comprised of PDX1 sites,
consistently bound in multiple datasets from this study and previous
studies from hESC-derived PPs and islets cells [18,22,24,28]. Of the
4978 high confidence binding sites in PP cells, 1018 (20.4%) were
identified in the islet binding data (Figure 4D). This indicates that in PP
cells and adult islets only a minority of PDX1 binding sites are
conserved, while the majority of sites change during the differentiation
and maturation processes. Correspondingly, among the genes near
PP-specific high confidence binding sites, we found important genes
for pancreas development, such as GATA4, HES1, HHEX, HNF1A,
NEUROG3, ONEUCUT1, TBX1, and YAP1, while genes near islet-
specific binding sites, including GLPR1, KCNJ11, SLC2A2, NKX6-1,
and MAFA, are associated with mature b-cell functions, e.g. insulin
secretion, glucose sensing and b-cell maturation and identity64 MOLECULAR METABOLISM 9 (2018) 57e68  2018 The Authors. Published by Elsevier GmbH. Thi(Figure 4DeE). Genes in the vicinity of shared binding sites are
implicated in endocrine development and include NKX2-2, PAX4,
RBPJ, and TGFB1. Of note, we also observed genes that show stage-
specific binding of PDX1 that can occur in combination with common
binding sites. These include HNF1B, RFX3, and RFX6, MNX1, FOXA2,
the MEG3 locus, and other important pancreatic genes (Figure 5C and
Suppl. Figure 7). Together, these results suggest that PDX1 binding
sites change during the process of pancreas and endocrine cell
development to meet the functional requirements of the different
stages during development and homeostasis.
3.5. Analysis of T2DM SNPs in XM001 PPs and adult islets
In a worldwide effort, genome-wide association studies (GWAS)
identified more than 300 genes that are linked to T2DM [29]. Of these
genes, 104 (32%) were bound by PDX1 in XM001 PPs. While harsh
mutations in MODY genes lead to monogenic forms of diabetes, an
increased susceptibility to T2DM is linked to SNPs occurring mostly in
non-coding regions. Moreover, it has been shown that islet enhancers
are enriched in T2DM-associated SNPs [18,30]. Therefore, we
analyzed whether XM001 PP active chromatin regions, as determined
by enrichment of H3K27ac, are also enriched in T2DM-associateds is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 5: Analysis of T2DM SNPs in XM001 PPs and adult islets. (A) Venn diagram depicting the overlap of T2DM SNPs found in active regions of adult islets and XM001 PPs.
(B) P-values of T2DM SNPs near known T2DM-associated genes found in active regions of adult islets [18,22] and XM001 PPs. P-values of SNPs bound by PDX1 in PPs and islets
are shown as black circles and triangles, respectively. (C) ChIP-seq data tracks showing H3K27ac and PDX1 from PP and islet [18,22,28] cells at the HNF1B locus. The SNP
rs11263763 is located in a PP specific PDX1 binding site in the first intron of HNF1B. The PP specific enhancer regions are shaded in gray.SNPs and if there are different variants in XM001 PPs and adult islets.
To this end, we used the DIAGRAM 1000G GWAS meta-analysis data
[17] and identified SNPs with a high association significance (1788
SNPs, P  5  108) that overlap with active chromatin marks in
XM001 PPs and adult islets [18,22]. We found a significant enrich-
ment of T2DM-associated SNPs in active chromatin of both PPs (437
SNPs, P ¼ 1.0156  10106) and islets (918 SNPs,
P ¼ 8.2266  10263). Closer examination of the enriched SNPs
showed that of the 918 SNPs found in islet active chromatin, 380 fall
in regions that are also enriched in H3K27ac in the XM001 PP cells.
However, we could also identify 57 SNPs in regions, active specif-
ically in PPs (Figure 5A). When we mapped the SNPs to genes, we
identified 857 SNPs in the vicinity of known genes (20 kb up-/
downstream of or within a gene body), and these included mostly
known T2DM-associated genes, e.g. TCF7L2, IGF2BP2, HNF1B, and
FTO (Figure 5B). While most of these genes were associated with
SNPs in regulatory regions active in PP and islets, some genes were
associated with SNPs in cell type-specific active regions. SNPs in
islet-specific regions were found near the genes FTO, HNF1A,
KCNJ11, PPP2R2C, and SYN2 and SNPs in PP-specific regions near
SYN2, IGF2BP2, KIF11, and PPARG. Of note, the PPARG locus is the
only T2DM locus were a T2DM-associated SNP falls exclusively into a
PP-specific active region and that does not have any T2DM-
associated SNP in a commonly active or islet-specific active site.
The enrichment of T2DM SNPs in active regulatory regions of PP cells
raises the possibility that the susceptibility to T2DM is, at least inMOLECULAR METABOLISM 9 (2018) 57e68  2018 The Authors. Published by Elsevier GmbH. This is an ope
www.molecularmetabolism.comparts, already established during pancreatic development, possibly
through miss-regulation of key genes and developmental programs.
Interestingly, when overlapping the disease-associated SNPs with
PDX1 binding sites in PP and islet cells, we found only six SNPs that lie
in the PDX1-bound sites (3 SNPs in PP PDX1 sites and 3 SNPs in islet
PDX1 sites) (Figure 5B). The SNP rs8044769, SNP rs78681698 and
SNP rs150111048 are in PDX1-bound regions in islets and are near
FTO, THADA, and IGF2BP2. Another 3 SNPs near HNF1B and TCF7L2
are found in PDX1-bound regions of PP cells. At the HNF1B locus, the
SNP rs11263763 is located in a PP-specific PDX1 binding site in the
first intron of HNF1B (Figure 5C). In addition, there are PP-specific
active enhancer regions, in the 4th intron and downstream of
HNF1B, suggesting that HNF1B might be regulated in different ways
during development and adulthood. At the TCF7L2 locus, the SNPs
rs12762233 and rs7087006 are located in PP-specific PDX1 binding
sites that may regulate TCF7L2 expression during development. SNPs
near the TCF7L2 locus have the highest association to T2DM and
mutations of HNF1B can cause MODY5. Thus, mutations in cis-
regulatory regions of these genes may predispose to diabetes. This
further supports the notion that the risk for T2DM might be linked to
early pancreas development.
4. DISCUSSION
Even though, a recent study confirmed that the key events of
pancreatic endocrine cell formation in vivo are mimicked during in vitron access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 65
Original Articledifferentiation [31], the efficient generation of functional and mature b-
cells for cell-replacement therapy of diabetes still remains a challenge
[32e34]. To produce such functional cells fulfilling the physiological
properties of mature islets, it is important to understand the molecular
mechanisms and gene regulatory networks governing the specification
of early human pancreatic lineages that later differentiate into func-
tional b-cells. In this context, understanding the temporal progression
of key pancreatic TF target genes during development is valuable in-
formation that helps to better recapitulate the developmental steps
required for the differentiation of functional b-cells in vitro. However,
the access to primary human material of early pancreas development
is very limited and thus, in vitro approaches have to be employed to
study these early steps in a human system.
Although it is well known that Pdx1 plays a crucial role during mouse
pancreas development, its stage-specific role in human pancreatic
progenitors and adult b-cells has not been thoroughly studied. To
address this question, we combined integrated analysis of genome-
wide PDX1 binding sites and H3K27ac together with mRNA profiling
in PPs derived from a novel human iPSC line.
Global characterization of PDX1 binding sites in iPSC-derived PPs iden-
tified numerous target sites and associated genes, including develop-
mental regulatory factors, signaling molecules and factors important for
mature b-cell function as well as many of the genes, differentially
expressed between iPSCs and PPs. To our knowledge, this is the first
genome-wide characterization of PDX1 binding in iPSC-derived PPs and
comparison with previous PDX1 datasets from hESC-derived PPs of
similar stages shows significant differences in PDX1 binding [22,24].
There are many possible explanations for this discrepancy in PDX1
binding, including differences in the efficiency of differentiation, factors
used in the in vitro differentiation protocol, and the exact developmental
stage at the time of the experiments. This could explain many of the
differences between the XM001 data from this study and the data from
Wang et al. [22], as these cells are slightly further in development and
already express NKX6.1. Moreover, the developmental competence of a
given cell line has implications on the differentiation of the cells andmight
favor a set of target sites over another. Despite the differences, however,
sites bound by PDX1 in multiple datasets are useful to identify high
confidence stage-specific target genes.
Among the PDX1-bound genes were RFX3 and DLL1 that are important
for mouse pancreas development [25e27]. RFX3 is a member of the
regulatory factor  family of transcription factors that contain a highly
conserved winged helix DNA-binding domain [35]. It has been shown
that Rfx3 is required for the differentiation and function of mature b-
cells and regulates the expression of the glucokinase gene in mice [25].
DLL1 is a member of the delta/serrate/jagged family of Notch ligands.
Mice deficient for the Delta-like 1 gene (Dll1) show increased expres-
sion of Ngn3, which, in turn, causes an accelerated and increased
commitment to the endocrine lineage and depletes the progenitor pool,
ultimately leading to pancreatic hypoplasia [26,27]. Whether these
genes play important roles in human pancreas development has not
been characterized. Therefore, our analysis suggests a possible
evolutionary conserved function of RFX3 and DLL1 during human
pancreas development. In contrast, other PDX1-bound genes such as
TIMP2,MAFB, and SIX2, are known to be specifically express in human,
but not in mouse b-cells [36,37]. To address the function of newly
identified PDX1 target genes during development, the XM001 iPSCs has
been modified to express CRISPR/Cas9 under the control of an inducible
promoter, which will allow gene functional studies in the future [38].
PDX1 is a master regulator of early pancreatic development and is
expressed in all PPs in vivo but becomes restricted to b-and d-cells
during later stages of endocrine differentiation. Therefore, it is likely, that66 MOLECULAR METABOLISM 9 (2018) 57e68  2018 The Authors. Published by Elsevier GmbH. ThiPDX1 has different functions and targets at different stages of devel-
opment. When we compared genome-wide PDX1 binding sites from
iPSC-derived PPs and adult human islets, only 20.4% of the identified
PDX1 targets were common in both cell populations. Interestingly, the
function of genes near common and specific binding sites differed
markedly and reflects cellular function. PDX1-bound genes in islets
were related to b-cell-specific functions. For example, the Kþ channel
KCNJ11 as well as the glucose transporter SLC2A2 are essential for
adult b-cell function, whereas NKX6-1 and MAFA are important for b-
cell identity and maturation. On the other hand, in PP cells PDX1-bound
genes, such as GATA4 and ONECUT1, are associated with processes
and pathways in early pancreas development. This shows that,
depending on the developmental stage, PDX1 target sites change to
activate molecular programs that are required for stage-specific
functions.
The presence of H3K27ac in PP cells at regions carrying T2DM-
associated SNPs indicates that these regions participate in the regu-
lation of gene activity. Variation in these regions potentially interferes
with the regulation of T2DM-relevant genes at the PP stage and might
therefore impair developmental programs and lead to reduce b-cell
mass or function at birth that contributes to an increased susceptibility
to T2DM. It has been shown that b-cell mass in children is highly
variable between individuals [39] and diabetic patients show
decreased b-cell mass [40]. One of the SNPs that we detected in a PP-
specific PDX1 binding site, rs11263763, lies in the first intron of
HNF1B and has been shown to reduce HNF1B expression [41]. This
gene has several SNPs in the first and second intron that are linked to
T2DM. During mouse pancreatic development, Hnf1b is involved in
controlling proliferation and survival of multipotent pancreatic pro-
genitors and deletion of the gene causes pancreatic hypoplasia. Hnf1b
is also important for the specification of endocrine progenitors through
regulation of Ngn3 expression [42]. In humans, some mutations in
HNF1B cause MODY5 [43]. We also identified the SNPs rs12762233
and rs7087006 within PP-specific PDX1 binding sites at the TCF7L2
locus. This gene, also known as Tcf4, is a member of the HMG-box
containing T-cell factor (Tiff)/Lymphoid enhancer factor (Lef) tran-
scription factor family of DNA-binding proteins and acts downstream of
the canonical Wnt pathway [44]. GWAS studies have identified TCF7L2
as the locus conveying the highest risk for developing T2DM in Eu-
ropean [45]. In mouse, Tcf7l2 is an important regulator of b-cell
development [46], whereas in human it regulates b-cell survival and
function [47]. Genetic and metabolic studies show that people carrying
TCF7L2 polymorphisms have insulin secretion defects in the presence
of normal incretin plasma levels [48]. HNF1B and TCF7L2 are therefore
important developmental regulatory factors and SNPs in PDX1-bound
regions in these loci might impair early developmental processes
that result in a higher risk to develop T2DM later in adulthood. The
three SNPs we found in islet-specific binding sites are near the FTO,
THADA, and IGF2BP2 genes, suggesting that these SNPs might
modulate adult b-cell function.
In summary, our study provides a PDX1 regulated human pancreas
developmental program that can be used to investigate the effects of
PDX1 mutations, e.g. in point mutations in the transactivation domain
found in T2DM patients, on pancreas developmental and islet PDX1
program [49,50]. Also, we find more than 430 T2DM-associated SNPs
in active regulatory regions and 32% of T2DM genes to be bound by
PDX1 in XM001 PPs, demonstrating that PDX1 occupancy is an effi-
cient way to identify important pancreatic developmental and disease
genes. This provides the base for further disease modeling in vitro
using stem cell and gene editing technologies to understand the causal
pathomechanisms underlying diabetes.s is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Original ArticlePoint mutations in the PDX1 transactivation
domain impair human b-cell development and
functionXianming Wang 1,2,3, Michael Sterr 1,2,3, Ansarullah 1,2, Ingo Burtscher 1,2, Anika Böttcher 1,2,
Julia Beckenbauer 1,2, Johanna Siehler 1,2,3, Thomas Meitinger 4, Hans-Ulrich Häring 5,6,8, Harald Staiger 5,7,8,
Filippo M. Cernilogar 9, Gunnar Schotta 9, Martin Irmler 10, Johannes Beckers 8,10,11,
Christopher V.E. Wright 12,13, Mostafa Bakhti 1,2,8, Heiko Lickert 1,2,3,8,*ABSTRACT
Objective: Hundreds of missense mutations in the coding region of PDX1 exist; however, if these mutations predispose to diabetes mellitus is
unknown.
Methods: In this study, we screened a large cohort of subjects with increased risk for diabetes and identified two subjects with impaired glucose
tolerance carrying common, heterozygous, missense mutations in the PDX1 coding region leading to single amino acid exchanges (P33T, C18R)
in its transactivation domain. We generated iPSCs from patients with heterozygous PDX1P33T/þ, PDX1C18R/þ mutations and engineered isogenic
cell lines carrying homozygous PDX1P33T/P33T, PDX1C18R/C18R mutations and a heterozygous PDX1 loss-of-function mutation (PDX1þ/).
Results: Using an in vitro b-cell differentiation protocol, we demonstrated that both, heterozygous PDX1P33T/þ, PDX1C18R/þ and homozygous
PDX1P33T/P33T, PDX1C18R/C18R mutations impair b-cell differentiation and function. Furthermore, PDX1þ/ and PDX1P33T/P33T mutations reduced
differentiation efficiency of pancreatic progenitors (PPs), due to downregulation of PDX1-bound genes, including transcription factors MNX1 and
PDX1 as well as insulin resistance gene CES1. Additionally, both PDX1P33T/þ and PDX1P33T/P33T mutations in PPs reduced the expression of PDX1-
bound genes including the long-noncoding RNA, MEG3 and the imprinted gene NNAT, both involved in insulin synthesis and secretion.
Conclusions: Our results reveal mechanistic details of how common coding mutations in PDX1 impair human pancreatic endocrine lineage
formation and b-cell function and contribute to the predisposition for diabetes.
 2019 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords PDX1; Transactivation domain; b-Cell differentiation; Insulin secretion; PDX1-Bound genes1. INTRODUCTION
Diabetes mellitus is a group of heterogeneous disorders character-
ized by high blood glucose levels that are caused by the loss and/or
dysfunction of the pancreatic insulin-producing b-cells. The mech-
anisms leading to the onset of this multifactorial disease still need to
be identified, and advancements will aid in improved diagnostics and
personalized therapy [1]. The major forms of diabetes include type 1
(T1D) and type 2 diabetes (T2D), gestational diabetes, and maturity-
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inheritance that result from loss-of-function mutations in key genes
involved in b-cell development or function [3]. In humans 13 different
MODYs have been characterized so far including MODY4, which is
associated with haploinsufficiency of the transcription factor (TF)
pancreas/duodenum homeobox protein 1 (PDX1) [4,5], one of the
master regulators of pancreas development and b-cell function. The
PDX1 gene encodes a TF containing a transactivation domain and
DNA binding homeodomain. In mouse, Pdx1 not only is important for
induction and growth of the embryonic pancreas but also plays a764 Neuherberg, Germany 2Institute of Stem Cell Research, Helmholtz Zentrum
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crucial role during insulin-producing b- and somatostatin-producing
d-cell development and function in the adult organ [6e9]. Homozy-
gous Pdx1-deficient mice fail to generate a pancreas [10], while
heterozygous animals develop a pancreas but become diabetic in
adulthood due to b-cell apoptosis [11e13]. In humans, several
missense coding mutations in PDX1 gene such as the P33T and C18R
mutations in the transactivation domain have been associated with
and increased risk for diabetes of the carrier individuals [14e16].
Currently, there are more than 150 missense coding mutations
described for PDX1 among which mutations at amino acid position 18
and 33 are rather common (gnomad.broadinstitute.org); however,
causal link to increased risk for type 2 diabetes is still missing for
most mutations [17]. In contrast, PDX1P33T/þ and PDX1C18R/þ mu-
tations have been shown to perturb the activity of the PDX1 protein
and reduce the expression of insulin gene in INS-1 and NES2Y cell
lines [15,16] although the exact mechanisms by which these mu-
tations contribute to diabetes predisposition are not understood.
Moreover, whether these mutations exert their effects through
impairment in developmental programs, regulating b-cell differenti-
ation or adult b-cell function remains unclear. Although several
studies have shed light on the developmental impacts of other coding
mutations of pancreatic TFs such as PDX1, HNF1B, GATA4, and
GATA6 [18e20], how common mutations in the PDX1 gene affect
human pancreatic progenitors and b-cells still needs to be
addressed. The major obstacle is a lack of appropriate modeling
systems to investigate the effect of loss-of-function or point muta-
tions in certain genes on human pancreas development. One of the
appealing approaches is the generation of induced pluripotent stem
cells (iPSCs) from somatic cells from diabetic patients [21,22]. In
such a system, patient-derived somatic cells are reprogrammed to
generate patient-specific stem cells, which can be further differen-
tiated into the endocrine lineage cells, mimicking human b-cell
development in a culture dish [19,23,24]. Alternatively, advance-
ments in CRISPR-Cas9 gene-editing technology offer targeting of
specific mutations in the genes of interest to generate disease-
specific cells and investigate the corresponding consequences
[20,25].
Previously, we identified the genome-wide target gene profile of PDX1
in human pancreatic progenitors [26]. However, how PDX1 coordinates
human pancreatic cell development is not understood in detail. To
address this, we investigated the impact of PDX1 coding mutations as
well as its haploinsufficiency (PDX1þ/) on differentiation of human
pancreatic cells from progenitor stage to b-cells. First, we screened a
large cohort of human subjects with high risk to develop diabetes and
identified individuals with insulin secretion deficiency associated with
heterozygous PDX1P33T/þ and PDX1C18R/þ missense mutations. Using
patient-derived iPSCs, we found that both heterozygous mutations
impair in vitro b-cell differentiation and function. To further exclude
genetic background variations in the human population and investigate
dose-dependent effects, we generated isogenic iPSC lines carrying
homozygous PDX1P33T/P33T and PDX1C18R/C18R point mutations. Our
results indicate that homozygous point mutations in the PDX1 trans-
activation domain do not only impact pancreatic endocrine lineage
development, but also impair glucose-responsive function of b-cells
through misregulation of several PDX1 target genes involved in b-cell
development, maturation, and function. Altogether, our data provide
novel insight into the mechanisms by which common point mutations
in the PDX1 transactivation domain impair human pancreatic b-cell
formation and function and contribute to increased risk for diabetes in
the general population.MOLECULAR METABOLISM 24 (2019) 80e97  2019 The Authors. Published by Elsevier GmbH. This is an open ac
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2.1. Ethics statement
The choice of appropriate human donors, the procedures for skin bi-
opsy, isolation of dermal fibroblasts, generation of iPSCs, and their use
in further scientific investigations were performed under the positive
vote of the Ethics Committee of the Medical Faculty of the Eberhard
Karls University, Tübingen. The study design followed the principles of
the Declaration of Helsinki. All study participants gave informed con-
sent prior to entry into the study.
2.2. Cell culture
hiPSCs were cultured on 1:100 diluted Matrigel (BD Biosciences, CA,
Cat #354277) in mTeSR1 medium (STEMCELL technologies, Cat
#85850). At w70e80% confluency, cultures were rinsed with
1  DPBS without Mg2þ and Ca2þ (Invitrogen, Cat #14190) followed
by incubation with TrypLE Select Enzyme (1 ) (Life Technologies, Cat
#12563011) for 3e5 min at 37 C. Single cells were rinsed with
mTeSR1 medium, and spun at 1,000 rpm for 3 min. The resulting
cell pellet was resuspended in mTeSR1 medium supplemented with
Y-27632 (10 mM; SigmaeAldrich; MO, Cat #Y0503), and the single cell
suspension was seeded atw0.75 105 cells/cm2 on Matrigel-coated
surfaces. Cultures were fed every day with mTeSR1 medium and
differentiation was initiated 72 h following seeding with w90%
starting confluency. All the cell lines were confirmed mycoplasma-free
by using the Lonza MycoAlert Mycoplasma Detection Kit (Lonza, Cat
#LT07-418).
2.3. 1st pancreatic lineage differentiation protocol
2.3.1. S1: definitive endoderm (3 d)
Cells were first rinsed with 1  DPBS without Mg2þ and Ca2þ and
then exposed to MCDB 131 medium (Life Technologies, Cat #10372-
019) further supplemented with 1.5 g/l sodium bicarbonate (Sigma,
MO, Cat #S6297), 1 Glutamax (Life Technologies, Cat #35050-079),
10 mM final glucose (Sigma, Cat #G8769) concentration, 0.5% bovine
serum albumin fraction V, fatty acid free (Sigma, Cat # 10775835001),
100 ng/ml Activin-A (R&D Systems Inc, Cat #338-AC-050/CF), and
3 mM or 5 mM of CHIR-99021 (GSK3b inhibitor, SelleckChem, Cat
#S2924) for day 1. For day 2, cells were cultured in MCDB 131 me-
dium with 0.5% BSA, 1.5 g/l sodium bicarbonate, 1  Glutamax,
10 mM glucose, 100 ng/ml Activin-A and 0.3 mM CHIR-99021. On day
3, cells were cultured in MCDB 131 with 0.5% BSA, 1.5 g/l sodium
bicarbonate, 1  Glutamax, 10 mM glucose and 100 ng/ml Activin-A.
2.3.2. S2: primitive gut tube (2 d)
Cells were rinsed with 1  DPBS without Mg2þ and Ca2þ and then
exposed to MCDB 131 medium further supplemented with 1.5 g/l
sodium bicarbonate, 1  Glutamax, 10 mM final glucose concentra-
tion, 0.5% BSA, 0.25 mM ascorbic acid (Sigma, Cat #A4544), 50 ng/ml
FGF7 (R & D Systems, Cat #251-KG-010/CF) or/and 1.25 mM IWP-2
(Tocris Bioscience, Cat #3533) for 2 d.
2.3.3. S3: posterior foregut (2 d)
Cells were then added for 2 d in MCDB 131 medium supplemented
with 2.5 g/l sodium bicarbonate, 1  Glutamax, 10 mM glucose
concentration, 2% BSA, 0.25 mM ascorbic acid, 50 ng/ml FGF7,
0.25 mM SANT-1 (Sigma, Cat #S4572), 1 mM retinoic acid (RA; Sigma,
Cat #R2625), 100 nM LDN193189 (LDN; BMP receptor inhibitor,
Stemgent, CA, Cat #04-0019), 1:200 ITS-X (Life Technologies, Catcess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 81
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2.3.4. S4: pancreatic endoderm (3 d)
Cells were exposed to MCDB 131 medium supplemented with 2.5 g/l
sodium bicarbonate, 1  Glutamax, 10 mM final glucose concentra-
tion, 2% BSA, 0.25 mM ascorbic acid, 2 ng/ml of FGF7, 0.25 mM
SANT-1, 0.1 mM retinoic acid, 200 nM LDN193189, 1:200 ITS-X, and
100 nM TPB for 3 d.
After 3 d of culture, the S4 cells were treated for 4 h with 10 mM Y-
27632. Cells were then rinsed with 1 DPBS without Mg2þ and Ca2þ
and exposed to TrypLE Select Enzyme (1  ) (Life Technologies, Cat
#12563011) for 3e5 min at 37 C. The released cells were washed
with basal MCDB 131 medium and spun at 1,000 rpm for 3 min. Cell
pellets were resuspended in S5-7 media with S5 chemical supple-
ments atw50 million cells/ml and spotted onto Transwell insert filters
(6-well plate: Corning 3414) for culture in air-liquid interface at 10 ml/
spot and w10 spots per well. S5-7 media with supplements were
added to the bottom of each insert:w1.5 ml per well.
2.3.5. S5: pancreatic endocrine precursors (3 d)
Cells were further cultured in MCDB 131 medium supplemented with
1.5 g/l sodium bicarbonate, 1  Glutamax, 20 mM glucose, 2% BSA,
0.25mMSANT-1, 0.05mM retinoic acid, 100 nM LDN193189, 1:200 ITS-
X, 1mMT3 (3,30,5-Triiodo-L-thyronine sodiumsalt, Sigma, T6397), 10mM
ALK5 inhibitor II (Enzo Life Sciences, NY, Cat #ALX-270-445), 10 mM zinc
sulfate (Sigma, Z0251) and 10 mg/ml of heparin (Sigma, H3149).
2.3.6. S6: immature b-like cells (7 d)
Cells were exposed to the MCDB 131 medium further supplemented
with 1.5 g/l sodium bicarbonate, 1  Glutamax, 20 mM glucose, 2%
BSA, 100 nM LDN193189, 1:200 ITS-X, 1 mM T3, 10 mM ALK5 in-
hibitor II, 10 mM zinc sulfate, 100 nM gamma secretase inhibitor XX
(EMD MilliPore, MA, Cat #565789) and 10 mg/ml of heparin for 7 d.
2.3.7. S7: mature b-like cells (14 d)
Cells were further cultured in MCDB 131 medium supplemented with
1.5 g/l sodium bicarbonate, 1  Glutamax, 20 mM final glucose
concentration, 2% BSA, 1:200 ITS-X, 1 mM T3, 10 mM ALK5 inhibitor II,
10 mM zinc sulfate, 1 mM N-acetyl cysteine (N-Cys, Sigma, Cat
#A9165), 10 mM Trolox (Vitamin E analogue, EMD, Cat #648471),
2 mM R428 (AXL inhibitor, SelleckChem, Cat #S2841) and 10 mg/ml of
heparin for 14 d. For all stages, the cultures were fed every day.
2.4. 2nd generation pancreatic progenitor differentiation protocol
2.4.1. S1: definitive endoderm (3 d)
iPSCs plated on 1:100 diluted Matrigel were first rinsed with 1 DPBS
without Mg2þ and Ca2þ (Invitrogen) and then cultured in RPMI 1640
medium (Invitrogen, Cat #21875-034) further supplemented with
1.2 g/L sodium bicarbonate (Sigma), 0.2% ESC-qualified FBS (Life
Technologies, Cat #16141-079), 100 ng/mL Activin-A (R&D Systems),
and 20 ng/mL of Wnt3A (R&D Systems, Cat #5036-WN-010) for day 1
only. For the next 2 days, cells were cultured in RPMI with 0.5% FBS,
1.2 g/L sodium bicarbonate and 100 ng/mL Activin-A.
2.4.2. S2: primitive gut tube (3 d)
Cells were rinsed with 1  DPBS (without Mg2þ and Ca2þ) once and
then exposed to DMEM-F12 (Life Technologies, Cat #21041025)
medium further supplemented with 2 g/L sodium bicarbonate, 2% FBS
and 50 ng/mL of FGF7 for 3 days.82 MOLECULAR METABOLISM 24 (2019) 80e97  2019 The Authors. Published by Elsevier GmbH. T2.4.3. S3: posterior foregut (4 d)
Cultures were maintained for 4 days in DMEM-HG medium (Life
Technologies, Cat #41966029) supplemented with 0.25 mM SANT-1
(SigmaeAldrich), 2 mM retinoic acid (RA; SigmaeAldrich), 100 ng/
mL of Noggin (R&D Systems, Cat #6057-NG-025), and 1% B27
(Invitrogen, Cat #17504044).
2.5. Generation of clonal hiPSC mutant lines using gRNA or gRNA/
ssDNA transfection in hiPSCs
All mutant lines were generated using a previously established pro-
tocol [27]. The plasmid for transfection (pU6-(BbsI) sgRNA_CAG-
venus-bpA, Addgene ID86985) was a gift from from Dr. Ralf Kühn
and contained BbsI site for single or multiple gRNAs, the Venus gene
and the Cas9 gene. Human iPSCs were cultured for two days and
then dissociated using TrypLE select, replated onto Matrigel-coated
plates and transfected in suspension with gRNAs or gRNA/ssDNA
using Lipofectamine RNAiMAX (Thermo Fisher Scientific, Cat
#13778-150) following manufacturer’s instructions. For one well of
6-well plates, 0.75  106 cells were seeded. For the PDX1þ/
knockout cell line, 2.5 ug plasmid of gRNA was added for one
transfection. For the point mutations, 2.5 ug plasmid with the gRNA
and 30 pmol ssDNA were added in one transfection. gRNAs or gRNA/
ssDNA and Lipofectamine RNAiMAX were diluted separately in Opti-
MEM (Thermo Fisher Scientific, Cat # 31985070), mixed together,
incubated for 5 min at room temperature (R.T.), and added dropwise
to the hiPSCs before plating.
2.6. Establishment of clonal hiPSC mutant lines
Two days after the gRNA or gRNA/ssDNA transfection, hiPSCs were
dissociated into single cells and the transfected positive cells char-
acterized by Venus expression were sorted by FACS. After that, the
sorted cells were replated at a low density (500-1,000 cells per 10 cm
dish). The remaining cells were collected and genomic DNA was
extracted. T7 endonuclease I assay was then performed to assess the
CRISPR mutagenesis efficiency. The seeded cells were allowed to
grow and form colonies from single cells. Medium was changed every
2 days. 10 days later, individual colonies were picked, mechanically
disaggregated and replated in mTeSR1 medium into individual wells
of 96-well plates coated with Matrigel. Clonal lines were expanded. A
portion of the cells was lysed to gain genomic DNA. Then PCR was
performed using Herculase II Fusion DNA Polymerase (Agilent Tech-
nologies, Cat #600679) followed by Sanger sequencing to identify
mutant clones. Primers for PDX1 are as follows: forward:
TACCTGGGCCTAGCCTCTTAGTG, reverse: TGAGAACCGGAAAGGA-
GAAAGGG. Clonal cell lines carrying desired mutations were further
expanded and frozen down.
2.7. Immunofluorescence imaging
Cells were fixed with 4% paraformaldehyde for 30 min and then
permeabilized in PBS containing 0.2% Triton X-100. Cells were
blocked with PBS containing 3% BSA, and incubated with primary
antibodies overnight at 4 C. Then the cells were incubated with the
secondary antibodies for 1 h at room temperature after washing with
PBS. Images were acquired on a TCS SP5 laser-scanning microscope
(Leica). The following antibodies and dilutions were used: goat anti-
OCT-3/4 (1:500, Cat #sc-8628, Santa Cruz), goat anti-SOX2 (1:500,
Cat #sc-17320, Santa Cruz), mouse anti-TRA-1-81 (1:50, Cat
#MAB4381, Millipore), mouse anti-SSEA4 (1:500, Cat #4755, Cell
Signaling), rabbit anti-FOXA2 (1:250, Cat #8186, Cell Signaling), goat
anti-SOX17 (1:500, Cat #GT15094, Acris/Novus), goat anti-PDX1
(1:500, Cat #AF2419, R&D Systems), rabbit anti-NKX6.1 (1:300, Cathis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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#NBP1-82553, Acris/Novus), guinea pig anti-C-Peptide (1:100, Cat
#ab30477, Abcam), mouse anti-Glucagon (1:500, Cat #G2654,
Sigma), rat anti-Somatostatin (1:300, Cat #MA5-16987, Invitrogen).
2.8. Flow cytometry
Cells were dissociated using 1  TrypLE Select Enzyme and collected.
After that, cells were washed with cold FACS buffer (5% FBS in
1  DPBS). Cells were fixed with 4% paraformaldehyde and per-
meabilized with donkey block solution (0.1% tween-20, 10% FBS,
0.1% BSA and 3% donkey serum) containing 0.5% saponin. The cells
were incubated with rabbit anti-FOXA2 (1:200, #8186, Cell Signaling),
goat anti-SOX17 antibody (1:200, Cat #GT15094, Acris/Novus), goat
anti-PDX1 antibody (1:100, Cat #AF2419, R&D Systems), rabbit anti-
NKX6.1 antibody (1:200, Cat #NBP1-82553, Acris/Novus), guinea pig
anti-C-Peptide antibody (1:100, Cat #ab30477, Abcam), mouse anti-
Glucagon (1:500, Cat #G2654, Sigma), for 30 min at room tempera-
ture and then stained with appropriate AlexaFluor-555 and -647
secondary antibody for 30 min at room temperature. Flow cytometry
was performed using FACS-Aria III (BD Bioscience). FACS data were
analyzed using FlowJo. For quantification of median fluorescence in-
tensity (MFI) for PDX1, the PDX1 positive population was first gated and
then MFI was calculated using BD FACS software.
2.9. RNA isolation and qPCR
Total RNA was extracted from cells with the miRNeasy mini kit (Qia-
gen). cDNA synthesis was performed with a high-capacity RNA-to-
cDNA kit (Applied Biosystems). TaqMan qPCR was performed under
standard conditions using ViiA7 (Applied Biosystems) and TaqMan Fast
Advanced Master Mix (Applied Biosystems). Samples were normalized
to the housekeeping genes 18S ribosomal RNA (RNA18S) and glyc-
eraldehyde 3-phosphate dehydrogenase (GAPDH). Taqman probes
(Applied Biosystems): INS, Hs02741908_m1; GCG, Hs01031536_m1;
SST, Hs00356144_m1; PDX1, Hs00236830_m1; GAPDH,
Hs02758991_g1; 18S, Hs99999901_s1; NKX6.1, Hs01055914_m1;
MAFA, Hs01651425_s1; NEUROD1, Hs01922995_s1; UCN3,
Hs00846499_s1; PAX6, Hs01088114_m1; ABCC8, Hs01093752_m1;
KCNJ11, Hs00265026_s1; SLC30A8, Hs00545183_m1.
2.10. Affymetrix microarray
For microarray analysis, total RNA from PDX1P33T/þ and XM001 PPs,
produced with the 2nd differentiation protocol, was extracted using
the miRNeasy Mini kit (Qiagen, Cat #217004). RNA integrity was
checked using the Agilent 2100 Bioanalyzer (Agilent RNA 6000 Pico
Kit) and cDNA was amplified with the Ovation PicoSL WTA System
V2 (Nugen, 3312) in combination with the Encore Biotin Module
(Nugen, USA). Amplified cDNA was hybridized on GeneChip Hu-
man Gene 2.0 ST arrays (Affymetrix, 902113). Expression console
(v.1.3.0.187, Affymetrix) was used for quality control. All subsequent
computational analysis was performed in R using Bioconductor
packages. Expression data were RMA normalized using the oligo
package (version 1.38.0) and probe sets were annotated using the
package hugene20sttranscriptcluster.db (version 8.5.0). Differential
expression analyses were performed on prefiltered data, containing
the 30562 probe sets with highest expression values, using the
limma package (version 3.30.7) and p-values were adjusted for
multiple testing by Benjamini-Hochberg correction. A gene was
considered differentially expressed if the adjusted p-value (FDR) was
below a threshold of 0.1 and the fold-change was greater than or
equal to 2. Functional enrichments were conducted using HOMER
[28]. Functional annotations were based on term affiliations pro-
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All samples for ChIP-seq were processed as described in [26].
PDX1P33T/þ PP cells (2  106 cells) were cross-linked in 1% form-
aldehyde in culture medium for 10 min at room temperature. The
cross-linking reaction was stopped by the addition of glycine to a final
concentration of 125 mM. For chromatin fragmentation, cells were
resuspended in lysis buffer (50 mM Tris-HCl (pH 8.0), 10 mM EDTA,
0.5% SDS) and sonicated in a Covaris S220 sonicator with a duty cycle
of 2%, a peak incident power of 105 W and 200 cycles per burst for
20 min. The fragmented chromatin was diluted 1:5 in IP-Buffer (10 mM
Tris-HCl (pH 7.5), 1 mM EDTA, 0.5 mM EGTA, 1% Triton X-100, 0.1%
SDS, 0.1% Na-Desoxycholate, 140 mM NaCl, H2O, Protease Inhibitors)
and directly used for immunoprecipitation. For PDX1 ChIP, 60% of the
chromatin (equivalent of 1.2 106 cells) was processed in two parallel
ChIPs using magnetic beads, preloaded with 3 ml goat anti PDX1
antibody (kindly provided by C. Wright), for each ChIP. For H3K27ac
ChIP, 40% of the chromatin (equivalent 0.4  106 cells) was pro-
cessed in three parallel IPs using magnetic beads, preloaded with 3 mg
anti H3K27ac antibody (Diagenode, C15410174). For all ChIPs, anti-
body incubation was performed at 4 C for 5 h. Beads were then
washed 5 times using (1.) IP-Buffer, (2.) Washing-Buffer 1 (500 mM
NaCl, 50 mM Tris-HCl (pH 8.0), 0.1% SDS, 1% NP-40), (3.) Washing-
Buffer 2 (250 mM LiCl, 50 mM Tris-HCl (pH 8.0), 0.5% Na-
Deoxycholate, 1% NP-40) and (4. & 5.) Washing-Buffer 3 (10 mM
Tris-HCl (pH 8.0), 10 mM EDTA). Subsequently, protein-DNA com-
plexes were eluted from the beads in Elution-Buffer (50 mM Tris-HCl
(pH 8.0), 10 mM EDTA, 1% SDS) at 65 C for 20 min. Cross-links
were reversed at 65 C overnight and DNA was purified for library
construction using the MicroPlex kit (Diagenode, C05010010).
2.12. ChIP-seq data analysis
For all processing and analysis steps, PDX1P33T/þ data from this study
was used together with data from XM001 cells, previously published
by our group (GSE106950) [26]. Raw reads from PDX1 and H3K27ac
ChIP-seq were processed with Trimmomatic (0.35) to remove low
quality bases and potential adapter contamination. Next, reads were
aligned to hg19 genome using bowtie2 (2.2.6) with very-sensitive
option and duplicate reads were removed using samtools (1.3). BAM
files from PDX1P33T/þ cells were subsampled to match the read depth
of the BAM files from XM001 cells using samtools. Binding sites of
PDX1 in XM001 and PDX1P33T/þ cells were then called using GEM (3.2)
in multi condition mode and filtered, after visual inspection, using a Q-
value cut-off of 104 (XM001) and 104.05 (PDX1P33T/þ). Subse-
quently, overlapping regions were merged. Regions of H3K27ac
enrichment were called using HOMER (4.10) on the merged data from
XM001 and PDX1P33T/þ cells using parameters -style histone -size
500 -minDist 2000. PDX1 binding sites and H3K27ac enriched regions
were further filtered by removing blacklist regions. H3K27ac read
counts from XM001 and PDX1P33T/þ cells were normalized using a set
of promoters from housekeeping genes [29]. Housekeeping genes
were derived from the microarray data and defined by an absolute log2
fold change (PDX1P33T/þ vs XM001) < log2 (1.1) and a linear coeffi-
cient of variation < 0.15. Reads were counted in a region from 1000
bp upstream to 100 bp downstream of the TSS of the housekeeping
genes and DESeq2 (1.20) was used to estimate size factors for
normalization. Normalized read counts where used when indicated in
the figures. Regions and binding sites within 20 kb of a TSS or within a
gene body were annotated with the respective gene using bedtools
(2.26.0). Motif analysis, annotations with genomic features and
pathway enrichment analysis were performed using HOMER. To
calculate enrichment of H3K27ac at PDX1-bound sites, three sets ofcess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 83
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PDX1P33T/þ cells using bedtools (2.26.0) shuffle. Then, H3K27ac reads
were counted and ratio of the mean read count at PDX1 sites over the
mean read count at shuffled sites was calculated. For visualization,
BIGWIG files were generated from downsampled BAM files and
normalized using the size factors previously determined by DESeq2
(H3K27ac only) using deeptools bamCoverage (3.1.0).
2.13. RNA-seq
RNA samples from PDX1þ/, PDX1P33T/P33T, PDX1C18R/C18R and
XM001 lines were collected at the PP1 stage were produced by the 1st
differentiation protocol. Total RNA from PDX1þ/, PDX1P33T/P33T,
PDX1C18R/C18R, and XM001 lines was extracted using miRNeasy Mini
kit (Qiagen, #217004) and RNA integrity was checked using Agilent
2100 Bioanalyzer (Agilent RNA 6000 Pico Kit). Libraries were prepared
using the TruSeq Stranded mRNA Library Prep (Illumina).
2.14. RNA-seq analysis
RNA-seq data was quantified using salmon (0.11.3) quant with options
e validateMappings e rangeFactorizationBins 4 e numBootstraps
100 e seqBias e gcBias. Quantification results were imported into R
using tximport. DESeq2 (1.20) [30] was used for differential expression
analysis as follows. Genes with less than 6 reads were discarded and
DESEq2 was run with default parameters. Results were calculated with
independent filtering and independent hypothesis weighting [31]. For
the comparison PPs against iPSCs, all data sets were used and all PP
samples (i.e. XM001, PDX1C18R/C18R, PDX1P33T/P33T, and PDX1þ/)
were compared with XM001 iPSCs using the lfcThreshold¼ 1.5 option
in the results function. For the comparison of the different PP cells, only
data from PPs were loaded into DESeq2. Results for these compari-
sons were generated without the lfcThreshold option. For all analyses,
fold changes were shrunken using the apeglm method [32] using the
results from independent hypothesis weighting. Genes were consid-
ered as differentially expressed when the FDR was>0.05 (PP vs iPSC)
or 0.1 (PDX1 mutations vs control) and absolute shrunken log2 fold
change was >2 (PP vs iPSC) or 1 (PDX1 mutations vs control). GO-
term and pathway analysis were performed using HOMER.
2.15. Static glucose stimulation insulin secretion
Static glucose stimulated insulin secretion (GSIS) of the generated b-
like cells was performed based on previous protocols [18,20]. Briefly, 5
aggregates were picked and rinsed three times with KRBH buffer
(129 mM NaCl, 4.8 mM KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, 1 mM
Na2HPO4, 1.2 mM KH2PO4, 5 mM NaHCO3, 10 mM HEPES and 0.1%
BSA in deionized water and sterile filtered) and then equilibrated in
KRBH buffer at 37 C for 1 h. Aggregates then were incubated in KRBH
buffer with 2.8 mM glucose for 60 min at R.T. Supernatants were
collected, and the aggregates were transferred to KRBH buffer with
16.7 mM glucose for 60 min. Supernatants were collected again. At
the end of the experiment, cell aggregates were dissociated into single
cells and the cell numbers were counted to normalize the GSIS.
Mercodia Human Insulin ELISA kit (Mercodia, Cat #10-1113-01) and
Human C-peptide ELISA kit (Mercodia, Cat #10-1141-01) was used to
measure the insulin and C-peptide content in supernatant samples
following manufacturer’s protocols.
2.16. Western blotting
Cells were harvested at PP1 stages and lysed using cell lysis buffer
containing protease inhibitors. Samples were separated on a 10%
SDS-PAGE gel and transferred to PVDF Pre-Cut Blotting Membranes
followed by blocking with 5% milk in Tris-based saline with Tween 2084 MOLECULAR METABOLISM 24 (2019) 80e97  2019 The Authors. Published by Elsevier GmbH. T(0.1% TBST) buffer for 1 h at R.T. The membrane was incubated with
primary antibodies overnight at 4 C, followed by incubation with HRP
conjugated secondary antibodies at R.T. for 1 h. ECL western blotting
detection reagent (Bio-rad, Cat #1705061) was used to visualize the
protein bands. The following antibodies were used with the dilution
ratio noted: goat anti-PDX1 (R&D, Cat #AF2419, 1:1,000), mouse
anti-ACTB (b-Actin) (Cell Signaling Technology, Cat #3700S,
1:10,000).
2.17. Statistics
Statistical significance was determined using one-way ANOVA fol-
lowed by Bonferroni’s multiple comparisons test using GraphPad Prism
(version 8.0.0 for Windows, GraphPad Software, San Diego, California
USA). A value of P < 0.05 was considered statistically significant.
2.18. Accession numbers
Microarray, RNA-seq and ChIP-seq data has been submitted to the
GEO database at NCBI under the accession number GSE125770.
3. RESULTS
3.1. Generation of b-like cells from patients carrying PDX1P33T/þ
and PDX1C18R/þ mutations
To obtain samples from subjects with PDX1 mutations, 2547 partici-
pants of the Tübingen Family Study for T2D (TÜF study, currently more
than 3000 participants, inclusion criteria given in Table 1) were
screened by mass spectrometry for known rare mutations in the
MODY4 gene PDX1 [33]. In this cohort, we identified six heterozygous
P33T (Pro-Thr) carriers (frequency w1:425) and one heterozygous
C18R (Cys-Arg) carrier (frequency w1:2500). Of note, both of the
mutations occur at highly conserved amino acids in the transactivation
domain of PDX1 (Suppl. Figure 1A,B). One of the PDX1 P33T carriers
and the PDX1 C18R carrier were recruited for full-thickness skin bi-
opsy, and primary dermal fibroblasts were isolated from the skin
specimens. The clinical characteristics of the two mutation carriers
compared to the average of the whole TÜF cohort showed decreased
insulin secretion (Table 1). We reprogramed the primary fibroblasts
into iPSCs using nucleofection with three episomal plasmids encoding
human OCT4, SOX2, NANOG, LIN28, KLF4, and L-MYC
(Suppl. Figure 1C) and several colonies were picked and expanded.
The established control cell line XM001 as well as the P33T (PDX1P33T/
þ) and C18R (PDX1C18R/þ) iPSC lines were reported previously
[26,34,35].
To investigate the disease-relevant phenotype of these mutations
during b-cell development, we differentiated patient-derived iPSCs into
b-like cells using a differentiation protocol which is based on Rezania
et al., 2014 (Figure 1A) [36]. Fluorescent activated cell sorting (FACS)
analysis revealed approximately 90% positive cells for the definitive
endoderm (DE) marker SOX17 (Suppl. Figure 2A-B). As expected, there
was no difference between the patients and the control iPSC lines in
endoderm differentiation, since PDX1 is not expressed until PP1 stage
(Suppl. Figure 2C). Moreover, we detectedw85% PDX1-positive cells
for all rounds of iPSC differentiation using FACS analysis at PP1 stage
(Suppl. Figure 3A-C), while the protein levels of PDX1 were the same in
cells derived from the patients (Suppl. Figure 3D-E). A similar differ-
entiation efficiency was also observed for late stage PP2 where we
detected w40% PDX1/NKX6.1 double-positive cells derived from all
iPSC cell lines by immunostaining and FACS analysis
(Suppl. Figure 4A-C). Altogether, these data indicate that PDX1P33T/þ
and PDX1C18R/þ mutations do not significantly impair early pancreatic
progenitor differentiation.his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Table 1 e Clinical characteristics of mutation carriers compared to the average of the TÜF study.
Trait PDX1 P33T/þ PDX1 C18R/þ TÜF overall (N ¼ 3029)
Gender Female Female 64.2% Females
Age (yrs) 40 33 42 31e54
BMI (kg/m2) 23.0a 20.6a 28.7 24.3e35.3
Body fat content (%) 29 24 33 24e45
Waist-hip ratio 0.819 0.766a 0.869 0.813e0.941
Glucose0 (mmol/L) 5.10 5.06 5.17 4.88e5.56
Glucose120 (mmol/L) 5.83 4.90
a 6.22 5.28e7.33
HbA1c (%) 4.7a 4.4a,b 5.5 5.2e5.8
Insulin0 (pmol/L) 39
a 40a 68 42e112
Insulin30 (pmol/L) 419 268
a 522 326e836
C-peptide0 (pmol/L) 643 427 554 415e777
C-peptide30 (pmol/L) 2372 1487 1824 1397e2407
Proinsulin0 (pmol/L) 3 4 3 2e6
Proinsulin30 (pmol/L) 12 16
a 8 4e13
AUC insulin0-30/AUC glucose0-30 (10
9) 28.8 25.7a 43.6 28.5e66.7
AUC C-peptide0-120/AUC glucose0-120 (10
9) 340 266 288 237e356
HOMA-IR (106 mol*U*L2) 1.47a 1.50a 2.61 1.57e4.47
ISI OGTT (1019 L2*mol2) 13.6 26.5a 9.8 5.8e16.0
FFA (mmol/L) 519 618 566 434e720
Leukocytes (ml1) 5140 2520a 6080 5118e7380
CRP (mg/dL) 0.11 0.14 0.16 0.07e0.48
GOT (U/L) 18 18 21 17e27
GGT (U/L) 14 23 19 12e31
Triglycerides (mg/dL) 61a 59a 101 72e144
Total cholesterol (mg/dL) 164a 190 191 167e217
HDL-cholesterol (mg/dL) 40a,b 66a 52 43e62
LDL-cholesterol (mg/dL) 106 122 113 94e137
TÜF inclusion criteria fulfilled Previous GDM FHD (one second-degree relative) IFG and/or BMI 27 kg/m2 and/or FHD and/or previous GDM
TÜF data represent proportion (gender) or medians and interquartile ranges (all other traits). Subscript numbers indicate time-points (in minutes) of the oral glucose tolerance test.
a Outside TÜF interquartile range.
b Outside clinical reference range (central laboratory data). AUC e area under the curve; BMI e body-mass index; CRP e C-reactive protein; FFA e free fatty acids; FHD e family
history of diabetes; GDM e gestational diabetes mellitus; GGT e g-glutamyl transferase; GOT e glutamate-oxaloacetate transaminase; HbA1c e glycated hemoglobin A1c; HDL e
high-density lipoprotein; HOMA-IR e homeostasis model assessment of insulin resistance; IFG e impaired fasting glycemia; ISI e insulin sensitivity index; LDL e low-density li-
poprotein; OGTT e oral glucose tolerance test; TÜF e Tübingen Family study for type-2 diabetes.To assess whether these two point mutations in PDX1 affect late
stages of b-cell development, we differentiated patient-derived iPSCs
towards b-like cells. Immunostaining analysis revealed that both pa-
tients and control iPSCs generate predominantly cells, co-expressing
C-peptide/NKX6.1 and C-peptide/PDX1, and minor populations
expressing the a-cell hormone glucagon or the d-cell hormone so-
matostatin (Figure 1B and Suppl. Figure 5A). Quantification of b-like
cell differentiation efficiency showed w25% C-peptide-positive cells
for the control but only w8% C-peptide-positive cells for the patient
samples (Figure 1C,D). The transcript level of INS was lower in cells
derived from the patients as revealed by q-PCR analysis (Figure 1E).
The impairment in b-cell differentiation was also reflected by a weaker
response to a glucose challenge in patient iPSCs-derived b-like cells
compared to those derived from the control iPSCs, as assessed by a
glucose-stimulated insulin secretion (GSIS) assay (Figure 1F and
Suppl. Figure 5B). This reduced GSIS might be due to impaired b-cell
glucose-responsive machinery components or delayed b-cell differ-
entiation programs. Altogether, these data indicate that PDX1 het-
erozygous point mutations in the transactivation domain impair the
differentiation of b-like cells and consequently impact their glucose-
responsive function.
3.2. Characterization of PDX1þ/, PDX1P33T/P33T and PDX1C18R/
C18R mutations at the early pancreatic stage (PP1)
Although we analyzed two different patient-derived iPSC lines, it is
possible that the observed phenotypes result from differences in the
genetic background of control and the patient iPSC lines and are not
due to the point mutations in the PDX1 transactivation domain. ToMOLECULAR METABOLISM 24 (2019) 80e97  2019 The Authors. Published by Elsevier GmbH. This is an open ac
www.molecularmetabolism.comexclude this possibility, we generated cell lines carrying homozy-
gous PDX1 P33T (PDX1P33T/P33T) and C18R (PDX1C18R/C18R) point
mutations from the control XM001 iPSC line. This approach also
allowed us to analyze dose-dependent effects of the common PDX1
mutations (Suppl. Figure 6A, C-D). Using targeted genetic modifi-
cations by the CRISPR/Cas9 system, we generated XM001 iPSC
lines carrying PDX1P33T/P33T or PDX1C18R/C18R mutations. Further-
more, to study the effects of PDX1 haploinsufficiency, we generated
a PDX1þ/ XM001 iPSC line (Suppl. Figure 6B) by targeting the
transactivation domain to generate a frame-shift mutation. Isogenic
cells with PDX1 haploinsufficiency or the point mutations on both
alleles, displayed normal karyotype (Suppl. Figure 7A) and
expressed pluripotency markers (TRA-1-81, SSEA-4, OCT3/4 and
SOX2; Suppl. Figure 7B).
To address whether PDX1 heterozygosity and homozygous point
mutations affect pancreas development, we differentiated the isogenic
control and mutant iPSCs towards the pancreatic lineage using an
improved differentiation protocol by increasing the concentration of
CHIR-99021 during S1 stage and adding IWP-2 during S2 stage. We
found that all iPSC lines differentiated normally into endoderm cells co-
expressing SOX17 and FOXA2 (w90%) as determined by immuno-
staining and FACS analysis (Suppl. Figure 8A-C). At the PP1 stage, all
control and mutant iPSC lines generated pancreatic progenitors with
similar efficiency (w90%) (Figure 2AeC), however, PDX1 protein
levels (Figure 2D) as measured by FACS and immunofluorescence
(Figure 2E,F) were substantially lower in PP1 cells differentiated from
the PDX1P33T/P33T and PDX1þ/ iPSCs as compared to the control and
PDX1C18R/C18R iPSCs.cess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 85
Figure 1: Generation of b-like cells from patients carrying PDX1P33T/þ and PDX1C18R/þ mutations. (A) Schematic of iPSC-derived b-like cells protocol. (B) Immunostaining
for CPEP, GCG, PDX1, and NKX6.1 in the XM001, PDX1P33T/þ and PDX1C18R/þ cells at the S7 stage. Scale bar indicates 25 mm. (C) Representative FACS plots of CPEPþ cells in the
XM001, PDX1P33T/þ and PDX1C18R/þ cells at the S7 stage. (D) FACS quantification of the percentage of CPEPþ cells in the XM001, PDX1P33T/þ and PDX1C18R/þ cells at the S7 stage
(n ¼ 3). (E) RT-qPCR analysis of INS gene expression in the XM001, PDX1P33T/þ and PDX1C18R/þ cells at the S7 stage (n ¼ 3). (F) Glucose-stimulated insulin secretion assay for the
XM001, PDX1P33T/þ, and PDX1C18R/þ cells at the S7 stage. The fold change of insulin secretion with high glucose (16.7 mM) relative to low glucose (2.8 mM) treatment is shown
(n ¼ 3).
Original Article3.3. Characterization of PDX1þ/, PDX1P33T/P33T and PDX1C18R/
C18R mutations at the late pancreatic stage (PP2)
Although we detected PDX1 and NKX6.1 double-positive cells in all
isogenic cell lines, the number of double-positive cells were signifi-
cantly lower in PDX1P33T/P33T and PDX1þ/ iPSC lines, as compared to
PDX1C18R/C18R and control iPSC lines (Figure 3AeC), clearly demon-
strating that the expression of NKX6.1 and pancreatic differentiation
into PP2 cells were impaired.86 MOLECULAR METABOLISM 24 (2019) 80e97  2019 The Authors. Published by Elsevier GmbH. T3.4. Characterization of the impact of PDX1þ/, PDX1P33T/P33T and
PDX1C18R/C18R mutations on b-like cell differentiation
To investigate the functional consequences of haploinsufficient PDX1
levels or homozygous PDX1 point mutations in b-cell development, we
differentiated isogenic iPSCs towards b-like cells. Similar to cells
derived from the patient iPSCs, a majority of cells co-expressed C-
peptide/NKX6.1 and C-peptide/PDX1 and only few cells expressed
glucagon and somatostatin (Figure 4A and Suppl. Figure 9A). However,his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 2: Characterization of PDX1þ/, PDX1P33T/P33T, and PDX1C18R/C18R mutations at the early pancreatic stage (PP1). (A) Representative FACS plots of PDX1þ cells in
XM001, PDX1þ/, PDX1P33T/P33T, and PDX1C18R/C18R cells at the early pancreatic stage. (B) Representative immunofluorescence staining of PDX1 in XM001, PDX1þ/, PDX1P33T/
P33T, and PDX1C18R/C18R. Scale bar indicates 50 mm. (C) FACS quantification of the percentage of PDX1þ cells in XM001, PDX1þ/, PDX1P33T/P33T and PDX1C18R/C18R cells at the
PP1 stage (n ¼ 3). (D) Representative immunoblot of PDX1 expression from XM001, PDX1þ/, PDX1P33T/P33T, and PDX1C18R/C18R cells at the PP1 stage. (E) Representative FACS
histograms comparing the differentiation efficiencies towards the PDX1þ cells in XM001, PDX1þ/, PDX1P33T/P33T, and PDX1C18R/C18R cells. (F) Median Fluorescence Intensity (MFI)
quantification for XM001, PDX1þ/, PDX1P33T/P33T, and PDX1C18R/C18R cells at the PP1 stage stained with PDX1 antibody (n ¼ 6).
MOLECULAR METABOLISM 24 (2019) 80e97  2019 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 3: Characterization of PDX1þ/, PDX1P33T/P33T and PDX1C18R/C18R mutations at the late pancreatic stage (PP2). (A) Representative immunofluorescence staining of
PDX1 and NKX6.1 in XM001, PDX1þ/, PDX1P33T/P33T, and PDX1C18R/C18R cells. Scale bar indicates 50 mm. (B) Representative FACS plots of PDX1þ and NKX6.1þcells in XM001,
PDX1þ/, PDX1P33T/P33T, and PDX1C18R/C18R cells at the PP2 stage. (C) FACS quantification of the percentage of PDX1þ and NKX6.1þcells in XM001, PDX1þ/, PDX1P33T/P33T, and
PDX1C18R/C18R cells at the PP2 stage (n ¼ 3).
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the number of total C-peptide-positive cells, monohormonal C-peptide-
positive cells and cells expressing both C-peptide and NKX6.1 derived
from PDX1þ/ and PDX1P33T/P33T and PDX1C18R/C18R mutant isogenic
iPSC lines were less compared to the control (Figure 4BeD and
Figure 5A,B).
3.5. PDX1 mutations reduce glucose-responsive function of b-like
cells
Furthermore, we performed functional analysis of isogenic iPSC-
derived b-like cells using GSIS that revealed a significant impair-
ment in the response to glucose in cells derived from the isogenic
mutants compared to the control cells (Figure 5C andFigure 4: Characterization of the impact of PDX1þ/, PDX1P33T/P33T, and PDX1C18R/C
staining for C-peptide, Glucagon, PDX1 and NKX6.1 in XM001, PDX1þ/, PDX1P33T/P33T, a
FACS plots of CPEPþ and GCGþ cells in XM001, PDX1þ/, PDX1P33T/P33T, and PDX1C18R/C18
the XM001, PDX1þ/, PDX1P33T/P33T, and PDX1C18R/C18R cells at the S7 stage (n ¼ 3). (D
PDX1þ/, PDX1P33T/P33T, and PDX1C18R/C18R cells at the S7 stage (n ¼ 3).
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www.molecularmetabolism.comSuppl. Figure 9B). To explain how PDX1 mutations cause defects in b-
like cell function, we performed q-PCR analysis of differentiated
endocrine cells. The transcript levels of INS and SST but not GCG were
lower in cells derived from PDX1þ/ and PDX1C18R/C18R compared to
the control and the transcript levels of INS, SST, and GCG were lower in
cells derived from PDX1P33T/P33T (Figure 5D). We also found lower
expression levels of NEUROD1, ISLI, ABCC8, and UCN3 in cells derived
from all isogenic mutations. Importantly, the expression levels of PDX1,
NKX6-1, MAFA, PAX6, SLC30A8, and KCNJ11 were less in the PDX1þ/
 and PDX1P33T/P33T iPSCs-derived b-like cells but not in those orig-
inated from the PDX1C18R/C18R (Figure 5D), highlighting distinct effects
on gene expression of different mutations in PDX1. Of note, with the18R mutations on b-like cell differentiation. (A) Representative immunofluorescence
nd PDX1C18R/C18R cells at the S7 stage. Scale bar indicates 50 mm. (B) Representative
R cells at the S7 stage. (C) FACS quantification of the percentage of total CPEPþ cells in
) FACS quantification of the percentage of mono-hormonal CPEPþ cells in the XM001,
cess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 89
Figure 5: PDX1 mutations reduce glucose-responsive function of b-like cells. (A) Representative FACS plots for C-peptideþ and NKX6.1þ in XM001, PDX1þ/, PDX1P33T/P33T
and PDX1C18R/C18R cells at the S7 stage. (B) FACS quantification of the percentage of total CPEPþ and NKX6.1þ cells in the XM001, PDX1þ/, PDX1P33T/P33T, and PDX1C18R/C18R
cells at the S7 stage (n ¼ 3). (C) GSIS assay for the XM001, PDX1þ/, PDX1P33T/P33T, and PDX1C18R/C18R cells at the S7 stage. The fold change of insulin secretion with high
glucose (16.7 mM) relative to low glucose (2.8 mM) treatment is shown (n ¼ 3). (D) RT-qPCR analysis of expression of b-cell transcription factors, hormonal markers and b-cell
functional markers at the S7 stage (n ¼ 4).
Original Articleexception of UCN3, GCG, and SST, all tested genes are bound by PDX1
in either adult islets (high confidence PDX1 binding sites [26]), XM001
PP1 cells [26] or both (Figure 5D). These data indicate that point90 MOLECULAR METABOLISM 24 (2019) 80e97  2019 The Authors. Published by Elsevier GmbH. Tmutations in the transactivation domain reduce the potential of the
PDX1 TF to activate the expression of its target genes during b-like cell
development and maturation. Furthermore, the PDX1P33T/P33T mutationhis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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causes greater impact on b-like cell formation and function than the
PDX1C18R/C18R mutation.
3.6. RNA-seq profiling of pancreatic progenitors (PP1) from PDX1þ/
, PDX1P33T/P33T and PDX1C18R/C18R iPSC lines
To identify the immediate early PDX1 target genes, which react to
haploinsufficiency and the homozygous point mutations in the trans-
activation domain and which could explain the impaired PP2 differ-
entiation, we performed RNA-seq at the PP1 stage. As quality control,
we compared control iPSCs at pluripotency to the average of all other
tested cell lines at PP1 stage and, as expected, identified upregulation
of a pancreatic gene program (PDX1, HNF1B, SOX9, ONECUT1, HHEX,
FOXA2, and RFX6) as well as downregulation of a pluripotency pro-
gram (Figure 6A,B). Furthermore, principal component analysis (PCA)Figure 6: RNA-seq profiling of pancreatic progenitors (PP1) from PDX1þ/, PDX1P3
against the log2-fold change of the RNA-Seq data obtained from XM001 iPSCs and PPs from
fold change  2 and adjusted p-value  0.05) are drawn in color. Red depicts increased ex
p-values from pathway enrichment analysis, showing selected GO terms and KEGG and Re
(PCA) of iPSCs and PP1 cells. (DeF) MA plots showing the mean log2 expression against
PDX1C18R/C18R compared to XM001. Genes with significantly different expression (log2 fol
expression in XM001 control PPs, blue, green and purple depict increased expression in P
binding sites in XM001 PPs. (G) Venn diagrams showing the overlap of up- and downregu
PPs. Some relevant pancreatic and disease associated genes are set in bold.
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www.molecularmetabolism.comshowed two distinct clusters along the first principal component,
corresponding to control iPSCs and the different PPs. Moreover, the
second principal component separates the PDX1þ/, PDX1P33T/P33T,
and PDX1C18R/C18R PPs from XM001 control PPs and shows that
PDX1þ/ and PDX1P33T/P33T are more similar to each other compared
to PDX1C18R/C18R and control cells (Figure 6C). Next, we compared
mRNA profiles from PP1 cells with isogenic PDX1 mutation to control
PP1 cells. When compared to the control PPs, we found 112, 196 and
199 deregulated genes in PDX1þ/, PDX1P33T/P33T, and PDX1C18R/C18R
PPs, respectively. Among these, 20, 41, and 54 genes were bound by
PDX1, respectively (Figure 6DeF). Interestingly, we found the diabetes
risk genes LARGE1 and ANPEP and insulin resistance genes MEG3 and
CES1 to be consistently downregulated among all PPs with PDX1
mutations (Figure 6G). Moreover, genes such as the metabolic disease3T/P33T, and PDX1C18R/C18R iPSC lines. (A) MA plot showing the mean log2 expression
XM001 and isogenic PDX1 mutants. Genes with significantly different expression (log2
pression in PPs, whereas orange depicts increased expression in iPSCs. (B) Bar graph of
actome pathways from differentially expressed genes. (C) Principal component analysis
the log2 fold change of the RNA-Seq data obtained from PDX1
þ/, PDX1P33T/P33T, and
d change  1 and adjusted p-value  0.1) are drawn in color. Red depicts increased
DX1þ/, PDX1P33T/P33T, and PDX1C18R/C18R, respectively. Black circles genes with PDX1
lated genes from PDX1þ/, PDX1P33T/P33T, and PDX1C18R/C18R PPs compared to XM001
cess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 91
Original Articleassociated genes HAPLN1, the b-cell hallmark gene DCX, the fibro-
calculous pancreatic diabetes associated genes PRSS1/2, which are
the main contributors to the difference between PPs from mutant and
control isogenic cell lines, were consistently deregulated
(Suppl. Figure 10). Since PDX1 levels are reduced in PDX1P33T/P33T
PPs, we compared the downregulated genes with those from PDX1þ/
PPs. Among these genes, we found the transcription factor MNX1 and
the proteolipid NNAT, as well as genes that seem to distinguish
PDX1P33T/P33T and PDX1þ/ from PDX1C18R/C18R and XM001 PPs like
TF and METTL9 (Figure 6D,E and G and Suppl. Figure 10).
3.7. Characterization of PDX1 binding in patient-derived PDX1P33T/
þ pancreatic progenitors (PP1)
Since the PDX1P33T/P33T mutation in isogenic cells severely reduced
PP2 cell differentiation and the PDX1P33T/þ patient was diagnosed with
gestational diabetes, we sought to identify genes that might beFigure 7: Characterization of PDX1 binding in patient-derived PDX1P33T/þ pancreat
PDX1P33T/þ binds predominantly to intergenic, intronic and promoter regions. (B) Meta-gen
target genes displayed as binding sites per base pair (bp) per gene over the genomic region
known PDX1 consensus sequence and is identified in 71.3% of all PDX1-bound sequence
shows enrichment of H3K27ac at PDX1-bound sites. (E) Venn diagram showing the overlap
seq signal at all PDX1 binding sites in XM001 and PDX1P33T/þ PPs, showing high resembla
H3K27ac (blue) and PDX1 (red) at the loci of important pancreatic genes.
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allele. To this end, we first differentiated iPSCs from the PDX1P33T/þ
patient and the control iPSC into PP1 using the 2nd differentiation
protocol. To understand whether the heterozygous P33T mutation
affects PDX1 DNA-binding activity, we employed ChIP-seq analysis to
profile genome-wide PDX1 binding sites in control [26] and PDX1P33T/þ
patient iPSC-derived PPs. We identified 8970 PDX1 binding sites in the
patient iPSC-derived PP cells that were predominantly found in inter-
genic and intronic regions and showed a clear enrichment at pro-
moters and 5’ UTRs (Figure 7A,B and Suppl. Figure 11A-B). Motif
analysis showed that 71% of the binding sites harbor a PDX1
consensus sequence, confirming the high quality of our data
(Figure 7C). Moreover, ChIP-seq of the active histone modification
H3K27ac in control [26] and patient-derived PPs showed a w5 fold
enrichment of H3K27ac at the PDX1-bound sites (Figure 7D and
Suppl. Figure 11C). Compared to the ChIP-seq data from control PPic progenitors (PP1). (A) Distribution of PDX1 binding sites among genomic features.
omic plot showing the enrichment of PDX1 at the transcriptional start sites (TSS) of its
s of all RefSeq genes. (C) Most enriched motif detected by motif analysis resembles the
s. (D) Average ChIP-seq Signal of H3K27ac (blue) and PDX1 (red) at PDX1 binding sites
of PDX1-binding sites in XM001 PPs and PDX1P33T/þ PPs. (F) Heatmap of PDX1 ChIP-
nce of PDX1 binding in these cells. (G) ChIP-seq data tracks showing the enrichment of
his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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cells [26], we did not find pronounced differences in PDX1 binding or
H3K27ac enrichment in cells derived from the patient compared to the
control (Figure 7E,F and Suppl. Figure 11D-K). Of the 8970 PDX1
binding sites in the patient, 6444 are shared with the control PPs
(Figure 7E). Next, we mapped PDX1 binding sites, shared between the
control and PDX1P33T/þ PPs, to genes and identified 3978 potential
target genes. Among those, we found important pancreatic genes such
as PDX1, MNX1, or HNF1B (Figure 7GeI).
3.8. mRNA profiles of patient-derived PDX1P33T/þ pancreatic
progenitors (PP1)
Furthermore, microarray analysis of control [26] and patient-derived
PDX1P33T/þ cells was performed at the pluripotency and PP stages.
A total of 2370 differentially expressed genes were identified betweenFigure 8: mRNA profiles of patient-derived PDX1P33T/þ pancreatic progenitors (PP1
microarray data obtained from XM001 iPSCs and PPs. Genes with significantly different ex
depicts increased expression in PPs, whereas brown depicts increased expression in iPSC
terms and KEGG and Reactome pathways from differentially expressed genes. (C) Heatm
control PPs. (D) Heat map and clustering showing consistently deregulated genes in patie
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www.molecularmetabolism.comiPSC and PP (FC  2, FDR  5%). Important pancreatic genes
including HNF1B, SOX9, ONECUT1, and HHEX were found to be
upregulated in PPs. In contrast, pluripotency associated genes such as
NANOG and LIN28A were specifically expressed in the iPSC stage
(Figure 8A). Functional analysis of deregulated genes by means of GO
term and pathway enrichment showed that genes upregulated in PPs
were associated with pancreas development while downregulated
genes were linked to embryonic stem cell, cell cycle and proliferation
(Figure 8B). Comparing the transcriptional profile of PPs from
PDX1P33T/þ with controls, we identified 88 deregulated genes (FC 2,
FDR  5%), among which 21 genes possessed PDX1 binding sites
(Figure 8C). Remarkably, we identified downregulation of MEG3 and
NNAT genes, which have PDX1 binding sites and are involved in
pancreas development and insulin secretion. Importantly, we also). (A) MA plot showing the mean log2 expression against the log2-fold change of the
pression (log2 fold change  1 and adjusted p-value  0.1) are drawn in color. Yellow
s. (B) Bar graph of p-values from pathway enrichment analysis, showing selected GO
ap of differentially expressed genes between patient-derived PDX1P33T/þ and XM001
nts PDX1P33T/þ and isogenic PDX1P33T/P33T PPs.
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Original Articleidentified a set of genes showing consistent deregulation between
PDX1P33T/P33T PPs and patient derived PDX1P33T/þ PPs that include
NNAT, MEG3, and POSTN (Figure 8D). Intriguingly, Periostin, which is
encoded by the POSTN gene, is involved in pancreas and b-cell
regeneration [37], and both NNAT and MEG3 are associated with in-
sulin secretion.
4. DISCUSSION
The translation of findings from successful preclinical reports from
animal models to human often fail due to the evolutionary diversity in
organ development and function among species. In this context,
discovering novel treatments for diabetes mellitus necessitates
comprehensive understanding of the mechanisms underlying human
endocrine cell formation, function and failure. Due to the limited access
to human primary samples and the unfeasibility of performing longi-
tudinal analyses in humans, the establishment of novel modeling
systems to study human pancreas homeostasis is essential [38]. Along
these lines, in vitro differentiation of b-cells from stem cells provides a
unique platform to study human endocrine cell development and to
model human disease [36,39,40]. In particular, this system enables
the study of defects in developmental programs, leading to an
increased predisposition to diabetes, by mimicking the phenotypes of
mutations in specific genes such as those associated with MODY.
Uncovering the consequence of such mutations will aid to identify the
carrier individuals and design personalized prevention and treatment
approaches, as has been shown for sulfonylurea treatment for patients
carrying KCNJ11 mutation in the potassium channel [41].
Here, using iPSCs endocrine differentiation culture, we investigated the
impact of two common heterologous mutations (P33T, C18R) in the
PDX1 gene on human b-cell development and function. Using iPSCs
from glucose intolerant patients as well as newly generated isogenic cell
lines, we found that these mutations impair endocrine progenitor and b-
cell development. However, our data revealed PDX1P33T/þ and
PDX1C18R/þ mutations in patient-derived cells do not affect early stages
of pancreatic differentiation. In comparison, PDX1P33T/P33T impaired the
induction of endocrine fate at the PP2 stage, suggesting a dose-
dependent effect of the P33T mutation on the endocrine lineage deci-
sion. Importantly, the levels of PDX1 protein were reduced at the PP1
stage in cells carrying a homozygous P33T mutation. In mouse, it has
been shown that Pdx1 can regulate its own expression through an auto-
regulatory positive feedback mechanism [42e44]. As the P33T muta-
tion lies in the transactivation domain of PDX1, it is tempting to spec-
ulate that this mutation weakens proteineprotein interactions and
impairs the recruitment of transcriptional co-activators required for the
induction of target gene expression and PDX1 itself. Interestingly, in the
PDX1P33T/P33T mutant PP cells, the lncRNA PLUTO is upregulated.
PLUTO, which is downregulated in T2D, regulates PDX1 expression by
promoting interactions between the PDX1 promoter and an upstream
enhancer cluster [45], suggesting that its upregulation in PDX1P33T/P33T
mutant PPs is due to a compensatory mechanism aiming to increase
PDX1 expression. The reduction in PDX1 levels at PP1 stage coincided
with the impaired PP2 differentiation. During endocrinogenesis, the
maintenance of high levels of PDX1 is essential for induction and dif-
ferentiation of endocrine progenitors [46]. Therefore, the reduced levels
of PDX1 likely hamper endocrine fate specification in human PDX1P33T/
P33T mutant progenitors, supporting an evolutionary conserved mech-
anism of PDX1 function during endocrine cell differentiation. Interest-
ingly, PDX1C18R/C18R mutation reduced neither PDX1 levels at PP1 stage
nor at PP2 cell development. This difference between the effects of the
two mutations might be due to the more severe changes in protein94 MOLECULAR METABOLISM 24 (2019) 80e97  2019 The Authors. Published by Elsevier GmbH. Tstructure, induced by the replacement of proline with threonine in P33T
mutation. Proline is the major amino acid generating tight turns in
protein sequences and its replacement with any other amino acid might
result in significant changes in transactivation domain structure and
proteineprotein interactions. Therefore, it is likely that changing proline
to threonine in PDX1 reduces its interaction with co-binding transcription
factors. This is also supported by the similar phenotype of cells carrying
PDX1P33T/P33T mutation and those carrying PDX1þ/, suggesting a
significant loss-of function upon this point mutation. However, at least in
the PDX1P33T/P33T and PDX1þ/ isogenic cell lines, the reduced
expression of PDX1 might cause binding patterns to change, since it is
possible that the remaining amount of PDX1 is not sufficient to activate
low affinity binding sites.
Gene expression analysis from PPs derived from patient and isogenic
cells carrying PDX1P33T/þ and PDX1P33T/P33T, identified downregulation
of several PDX1 target genes including MEG3 and NEURONATIN
(NNAT). Maternally expressed gene 3 (Meg3) is an imprinted gene,
coding for a long noncoding RNA, that resides in the distal region of
mouse chromosome 12, and its human homolog is located in the
syntenic region on chromosome 14. In mouse, the downregulation of
Meg3 affects insulin synthesis and secretion in pancreatic b-cells [47].
Furthermore, this gene is downregulated in islets from T2D, sug-
gesting an essential role for b-cell development and/or function [48].
NNAT is an imprinted gene coding for the proteolipid NEURONATIN, is
expressed in neuroendocrine and metabolic tissues in a hormone- and
glucose-sensitive manner. Rare single-nucleotide polymorphisms
(SNPs) at the human NNAT locus are associated with extreme child-
hood obesity [49]. Mice lacking Nnat specifically in b-cells, exhibit
reduced insulin content and impaired GSIS, demonstrating its
involvement in regulation of glucose homeostasis and insulin secretion
[50]. However, a function of this protein in pancreatic developmental
has not been reported so far; therefore, it will be exciting to explore
whether NNAT influences human b-cell development. Moreover, PPs
derived from all isogenic mutants exhibited downregulation of common
genes, i.e. MEG3, LARGE1, ANPEP, and CES1. It has been shown that
mutations in LARGE1might increase the risk of type 2 diabetes through
accumulation of visceral fat and increased insulin resistance [51]. In
the ANPEP locus, SNPs influencing the expression of the ANPEP gene,
coding for the aminopeptidase N, are associated with an increased risk
of T2D [52]. Furthermore, global Ces1/ mice have shown elevated
plasma levels of triglycerides, free cholesterol, FFAs, and insulin, and
displayed insulin resistance [53]. However, whether LARGE1, ANPEP,
and CES1 play a role during human b-cell development and/or function
needs further investigation. In addition, we detected the down-
regulation of MNX1 in PDX1P33T/P33T PPs. In mouse, this TF promotes
and maintains the b-cell program during embryonic and postnatal
stages, respectively, thereby regulating endocrine lineage allocation
and b-cell fate maintenance [54]. Although homozygous MNX1 mu-
tation causes permanent neonatal diabetes in humans [55], the
mechanisms by which this protein impacts human b-cell development
still need to be addressed.
Both PDX1P33T/P33T and PDX1C18R/C18R mutations deteriorated b-cell
development and function. We found the downregulation of several key
TFs regulating b-cell differentiation such as NEUROD1 and ISLI upon
homozygous single base-pair mutations. These data indicate that PDX1
fails to activate these target genes upon point mutations and further
highlight the essential role of this TF for human b-cell development. Of
note, we found significant reduction in the expression levels of UCN3 in
cells expressing homozygous PDX1 mutants, underlining the importance
of proper PDX1 function for b-cell maturation, similar to rodents.
Recently, we have shown that impairment in Pdx1 TF activity in doublehis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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knock-in reporter mice reduces b-cell maturation in male mice and
leads to diabetes, whereas female animals are protected until preg-
nancy when they develop gestational diabetes [56,57]. Due to the report
on gestational diabetes in the PDX1P33T/þ patient and the reduction in
UCN3 levels in b-like cells carrying this mutation, it is likely that b-cells
from this patient function sub-optimally, which becomes evident upon
metabolic demand similar to the above described mouse model. These
results suggest an evolutionary conserved function for PDX1 in regu-
lating b-cell maturation and function.
The differentiated b-cells carrying PDX1 point mutations were less
functional compared to WT cells in term of glucose responsiveness. In
mouse, Pdx1 is known to regulate GSIS. This TF not only directly
regulates insulin synthesis, but also induces the expression of
secretory machinery components required for insulin release [11]. We
showed the downregulation of INS, ABCC8, KCNJ11, and SLC30A8
upon PDX1P33T/P33T and PDX1C18R/C18R mutations in b-like cells,
highlighting the regulatory function of this protein for insulin synthesis
and secretion in human b-cells. This finding is supported by previous
studies, reporting decreased binding activity of heterozygous P33T and
C18R mutant PDX1 protein to human insulin promotor using electro-
phoretic mobility shift assay [15,16].
In summary, we report the impact of two common point mutations in
the transactivation domain of PDX1 on human b-cell development and
function and show that these mutations predispose to diabetes.
Characterizing the impact of such mutations will expand our under-
standing of disease heterogeneity in the general population and might
allow for diagnosing people at risk and predicting their susceptibility to
diabetes or gestational diabetes [1]. Our previous study has revealed
that the reduced level of Pdx1 promotes development of diabetes and
gestational diabetes in male and female mice, respectively [56]. Here,
we suggest a similar function of PDX1 in humans and propose that
developmental and compensatory b-cell formation and expansion
depends on a fully functional PDX1 TF.
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The Tübingen Family Study for T2DM (TÜF study, N = 2500) was
screened for known rare mutations in the MODY4 gene PDX1. By mass
spectrometry-based genotyping, one heterozygous PDX1 C18R carrier
could be identified and recruited for full-thickness skin biopsy. From
the biopsymaterial, the epidermal layer was separated from the dermis
by dispase digestion and fibroblasts were isolated from the dermis by
trypsin digestion using an established protocol (see the Materials andn access article under the CC BY-NC-ND license
293X. Wang et al. / Stem Cell Research 17 (2016) 292–295methods section). The PDX1 C18R fibroblasts were expanded using
commercially available growth media and deep-frozen in liquid nitro-
gen. From this collection of dermal fibroblasts, samples were tested
for the presence of viruses pathogenic to humans (HBV, HCV, HIV) asFig. 1. Generation of PDX1 C18R iPSCs. (A) An overview of the PDX1 protein structure. (B) Sch
Reprogramming protocol of skin fibroblasts into integration-free iPSCs using episomal vecto
shows heterozygous T N C mutation in PDX1. (F) Semi-quantitative PCR confirms that episom
H9 ESCs and two independent iPSC clones (#1 and #2) were used as negative controls, wherewell as for the presence of mycoplasma. All cultures were found to be
negative for all of these potential contaminants. PDX1 C18R primary fi-
broblasts were reprogrammed into iPSCs using nucleofection with
three episomal plasmids encoding human OCT4, SOX2, NANOG, LIN28,eme shows the reprogramming factors for the generation of the PDX1 C18R iPSC line. (C)
rs. (D) Normal karyotype (46, XX) of one PDX1 C18R iPSC clone. (E) Sequencing result
al vectors did not integrate into the genomic DNA of the selected PDX1 C18R iPSC clone.
as transfected fibroblast at day 6 were used as positive controls.
294 X. Wang et al. / Stem Cell Research 17 (2016) 292–295KLF4, and L-MYC (Fig. 1B). The reprogramming protocol (transfection,
reprogramming and expansion) is shown in Fig. 1C. 3 weeks after trans-
fection, many colonies with human embryonic stem cell (hESC)-like
morphology appeared that were hand picked by day 21, expanded
and frozen down as individual iPSC lines. The analysis of one of these
iPSC lines confirmed that PDX1 C18R fibroblasts were successfully
reprogrammed into iPSCs with a normal karyotype (Fig. 1D) and con-
taining the T N C mutation causing a C18R amino acid exchange in the
transactivation domain (Fig. 1A, E). Integration of the exogenous
transgenes in the genome of iPSCs was excluded by semi-quantitative
PCR (Fig. 1F). To confirm that this iPSC line was pluripotent, we per-
formed immunofluorescence staining for the pluripotency transcription
factors OCT4 and SOX2, as well as for the hESC surface markers SSEA-3,
SSEA-4 and TRA-1-81, which were all expressed in the PDX1 C18R iPSC
line (Fig. 2A). To further demonstrate pluripotency of the selected iPSC
line we injected 2 × 106 cells subcutaneously into NOD/SCID mice to
generate teratomas. The histological analysis of the induced teratomas
revealed that all tissues from all three germ layers were differentiated
confirming pluripotency in this in vivo assay (Fig. 2B). Taken together,
we have successfully reprogrammed PDX1 C18R dermal fibroblasts
into pluripotent iPSCs that can be used to study a point mutation in
the transactivation domain of PDX1 to study the development of
diabetes.Fig. 2. PDX1 C18R iPSCs are pluripotent and differentiate into all germ layers in vivo. (A) PDX1
several pluripotency markers. Scale bar indicates 50 μm. (B) Hematoxylin/eosin staining of
derivatives are clearly detectable in vivo. Scale bar indicates 100 μm.Materials and methods
Ethics statement
The study adhered to the Declaration of Helsinki. All participants
gave informed written consent, and the study protocols were approved
by the local ethics board (Ethics Committee of the Eberhard Karls Uni-
versity Tübingen).
Study participants
The ongoing TÜF study currently includes N3000 non-related individ-
uals at risk for type-2 diabetesmellitus (T2DM), i.e., healthy subjects with
a family history of T2DM, a bodymass index ≥27 kg/m2, impaired fasting
glycaemia, and/or previous gestational diabetes (Stefan et al., 2005). From
all TÜF participants, themedical history, smoking status, and alcohol con-
sumption habits were queried and documented. Furthermore, all partici-
pants underwent physical examination, routine blood tests, bioelectric
impedance measurement, and 5-point oral glucose tolerance tests
(OGTTs) with insulin and glucose measurements. The current study pop-
ulation comprised 2500 individuals who spent DNA for genotyping, were
not on anymedication known to influence glucose tolerance, insulin sen-
sitivity, or insulin secretion, and who had complete OGTT data sets.C18R iPSCs display typical morphological ESC-like characteristics and uniformly express
tissue sections of teratomas generated from the PDX1 C18R iPSC clone. All germ layer-
295X. Wang et al. / Stem Cell Research 17 (2016) 292–295Using themass spectrometry-based genotyping platformmassARRAY
fromSequenom (Hamburg, Germany) and themanufacturer's iPLEX soft-
ware, the 2500 subjects were screened for known rare mutations in ma-
turity onset of diabetes (MODY) genes that were described in the
literature to co-segregate with MODY phenotypes in families. We identi-
fied seven individuals with heterozygous mutations in PDX1 (MODY4)
(McKinnon and Docherty, 2001). From these cases, one glucose-tolerant
female PDX1 Cys18Arg (C18R) carrier (aged 33 years; BMI 20.6 kg/m2)
with history of diabetes could be recruited for full-thickness skin biopsy.
Skin biopsy, isolation and testing of dermal fibroblasts
A full-thickness skin specimen was taken by punch biopsy from the
upper arm in the deltoid muscle region. After removal of adipose tissue
remnants and visible blood vessels, the sample was digested overnight
at 4 °C with 10 U/ml dispase II (Roche Diagnostics, Mannheim, Germa-
ny) in 50 mM Hepes pH 7.4, 150 mM NaCl. Thereafter, the digest was
heated for 30 min at 37 °C under continuous shaking (1200 rpm).
Using forceps, the dermis was separated from the epidermal layer, and
fibroblasts were isolated from the dermis by digestion with 0.2% colla-
genase CLS I (Biochrom, Berlin, Germany) in DMEM, 10% BSA for
45 min at 37 °C under continuous shaking (1200 rpm). For purification
of thefibroblasts, the digestwasfiltered through a 70 μmmesh and cen-
trifuged. The pelleted cells were resuspended, grown for three days in
DMEM, 10% FCS, and subsequently further expanded in Medium 106
supplemented with low serum growth supplement (Invitrogen, Ther-
mo Fisher Scientific, Waltham, MA, USA). Samples of dermal fibroblasts
were tested for the presence of viruses pathogenic to humans, i.e., HBV,
HCV, and HIV, with Genesig PCR-based detection kits from
Primerdesign Ltd. (Chandler's Ford, UK) and for the presence of myco-
plasma with a PCR test kit from PanReac AppliChem (Darmstadt, Ger-
many) and, in parallel, by DNA staining with DAPI. All cultures were
found to be negative for the tested contaminants.
iPSC generation
Primary fibroblasts frompatientwere reprogrammed into pluripotent
stem cells by using a non-integrating Episomal iPSC Reprogramming Kit
(Invitrogen, Cat. no. A14703). This kit contains mixture of three vectors
which has the oriP/EBNA-1 (Epstein-Barr unclear antigen-1) backbone
that delivers six reprogramming factors: OCT4, SOX2, NANOG, LIN28,
KLF4, and L-MYC (Yu et al., 2011). Humanfibroblasts at 75–90% confluent
were transfected using the Amaxa 4D-Nucleofector transfection system
and a nucleofector kit for human dermal fibroblast (Lonza, Cat. no. VPD-
1001), plated onto geltrex-coated culture dishes, incubated in supple-
mented fibroblast medium. This medium contained knockout DMEM/F-
12 (Life technologies), 10% FBS of ESC-qualified (Life technologies), 1%
MEM non-essential amino acids (Life technologies), 10 μM HA-100
(Santa Cruz) and 4 ng/ml bFGF (Life technologies). At 24 h after transfec-
tion, the medium were exchanged with N2B27 medium supplemented
with 0.5 μM PD0325901 (Stemgent), 3 μM CHIR99021 (Stemgent),
0.5 μM A-83-01 (Stemgent), 10 μM HA-100 (Santa Cruz), 10 ng/ml hLIF
(Life technologies) and 100 ng/ml bFGF. The basic N2B27 medium
contained DMEM/F12withHEPES (Life technologies), 1×N2 supplement
(Life technologies), 1×B27 supplement (Life technologies), 1%MEMnon-
essential amino acids, 1× Glutamax (Life technologies) and 1× β-
Mercaptoethanol (Life technologies). On day 15 after transfection, the
medium was exchanged with Essential 8 medium and monitored for
the emergence of iPSC colonies. Around 3weeks after transfection, undif-
ferentiated iPS colonies were picked and transferred onto fresh geltrex-
coated culture dishes for expansion.
iPSC characterization
DNA was extracted from iPSCs by using standard procedure. Markers
for the episomal backbone were amplified by semi-quantitative PCR toexclude transgene integration. Primers are as follows: oriP forward:
TTCCACGAGGCTAGTGAACC. oriP reverse: TCGGGGGTGTTAGAGACAAC;
EBNA-1 forward: ATCGTCAAAGCTGCACACAG. EBNA-1 reverse:
CCCAGGAGTCCCAGTAGTCA. For karyotype analysis, we used the cells
growing in logarithmic phase. They were fed with fresh medium the
night before adding colcemid for 2 h. Cells were then trypsinized, treated
with hypotonic solution (0.075 M KCl) for 20 min and fixed with
methanol:acetic acid (3:1). Metaphases were spread on microscope
slides, and chromosomes were classified according to the International
System forHumanCytogenicNomenclature using the standardGbanding
technique. At least, 20 metaphases were counted per cell line, and the
final karyotype was stated if it was present in N85% of them. For terato-
mas, 2 × 106 iPSCs were injected into the right hind leg of immunocom-
promised NOD/SCID mice. Tumors were excised after 8 weeks, fixed,
embedded in paraffin, sectioned and stained with hematoxylin/eosin
(Takahashi et al., 2007).
Mutation analysis
Genomic DNA was isolated from PDX1 C18R and control iPSCs using
standard procedure. PCR amplification with a set of primers flanking the
mutation site was performed in those two samples. PCR products were se-
quencedusing the reverseprimerbySanger sequencingonanABI3130ge-
netic analyzer (Applied Biosystems). Primers are as follows: PDX1 forward:
GGAGTGTGCAGCAAACTCAG, PDX1 reverse: ACGCGTGAGCTTTGGTAGAC.
Immunofluorescence imaging
Cells were fixed with 4% paraformaldehyde for 30 min and then
permeabilized in PBS containing 0.2% Triton X-100. Cells were blocked
with PBS containing 3% BSA, and incubated with primary antibodies
overnight at 4 °C. Then secondary antibodies were incubated for 1 h at
room temperature after washing with PBS. Images were acquired on a
laser scanning microscope. The following antibodies and dilutions were
used: goat anti-OCT3/4 (1:500, Santa Cruz), goat anti-SOX2 (1:500,
Santa Cruz), rat anti-SSEA3 (1:50, Invitrogen), mouse anti-SSEA4
(1:500, cell signaling) and mouse anti-TRA-1-81 (1:50, Millipore).
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The Tübingen Family Study for T2DM (TÜF study, N = 2500) was
screened for known rare mutations in the MODY4 gene PDX1. By mass
spectrometry-based genotyping, one heterozygous PDX1 P33T carrier
could be identified and recruited for full-thickness skin biopsy. From
the biopsymaterial, the epidermal layer was separated from the dermis
by dispase digestion and fibroblasts were isolated from the dermis by
trypsin digestion using an established protocol (see Materials and
methods section). The PDX1 P33T fibroblasts were expanded using
commercially available growth media and deep-frozen in liquid nitro-
gen. From this collection of dermal fibroblasts, samples were tested
for the presence of viruses pathogenic to humans (HBV, HCV, HIV) as
well as for the presence of mycoplasma. All cultures were found to be
negative for all of these potential contaminants. PDX1 P33T primary fi-
broblasts were reprogrammed into iPSCs using nucleofection with
three episomal plasmids encoding human OCT4, SOX2, NANOG, LIN28,
KLF4, and L-MYC (Fig. 1B). The reprogramming protocol (transfection,
reprogramming and expansion) is shown in Fig. 1C. Three weeks after
transfection, many colonies with human embryonic stem cell (hESC)-article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Generation of PDX1 P33T iPSCs. (A) An overview of the PDX1 protein structure. (B) Scheme shows the reprogramming factors for the generation of the PDX1 P33T iPSC line. (C)
Reprogramming protocol of skin fibroblasts into integration-free iPSCs using episomal vectors. (D) Normal karyotype (46, XX) of one PDX1 P33T iPSC clone. (E) Sequencing result
shows heterozygous CNA mutation in PDX1. (F) Semi-quantitative PCR confirms that episomal vectors did not integrate into the genomic DNA of the selected PDX1 P33T iPSC clone.
H9 ESCs were used as a negative control, whereas transfected fibroblasts at day 6 were used as positive controls.
274 X. Wang et al. / Stem Cell Research 17 (2016) 273–276like morphology appeared that were hand picked by day 21, expanded
and frozen down as individual iPSC lines. The analysis of one of these
iPSC lines confirmed that PDX1 P33T fibroblasts were successfully
reprogrammed into iPSCs with a normal karyotype (Fig. 1D) and con-
taining the CNA mutation causing a P33T amino acid exchange in the
transactivation domain (Fig. 1A, E). Integration of the exogenous
transgenes in the genome of iPSCs was excluded by semi-quantitative
PCR (Fig. 1F). To confirm that this iPSC line was pluripotent, we per-
formed immunofluorescence staining for the pluripotency transcription
factors OCT4 and SOX2, as well as for the hESC surface markers SSEA-3,
SSEA-4 and TRA-1-81, which were all expressed in the PDX1 P33T iPSC
line (Fig. 2A). To further demonstrate pluripotency of the selected iPSC
line we injected 2 × 106 cells subcutaneously into NOD/SCID mice to
generate teratomas. The histological analysis of the induced teratomas
revealed that all tissues from all three germ layers were differentiated
confirming pluripotency in this in vivo assay (Fig. 2B). Taken together,
we have successfully reprogrammed PDX1 P33T dermal fibroblastsinto pluripotent iPSCs that can be used to study a point mutation in
the transactivation domain of PDX1 to study the development of
diabetes.
3. Materials and methods
3.1. Ethics statement
The study adhered to the Declaration of Helsinki. All participants
gave informed written consent, and the study protocols were approved
by the local ethics board (Ethics Committee of the Eberhard Karls Uni-
versity Tübingen).
3.2. Study participants
The ongoing TÜF study currently includes N3000 non-related individ-
uals at risk for type-2 diabetesmellitus (T2DM), i.e., healthy subjects with
Fig. 2. PDX1 P33T iPSCs are pluripotent and differentiate into all germ layers in vivo. (A) PDX1 P33T iPSCs display typical morphological ESC-like characteristics and uniformly express
several pluripotency markers. Scale bar indicates 50 μm. (B) Hematoxylin/eosin staining of tissue sections of teratomas generated from the PDX1 P33T iPSC clone. All germ layer-
derivatives are clearly detectable in vivo. Scale bar indicates 100 μm.
275X. Wang et al. / Stem Cell Research 17 (2016) 273–276a family history of T2DM, a bodymass index ≥27 kg/m2, impaired fasting
glycemia, and/or previous gestational diabetes (Stefan N, Machicao F,
Staiger H, Machann J, Schick F, Tschritter O, Spieth C, Weigert C, Fritsche
A, Stumvoll M, Häring HU. Polymorphisms in the gene encoding
adiponectin receptor 1 are associated with insulin resistance and high
liver fat. Diabetologia 2005;48:2282-2291). From all TÜF participants,
the medical history, smoking status, and alcohol consumption habits
were queried and documented. Furthermore, all participants underwent
physical examination, routine blood tests, bioelectric impedance mea-
surement, and 5-point oral glucose tolerance tests (OGTTs) with insulin
and glucose measurements. The current study population comprised
2500 individuals who spent DNA for genotyping, were not on any medi-
cation known to influence glucose tolerance, insulin sensitivity, or insulin
secretion, and who had complete OGTT data sets.
Using the mass spectrometry-based genotyping platform
MassARRAY from Sequenom (Hamburg, Germany) and the
manufacturer's iPLEX software, the 2500 subjects were screened for
known rare mutations in maturity onset of diabetes (MODY) genes
thatwere described in the literature to co-segregatewithMODYpheno-
types in families. We identified seven individuals with heterozygous
mutations in PDX1 (MODY4) (McKinnon andDocherty, 2001).We iden-
tified seven individuals with heterozygous mutations in PDX1
(MODY4). From these cases, one glucose-tolerant female PDX1
Pro33Thr (P33T) carrier (aged 40 years; BMI 23.0 kg/m2) could be re-
cruited for full-thickness skin biopsy.3.3. Skin biopsy, isolation and testing of dermal fibroblasts
A full-thickness skin specimen was taken by punch biopsy from
the upper arm in the deltoid muscle region. After removal of adi-
pose tissue remnants and visible blood vessels, the sample was
digested overnight at 4 °C with 10 U/ml dispase II (Roche Diagnos-
tics, Mannheim, Germany) in 50 mM Hepes pH .4, 150 mM NaCl.
Thereafter, the digest was heated for 30 min at 37 °C under con-
tinuous shaking (1200 rpm). Using forceps, the dermis was sepa-
rated from the epidermal layer, and fibroblasts were isolated
from the dermis by digestion with 0.2% collagenase CLS I
(Biochrom, Berlin, Germany) in DMEM, 10% BSA for 45 min at
37 °C under continuous shaking (1200 rpm). For purification of
the fibroblasts, the digest was filtered through a 70 μm mesh
and centrifuged. The pelleted cells were resuspended, grown for
three days in DMEM, 10% FCS, and subsequently further expanded
in Medium 106 supplemented with low serum growth supplement
(Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA). Sam-
ples of dermal fibroblasts were tested for the presence of viruses
pathogenic to humans, i.e., HBV, HCV, and HIV, with Genesig
PCR-based detection kits from Primerdesign Ltd. (Chandler's
Ford, UK) and for the presence of mycoplasma with a PCR test
kit from PanReac AppliChem (Darmstadt, Germany) and, in paral-
lel, by DNA staining with DAPI. All cultures were found to be neg-
ative for the tested contaminants.
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Primary fibroblasts frompatientwere reprogrammed into pluripotent
stem cells by using a non-integrating Episomal iPSC Reprogramming Kit
(Invitrogen, Cat. no. A14703). This kit contains mixture of three vectors
which has the oriP/EBNA-1 (Epstein-Barr unclear antigen-1) backbone
that delivers six reprogramming factors: OCT4, SOX2, NANOG, LIN28,
KLF4, and L-MYC (Yu et al., 2011). Human fibroblasts at 75–90% confluent
were transfected using the Amaxa 4D-Nucleofector transfection system
and a nucleofector kit for human dermal fibroblast (Lonza, Cat. no.VPD-
1001), plated onto geltrex-coated culture dishes, incubated in supple-
mented fibroblast medium. This medium contained knockout DMEM/F-
12 (Life Technologies), 10% FBS of ESC-qualified (Life Technologies), 1%
MEM non-essential amino acids (Life Technologies), 10 μM HA-100
(Santa Cruz) and 4 ng/ml bFGF (Life Technologies). At 24 h after transfec-
tion, the medium was exchanged with N2B27 medium supplemented
with 0.5 μM PD0325901 (Stemgent), 3 μM CHIR99021 (Stemgent),
0.5 μM A-83-01 (Stemgent), 10 μM HA-100 (Santa Cruz), 10 ng/ml hLIF
(Life Technologies) and 100 ng/ml bFGF. The basic N2B27 medium
containedDMEM/F12withHEPES (Life Technologies), 1×N2 supplement
(Life Technologies), 1× B27 supplement (Life Technologies), 1% MEM
non-essential amino acids, 1× Glutamax (Life Technologies) and 1× β-
Mercaptoethanol (Life Technologies). On day 15 after transfection, the
medium was exchanged with Essential 8 medium and monitored for
the emergence of iPSC colonies. Around 3weeks after transfection, undif-
ferentiated iPS colonies were picked and transferred onto fresh geltrex-
coated culture dishes for expansion.
3.5. iPSC characterization
DNA was extracted from iPSCs by using standard procedure. Markers
for the episomal backbone were amplified by semi-quantitative PCR to
exclude transgene integration. Primers are as follows: oriP forward:
TTCCACGAGGCTAGTGAACC. oriP reverse: TCGGGGGTGTTAGAGACAAC;
EBNA-1 forward: ATCGTCAAAGCTGCACACAG. EBNA-1 reverse:
CCCAGGAGTCCCAGTAGTCA. For karyotype analysis, we used the cells
growing in logarithmic phase. They were fed with fresh medium the
night before adding colcemid for 2 h. Cells were then trypsinized, treated
with hypotonic solution (0.075 m KCl) for 20 min and fixed with
methanol:acetic acid (3:1). Metaphases were spread on microscope
slides, and chromosomes were classified according to the International
System forHumanCytogenicNomenclature using the standardGbanding
technique. At least, 20 metaphases were counted per cell line, and the
final karyotype was stated if it was present in N85% of them. For terato-
mas, 2 × 106 iPSCs were injected into the right hind leg of immunocom-
promised NOD/SCID mice. Tumors were excised after 8 weeks, fixed,
embedded in paraffin, sectioned and stained with hematoxylin/eosin
(Takahashi et al., 2007).3.6. Mutation analysis
Genomic DNA was isolated from PDX1 P33T and control iPSCs
using standard procedure. PCR amplification with a set of primers
flanking the mutation site was performed in those two samples. PCR
products were sequenced using the reverse primer by Sanger sequenc-
ing on an ABI 3130 genetic analyzer (Applied Biosystems). Primers are
as follows: PDX1 forward: GGAGTGTGCAGCAAACTCAG, PDX1 reverse:
ACGCGTGAGCTTTGGTAGAC.
3.7. Immunofluorescence imaging
Cells were fixed with 4% paraformaldehyde for 30 min and then
permeabilized in PBS containing 0.2% Triton X-100. Cells were blocked
with PBS containing 3% BSA, and incubated with primary antibodies
overnight at 4 °C. Then secondary antibodies were incubated for 1 h at
room temperature after washing with PBS. Images were acquired on a
laser scanning microscope. The following antibodies and dilutions
were used: goat anti-OCT3/4 (1:500, Santa Cruz), goat anti-SOX2
(1:500, Santa Cruz), rat anti-SSEA3 (1:50, Invitrogen), mouse anti-
SSEA4 (1:500, Cell signaling) and mouse anti-TRA-1-81 (1:50,
Millipore).
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